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Introduction 
Malignant gliomas are the most common primary brain tumors in adults [Becker and 
Wahrendorf, 1998] and generally rapidly fatal despite current therapies. They are thought to 
be primarily astrocytic in origin, with the most malignant form being WHO grade IV 
astrocytoma (also called glioblastoma multiforme, GBM). Although a lot of research has been 
carried out on their etiology, the only confirmed risk factors are hereditary predisposition and 
high dose of ionizing radiation. Inconsistently reported risk factors are several occupational 
exposures (e.g. to chemical substances and metals), head injuries and other medical 
conditions, environmental and dietary risk factors (e.g. N-nitroso-compounds) [Wrensch et 
al., 2002; Preston-Martin, 1996].  
Among the potential medical risk factors discussed in the literature is the occurrence of 
common infections, for which an inverse association has been reported in an international 
multicenter case-control study including glioma patients and population-based controls 
[Schlehofer et al., 1999]. This inverse correlation might possibly be due to a stimulation of the 
immune system. Furthermore, viruses and other infectious agents are suggested to be involved 
in brain tumor pathogenesis or progression since years. Multiple studies focused on the 
presence of infectious agents in brain tumor tissues as well as on antibodies to several 
infectious agents. Astrocytomas have been positively associated with antibodies to 
Toxoplasma gondii by some investigators whereas others could not confirm these findings 
[Wrensch et al., 2002; Preston-Martin, 1996; Inskip et al., 1995; Ryan et al., 1993]. 
Furthermore, a Simian virus 40 (SV40) contaminated polio vaccine was administered between 
1954 and 1962, which was suggested to increase brain tumor incidence in vaccinated 
individuals. This polyomavirus is well known to induce brain tumors in hamsters if inoculated 
intracerebrally; however, epidemiological studies on brain tumor development among 
numerous subjects vaccinated with this contaminated vaccine remain conflictive [Sabatier et 
al., 2005a; Brenner et al., 2003; Bondy and Wrensch, 1996; Preston-Martin and Mack, 1996].  
Recently, Cobbs et al. [2002] hypothesized that human cytomegalovirus (HCMV, human 
herpesvirus-5) might be involved in the development or progression of gliomas. In all 27 
glioma biopsies examined in their study, multiple HCMV gene products were expressed in 
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contrast to samples from other brain tumors, several non-tumor brain diseases, and normal 
brain tissue.  
There is strong evidence that human herpesviruses are implicated in the pathogenesis of 
several human malignancies (e.g. Kaposi’s sarcoma, Burkitt’s lymphoma, and Hodgkin’s 
disease). Herpesviruses establish latency and reactivation occurs after years and may lead to 
neoplasms, including brain tumors. Higher titers of anti-herpes simplex virus (HSV) serum 
antibodies in glioblastoma and pituitary adenoma patients compared to patients with 
astrocytoma, medulloblastoma, meningioma or metastatic tumors had been reported in a 
seroepidemiological study [Hadfield et al., 1984]. Furthermore, Wohlrabe et al. [1984] 
reported that patients with cerebral tumors were more likely to have an acute herpesvirus 
infection. In contrast, the mean geometric antibody titers against herpesvirus in brain tumor 
patients did not differ from age- and gender-matched healthy controls in this clinical survey.  
In an epidemiological study, infection with some herpesviruses (notably varicella-zoster virus, 
VZV) was suggested to counteract glioma development; an inverse association between onset 
of adult glioma and history of chickenpox and shingles was reported by Wrensch et al. 
[1997a]. In another case-control study by the same study group, an inverse association with 
immunoglobulin G (IgG) antibodies to VZV in those glioma patients with positive self-
reported history of chickenpox was found [Wrensch et al., 1997b]. This inverse association 
could be specified in another population-based case-control study by the same investigators 
addressing the occurrence of IgG antibodies to several herpesviruses in brain tumor patients 
[Wrensch et al., 2001]. In this epidemiological study, glioblastoma cases were significantly 
less likely to have IgG antibodies to VZV. In addition, glioblastoma cases were less likely to 
have antibodies to EBV and more likely to have antibodies to HSV and HCMV than controls.  
Given the fact that so far few definite etiological factors for brain tumor development have 
been identified, further research is needed to understand more about brain tumor pathogenesis 
for the prevention of this disease. As the oncogenicity of several viruses is well known, and 
ensuing from the above-mentioned studies, a scientific focus on the role of herpesviruses in 
brain tumor etiology is warranted. The present study was particularly conducted to evaluate 
the role of herpesviruses as a possible risk factor for the development of gliomas, 
meningiomas and acoustic neurinomas. 
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Study Intention 
The main intention of this study was to evaluate the role of herpesviruses, especially of 
HCMV, in the development or progression of primary brain tumors as previously suggested. 
For this, 76 patients with incident primary brain malignancies could be recruited.  
No information on the serological status towards any herpesviruses was available prior to the 
analyses. 
The following questions were addressed in the present study: 
¾ Presence of HCMV molecules in primary brain tumor tissues 
¾ Frequency of HCMV viremia in brain tumor patients’ blood 
¾ Prevalences of IgG antibodies to HCMV, HSV, EBV and VZV in brain tumor 
patients to assess previous infections with these viruses 
¾ Prevalences of IgM antibodies to HCMV, HSV, EBV and VZV to assess acute 
herpesvirus infections 
¾ Comparison of brain tumor patients’ prevalences of IgG antibodies to HCMV, 
HSV, EBV and VZV with previous publications concerning the serological status 
in the German population 
¾ Evaluation of previous herpesvirus infections and putative risk factors indicative 
for a viral pathogenesis of primary brain tumors using a questionnaire inquiring 
medical and occupational history by telephone or direct interview 
¾ Assessment of demographic data and several other medical risk factors  
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1 Background and State of the Art 
(A) Clinical Background 
 
Because there is no overall German cancer registry, as it is in other countries, and because of 
the low incidence of primary brain tumors, a major problem in describing these neoplasms is 
the frequent lack of tumor-type specific descriptive German data. Therefore, this section first 
describes data available for all primary brain tumors combined, followed by sections about 
the three histological brain tumor types included in the present study (gliomas, meningiomas, 
and acoustic neurinomas). Data from countries other than Germany are given if procurable. 
 
1.1 Primary Brain Tumors in Humans 
1.1.1 Epidemiology and Classification 
Primary brain tumors include a broad variety of histologically different cancers. They 
comprise tumors of the neuroepithelial tissue, like gliomas (which build the great majority), 
embryonal tumors (e.g. medulloblastomas), and schwannomas (neurinomas). Furthermore, 
primary brain tumors include tumors of meningothelial cells (meningiomas), lymphomas and 
hemopoietic neoplasms, germ cell tumors and tumors of the sellar region [Grisold et al., 
2000]. Whereas this definition of primary brain tumors includes all tumors primarily arising 
in the brain, narrower definitions only include tumors arising from brain tissues.  
Brain tumor classification is based on the WHO classification of tumors of the nervous 
system. Earlier attempts to develop a TNM-based classification were dropped: tumor size (T) 
is less relevant than tumor histology and location, nodal status (N) does not apply because the 
brain has no lymphatics, and metastatic spread (M) rarely occurs because most patients with 
CNS neoplasms do not live long enough to develop metastases [Kleihues et al., 2002]. The 
first edition of the WHO classification system was published in 1979 by Zülch and it took 
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almost a decade to complete. Since then, the WHO system has been revised for several times. 
It classifies all tumors in four grades, from benign (differentiated, slow growing tumor 
without metastases, WHO grade I) to malignant (undifferentiated, fast growing tumor with 
metastases, WHO grade IV). However, classification of CNS tumors is a dynamic issue 
requiring constant review as application of newly established laboratory methods helps to 
improve diagnostic tools. There is agreement that the WHO grading can only be an estimate 
of malignancy for most brain neoplasms. However, for diffuse glial tumors, for which a 
spectrum of progression from low to high grade exists, this system may be a true grading 
system [Kleihues et al., 2002].  
A further attempt is to classify all tumors according to the ICD codes (International 
Classification of Diseases*). This is a system to encode diseases and causes of death 
according to their localization. The 9th revision of this classification system (ICD-9) has been 
replaced by ICD-10 in 2000. Because the ICD-9 codes are still frequently used, Tab. 1 gives 
ICD-9 as well as ICD-10 codes for neoplasms of the central nervous system.  
 
Table 1: International classification of diseases according to the World Health Organization  
   
Tumor Types ICD-10  ICD-9 
     
 Malignant  Benign  Malignant  Benign 
Neoplasms of the brain        
excludes: cranial nerves, retrobulbar tissue C71  D33  191  225.0 
Cerebrum, except lobes and ventricles C71.0  D33.0  191.0  225.0 
Frontal lobe C71.1  D33.0  191.1  225.0 
Temporal lobe C71.2  D33.0  191.2  225.0 
Parietal lobe C71.3  D33.0  191.3  225.0 
Occipital lobe C71.4  D33.0  191.4  225.0 
Cerebral ventricle; excludes: 4th ventricle C71.5  D33.0  191.5  225.0 
Cerebellum C71.6  D33.1  191.6  225.0 
Brain stem; includes: 4th ventricle C71.7  D33.1  191.7  225.0 
Overlapping lesion of brain C71.8  -  191.8  225.0 
Brain, unspecified C71.9  D33.2  191.9  225.0 
        
Neoplasms of the meninges C70  D32  192  225.2 
Cerebral meninges C70.0  D32.0  192.1  225.2 
Spinal meninges C70.1  D32.1  192.3  225.2 
Meninges, unspecified C70.9  D32.9  192.1  225.2 
        
Neoplasms of the cranial nerves C72  D33  192  225 
Acoustic nerve C72.4  D33.3  192.1  225.1 
 
                                                          
* under: http://www.who.int/classifications/icd/en/ 
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Furthermore, all neoplasms are additionally coded according to the “International 
Classification of Diseases for Oncology” (ICD-O). The ICD-O is a dual classification and 
coding system for both topography and morphology of a neoplasm. The topography code uses 
the same three- and four-character categories as ICD-10 for malignant neoplasms (C00.0-
C80.9), allowing greater specificity for the site of nonmalignant neoplasms than is possible in 
ICD-10. The morphology code describes the specific histologic cell type and its behavior. It 
indicates the specific histologic term. These morphology terms have five-digit codes ranging 
from M-8000/0 to M-9989/3. The first four digits indicate the specific histologic term. The 
fifth digit is a behavior code, which indicates whether a tumor is malignant, benign, in situ, or 
uncertain whether malignant or benign. The specific ICD-O-3 codes (3rd version of this 
classification scheme) for each brain tumor are given in the respective chapters. 
Of all intracranial neoplasms, about 60% are of neuroepithelial origin (gliomas), 28% derive 
from the meninges and 7.5% are located in the cranial and spinal nerves [IARC and WHO, 
2003]. According to the Central Brain Tumor Registry of the US (CBTRUS), more than 44% 
of all incident primary brain and CNS tumors are gliomas, followed by meningiomas with 
27% [2002] (Fig. 1). 
 
 
Figure 1: Incidences of brain tumors in the US according to CBTRUS [2002] 
 
In European countries, the age-standardized incidence rate differs from 4-8/100 000 per year 
[IARC and WHO, 2003], thus, primary brain tumors in humans are a very rare type of cancer. 
However, age-adjusted incidence rates differ within different publications. In a more recent 
Clinical Background 
 
7
review by Ohgaki and Kleihues [2005], incidence rates from 6-11 per 100 000 per year in 
men and from 4-11 per 100 000 in women were given for western European countries. Of all 
tumors in Germany, 2.8% (West) and 2.9% (East) in males and 3.3% (West) and 3.2% (East) 
in females are brain cancers [Becker and Wahrendorf, 1998]. For 2002, the Krebsregister 
Saarland† reported an age-adjusted incidence for all brain tumors (ICD-9 191) of 5.1 and 4.4 
per 100 000 for men and women, respectively. Furthermore, an increase in incidence can be 
observed over the last decades. There has been some controversy regarding a possible overall 
increase in incidence during the last decades, especially in developed countries; however, this 
increase appears to be largely due to the introduction of better diagnostic tools [Ohgaki and 
Kleihues, 2005].  
 
 
Figure 2: Mortality of brain tumors in the German population, 
taken from the German Atlas of Cancer Mortality [Becker and 
Wahrendorf, 1998] 
                                                          
† under: http://www.krebsregister.saarland.de 
Clinical Background 
 
8
For all brain tumors combined, rates are higher in men than in women at all ages [Preston-
Martin, 1996], because gliomas, which have a higher prevalence in men, are more frequent 
than meningiomas, resulting in a small overall male predominance for all brain tumors 
combined [Inskip et al., 1995]. Generally, men were reported to be 1.1-1.7 times more likely 
to develop any type of primary brain tumor [Bondy and Wrensch, 1996].  
Mortality increases with increasing age, with a peak at the age of around 80 years (Fig. 2). 
Although brain cancers are very rare, they are among the 20 most frequent causes of cancer 
deaths in Germany [Becker and Wahrendorf, 1998], in women even under the top ten (Fig. 3).  
 
 
Figure 3: The 20 most frequent causes of cancer deaths in Germany, taken from the Atlas of Cancer 
Mortality in the Federal Republic of Germany [Becker and Wahrendorf, 1998] 
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For Western Europe, annual mortality rates are approximately 4-7 per 100 000 in men and 3-5 
per 100 000 in women [Ohgaki and Kleihues, 2005]. The age-standardized mortality in the 
Saarland, Germany, was reported to be 6.5 per 100 000 for men and 4.8 per 100 000 in 
women in 2002 (Krebsregister Saarland‡). 
Due to the heterogeneity of these tumors, prognosis is highly variable. In Germany, the 
relative 5-year survival rates are 26.8% (West) and 21.5% (East) for males and 33.3% (West) 
and 21.1% (East) for females [Becker and Wahrendorf, 1998].  
Although several of these brain cancers are histologically defined as benign, these benign 
tumors may result in similar symptoms and clinical outcome as malignant tumors [Preston-
Martin and Mack, 1996]. They, too, can be lethal because of their expansive growth inside the 
cranium thereby increasing intracranial pressure whereby fatal cerebellar herniation through 
the foramen magnum may occur.  
 
1.1.2 Etiopathogenesis 
So far, the only confirmed risk factors besides high dose of ionizing radiation are hereditary 
cancer syndromes like Li-Fraumeni Syndrome, neurofibromatosis and tuberous sclerosis 
[Wrensch et al., 2002; Preston-Martin, 1996]. However, there are numerous putative risk 
factors controversially discussed in the literature.  
An association between epilepsy and the occurrence of brain tumors has been reported by 
several investigations while others could not find an association [Wrensch et al., 1997a; 
Carpenter et al., 1987; Hochberg et al., 1984; Choi et al., 1970]. 
Immunomodulation in general is thought to alter the risk of developing brain malignancies 
[Wrensch et al., 2002; Bondy and Wrensch, 1996; Inskip et al., 1995]. For instance, either the 
occurrence or treatment of previous cancers might have led to immunosuppression, which is a 
risk factor for the development of primary brain tumors [Salvati et al., 2003; Schiff et al., 
2001; Detry et al., 2000]. 
Besides that, immunological factors in general are highly suspicious to be involved in brain 
tumor pathogenesis. In a population-based case-control study, Schlehofer et al. [1999] 
                                                          
‡ under: http://www.krebsregister.saarland.de 
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reported that subjects who reported a history of common infections (i.e., common colds or 
flu) had a 30% risk reduction for glioma development. In addition, there is striking, but not 
yet established evidence that allergic conditions may play a role in brain tumor (especially 
glioma) development [Brenner et al., 2002; Wiemels et al., 2002; Schlehofer et al., 1999; 
Cicuttini et al., 1997]. An inverse association between adult onset glioma and history of 
chickenpox and shingles and an inverse association between glioblastoma cases and the 
occurrence or levels of IgG antibodies to VZV have previously been reported [Wrensch et al., 
2005; 2001; 1997b]. Furthermore, numerous studies tried to assess the possibly higher risk of 
primary brain tumors in patients vaccinated with a polyomavirus contaminated polio vaccine, 
but again with inconsistent results [Vilchez and Butel, 2004; Brenner et al., 2003].  
Among the various occupational exposures controversially discussed to be involved in brain 
tumor development too are several immunological factors. As infections can be transmitted 
from person to person or from animal to person, occupations with frequent contact to people 
and/or animals might increase the risk of neuro-oncogenic infections. For instance, elevated 
risks were found for physicians and surgeons [Krishnan et al., 2003; Musicco et al., 1988], 
among workers in particular industries [Wrensch et al., 2002; Inskip et al., 1995] and farmers 
and agricultural workers [Khuder et al., 1998; Musicco et al., 1988] in several 
epidemiological studies. Another case-control study, however, reported a decreased risk for 
general farm workers [Menegoz et al., 2002].  
Furthermore, zoonotic as well as immunologic factors are suspected to influence the 
development of brain malignancies. In a population-based case-control study, Efird et al. 
[2003] demonstrated significantly elevated odds ratios for childhood brain tumors in children 
living on a farm with pigs, horses, dogs or cats. Another case-control study confirmed the 
findings for contact to pigs and in addition showed an increased risk for contact with poultry 
[Holly et al., 1998]. In contrast, Menegoz et al. [2002], who investigated in contact to nine 
species of animals (dairy cattle, beef cattle, pigs, horses, sheep, goats, poultry, dogs and cats), 
did not find a relationship between either type of tumor (glioma or meningioma) and having 
contact with farm animals or pets.  
However, although numerous studies have been carried out, all these findings are equivocal 
and need to be scrutinized in further studies.  
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1.2 Glioma 
1.2.1 Epidemiology and Classification  
Gliomas, which belong to the group of neuroepithelial brain tumors, are the most common 
primary brain tumors in humans. According to the International Agency for Research on 
Cancer [IARC and WHO, 2003], approximately 60% of all intracranial neoplasms are of glial 
origin. In a great US survey conducted by CBTRUS [2002], 44% of all brain tumors were 
gliomas (Fig. 3) with glioblastoma (WHO grade IV) being the most common subtype (52%), 
followed by astrocytomas WHO grade I-III (approx. 26%) and ependymomas (5%; Fig. 4). 
 
 
Figure 4: Incidence of gliomas by histology subtypes in the US according to 
CBTRUS [2002] 
 
Gliomas derive from the neuroglia, a very heterogeneous group of cells originating from the 
ectoderm [Barres, 2003; Kintner, 2002]. The great majority of these cells are astrocytes (also 
known as macroglia) and oligodendrocytes. Astrocytes are phagocytosis-competent cells with 
numerous projections. They are connected with neurons and capillaries, thereby being part of 
the blood-brain-barrier. Oligodendrocytes are smaller cells with fewer projections than 
astrocytes. These cells are responsible for the formation of axon-surrounding myelin sheaths. 
Ependymal cells line the ventricles of the brain and the cavity of the spinal cord. Furthermore, 
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cells of the plexus chorioideus and the pituitary gland belong to the group of neuroglia. 
Gliomas can arise from every neuroglia. However, over 80% of gliomas are of astrocytic 
origin [Preston-Martin, 1996].  
The underlying grading system is “The WHO classification of Tumors of the Nervous 
System” [Kleihues et al., 2002]. Tab. 2 shows an abridged version of the classification of 
gliomas according to the WHO classification system and the corresponding ICD-O codes. 
 
Table 2: Classification of gliomas according to the WHO classification of tumors of the nervous system and 
the corresponding ICD-O codes (according to Kleihues et al., 2002) 
Astrocytic tumors WHO  ICD-O-3 Oligodendroglial tumors WHO  ICD-O-3 
 grade* code  grade* code 
Pilocystic astrocytoma I M9421/1 Oligodendroglioma II M9450/3 
Diffuse astrocytoma   Anaplastic oligodendroglioma III M9451/3 
  -Fibrillary astrocytoma II M9420/3    
  -Protoplasmic astrocytoma II M9410/3 Mixed gliomas   
  -Gemistocytic astrocytoma II M9411/3    
Anaplastic astrocytoma III M9401/3 Oligoastrocytoma II M9382/3 
Glioblastoma  M9440/3 Anaplastic oligoastrocytoma III M9382/3 
  -Giant cell g. IV M9441/3    
  -Gliosarcoma IV M9442/3 Ependymal tumors   
      
   Ependymoma II M9391/3 
   Anaplastic ependymoma III M9392/3 
   Myxopapillary ependymoma I M9394/1 
   Subependymoma I M9383/1 
* WHO, World Health Organization; WHO grade I=benign; WHO grade II=semi-benign; WHO grade III=(semi-) 
malignant; WHO grade IV=malignant; ICD-O-3, International Classification of Diseases for Oncology, 3rd version 
 
Age at clinical manifestation strongly depends on the histological type of the tumor. The most 
frequent brain neoplasm in children is pilocystic astrocytoma (74% are younger than 20 years 
of age). Diffuse astrocytoma is most common in 20 to 44 year-olds, whereas glioblastoma is a 
tumor of the elderly; 72% are above the age of 45 years at first clinical manifestation [IARC 
and WHO, 2003]. Anaplastic astrocytomas and glioblastomas often evolve from less 
malignant astrocytomas. However, some cases appear to arise de novo [Inskip et al., 1995]. 
For these, hereditary as well as genetic risk factors are discussed [Grisold et al., 2000].  
Oligodendrogliomas typically occur in persons above the age of 20 years, whereas 
ependymomas most commonly develop under 45 years-of-age [IARC and WHO, 2003]. 
Gradations of anaplasia are also seen in these tumors, although they most often occur as 
relatively benign forms [Kleihues et al., 2002]. 
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Glioma rates are higher in men than in women [Preston-Martin, 1996]. According to a 
descriptive epidemiological survey conducted by CBTRUS in the US, gliomas affect about 
40% more males than females [Surawicz et al., 1999]; another epidemiological study reported 
a male:female ratio in the US of 1.5 [Inskip et al., 1995]. However, there is no explanation for 
this relation up to now.  
The overall incidence of gliomas is increasing with increasing age. It has been suggested that, 
as for other tumors, this increase is a function of length of exposure required for malignant 
transformation and/or the necessity of multiple genetic alterations preceding malignancy 
[Bondy and Wrensch, 1996]. However, with two exceptions, these exposures are not 
characterized yet (see below).  
 
1.2.2 Etiopathogenesis 
So far, the only known risk factors for the development of primary brain tumors are high dose 
therapeutic radiation of the head and some hereditary diseases such as Li-Fraumeni syndrome, 
neurofibromatosis and tuberous sclerosis. However, these factors only account for less than 
five percent of all incident primary brain tumors [Inskip et al., 1995].  
Epidemiological studies on potential risk factors have produced controversial results. Risk 
factors that are discussed throughout the last decades include occupational and industrial 
chemicals (e.g. N-nitroso compounds, pesticides, and formaldehyde), electromagnetic fields, 
medical conditions (such as allergies, atopic and infectious diseases, and head injuries), 
medications, and other environmental and lifestyle factors, but the etiological relevance of 
these factors is not proven up to now [Wrensch et al., 2002; Wrensch et al., 2000; WHO, 
2000b; Schlehofer et al., 1999; Bondy and Wrensch, 1996; Preston-Martin and Mack, 1996].  
Therefore, further research is needed to recognize etiological pathways to avert this fatal 
malignancy. 
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1.2.3 Diagnosis, Therapy and Prognosis 
The most common reasons to take medical advice for persons with glial tumors are seizures 
and headache without improvement after medication. Other signs include paresis, emesis, 
speech disturbances and personality changes [IARC and WHO, 2003; Grisold et al., 2000; 
WHO, 2000b]. The presence of symptoms usually leads to a detailed neurological 
examination, using computed tomography (CT) and magnetic resonance imaging (MRI), 
during which intracranial masses can be detected. The tentative diagnosis may be confirmed 
by biopsy [IARC and WHO, 2003; Grisold et al., 2000; WHO, 2000b; Preston-Martin, 1996].  
The main target in glioma therapy is a complete surgical removal of the neoplasm. However, 
due to the commonly infiltrative character and the intracranial location, complete removal is 
frequently impossible. In this case, partial removal can alleviate symptoms and protract 
exacerbation. Post-operative radiotherapy may follow. Furthermore, adjuvant chemotherapy 
has been proven to be effective to remove remaining tumor cells after surgery [Grisold et al., 
2000].  
Prognosis is strongly related to patients’ age and histologic type. Patients with glioblastoma 
multiforme (WHO grade IV) have the poorest prognosis with less than 3% of the patients still 
alive 5 years after diagnosis [IARC and WHO, 2003; Preston-Martin, 1996]. In contrast, 
patients with pilocytic astrocytoma (WHO grade I) have a chance of more than 85% to be still 
alive after 5 years [IARC and WHO, 2003]. In gliomas of other histology, patients under the 
age of 44 years have a much better survival than older patients within each histological type 
[Wrensch et al., 2002]. Overall, higher age at diagnosis is the most powerful negative 
prognostic factor for gliomas that is operative through all age groups [Ohgaki et al., 2004].  
Unfortunately, despite several newly invented diagnostic and therapeutic methods, an 
Australian study group reported that there seems to be no improvement in the 5-year survival 
in any age group or histological type [Shugg et al., 1994].  
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1.3 Meningioma 
1.3.1 Epidemiology and Classification  
Intracranial meningiomas are the second most frequent type of primary brain malignancies. 
They account for 27% of all primary brain tumors in the US (CBTRUS, 2002; Fig. 1). 
Similarly, the International Agency for Research on Cancer reported a proportion of 28% 
[IARC and WHO, 2003].  
These usually benign and slow growing tumors develop from arachnoidal cells in the 
meninges. Being benign tumors, WHO grade I meningiomas do not infiltrate the brain but 
may cause symptoms only due to their intracranial location. These meningiomas can often be 
cured by total surgical resection. However, although this is rarely the case, they can progress 
to a malignant form. Of all meningiomas, approximately 6-9% are malignant (WHO grade II 
or III). They can infiltrate the brain, are often recidivating and have a less favorable clinical 
outcome. Meningiomas are graded according to “The WHO classification of Tumors of the 
Nervous System” (Kleihues et al., 2002; as shown in Tab. 3). 
 
Table 3: Classification of tumors of meningothelial cells according to the WHO classification of tumors of 
the nervous system and the corresponding ICD-O codes (according to Kleihues et al., 2002) 
Meningiomas with low risk of recurrence 
and/or aggressive growth 
 Meningiomas with greater risk of 
recurrence and/or aggressive growth 
     
Meningioma WHO 
grade* 
ICD-O-3 
code 
 Meningioma WHO 
grade* 
ICD-O-3 
code 
       
Meningothelial I M9531/0  Clear cell II M9538/1 
Fibrous (fibroblastic) I M9532/0  Chordoid II M9538/1 
Transitional (mixed) I M9537/0  Atypical II M9539/1 
Psammomatous I M9533/0  Papillary III M9538/3 
Angiomatous I M9534/0  Rhabdoid III M9538/3 
Microcystic I M9530/0  Anaplastic III M9530/3 
Secretory I M9530/0     
Lymphoplasmacyte-rich I M9530/0     
Metaplastic I M9530/0     
*WHO, World Health Organization; WHO grade I=benign; WHO grade II=semi-benign; WHO grade III=semi-
malignant; WHO grade IV=malignant; ICD-O-3, International Classification of Diseases for Oncology, 3rd 
version 
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The annual incidence rate of intracranial meningiomas is approximately 6 per 100 000 [WHO, 
2000a]. Women are more likely to have benign meningiomas, with a male:female ratio of 0.6 
[Inskip et al., 1995]. It has been reported by a descriptive epidemiological study of CBTRUS 
that meningiomas affect about 80% more females than males [Surawicz et al., 1999]. 
Interestingly, malignant meningiomas occur about equally in men and women [Inskip et al., 
1995].  
Primarily, meningioma is a disease of the middle and old age [Inskip et al., 1995] with a peak 
occurrence between 50-70 years of age [WHO, 2000b]. However, as this is usually a benign 
and very slow growing tumor, first diagnosis at autopsy occurs with a frequency of 1.4% 
[WHO, 2000b]. Therefore, epidemiologic and etiologic studies might be confused with 
determinants of diagnosis [Inskip et al., 1995]. 
 
1.3.2 Etiopathogenesis 
So far, few factors have been identified to be involved in meningioma pathogenesis. The fact 
that women are significantly more affected by meningiomas led to the suggestion that 
hormonal factors are of etiologic relevance [Preston-Martin and Mack, 1996; Inskip et al., 
1995]. However, no causative agent could be found up to now.  
As in glioma pathogenesis, therapeutical ionizing radiation is the only environmental 
exposure for which a causal association with meningioma development is established [Yousaf 
et al., 2003; Strojan et al., 2000; Preston-Martin, 1996]. Childhood radiotherapy has been 
reported to elevate the relative risk for meningioma pathogenesis 9.5 times by an 
epidemiological study in Israel [Ron et al., 1988]. The second well-established condition 
leading to meningioma disease is hereditary neurofibromatosis type 2 [Inskip et al., 1995].  
An inverse association of allergic diseases with meningioma has been reported by several 
large case-control studies [Brenner et al., 2002; Schlehofer et al., 1999]. Epidemiological 
studies on occupational risk factors, however, showed inconsistent results [Menegoz et al., 
2002; Wrensch et al., 2002; Preston-Martin, 1996; Preston-Martin and Mack, 1996; Inskip et 
al., 1995]. Other factors such as head trauma, smoking, and diet were investigated, but no 
definite etiological role could be demonstrated for any of these factors [Preston-Martin and 
Mack, 1996].  
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1.3.3 Diagnosis, Therapy and Prognosis 
Cerebral meningiomas cause clinical symptoms by compression of adjacent tissue. The 
specific symptoms depend on the location of the intracranial mass. Since meningiomas are 
slow growing tumors, deficits like headache, seizures or depression occur relatively late 
[WHO, 2000b].  
The preferred therapy is surgical excision. WHO grade I meningiomas are usually curable 
when resectable. However, the extent of resection depends on the localization, attachment to 
intracranial structures, and the age of the patient. In case of unresectable or high-grade 
meningiomas, surgery plus radiation therapy is applied [Grisold et al., 2000].  
The proportion of patients who survive 5 years is 69% according to a review of Wrensch et al. 
[2002] and up to 92% for patients with WHO grade I meningiomas (reviewed by Preston-
Martin, 1996).  
Malignant meningiomas may relapse locally [IARC and WHO, 2003]. According to the 
WHO, atypical meningiomas relapse in 29-40% of the cases and anaplastic meningiomas 
have a recurrence rate of 50-78% [WHO, 2000b]. Furthermore, they are associated with 
shorter survival times than benign ones. Interestingly, women are more likely to have benign 
meningiomas and they have a significantly longer survival than men who develop benign 
meningial tumors [Preston-Martin, 1996]. 
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1.4 Acoustic Neurinoma 
1.4.1 Epidemiology and Classification  
Acoustic neurinomas belong to the group of schwannomas. These are benign tumors arising 
from the myelin producing Schwann cells, which enfold the eighth cranial nerve 
(vestibulocochlear nerve).  
Acoustic neurinomas are consistently reported to account for about 8% of all intracranial 
primary brain tumors by various epidemiological studies [CBTRUS, 2002; WHO, 2000b; 
Preston-Martin, 1996]. Currently, the worldwide incidence for acoustic neurinoma is reported 
to be 1-20 per million population per year. An increase in incidence is observed over the last 
two decades; however, this increase may be due to better diagnostic tools [Howitz et al., 
2000; Lanser et al., 1992]. Acoustic neurinoma generally are histologically benign (ICD-10 
code D33.3, ICD-O-3 code M9560/0), corresponding to WHO grade I [Kleihues et al., 2002; 
WHO, 2000b]. Recurrence after surgical resection is very rare.  
Neurinomas of the acoustic nerve generally occur in people aged 50 years and above, except 
for tumors occurring in the course of neurofibromatosis type 2, where acoustic neurinomas 
often occur in younger persons and bilateral [Lanser et al., 1992]. In contrast to peripheral 
schwannomas, where no gender predilection can be seen, the female:male ratio in intracranial 
neurinomas is 2:1 [WHO, 2000b]. 
 
1.4.2 Etiopathogenesis 
As for gliomas and meningiomas, only two well-established risk factors for acoustic 
neurinoma development are figured out so far. Therapeutic radiation (e.g. of ringworm of the 
scalp in childhood) is a strong risk factor contributing to acoustic neurinoma development. 
This association is the strongest among all brain tumors for which an association was found 
[Inskip et al., 1995; Ron et al., 1988]. The role of diagnostic radiation, however, remains 
unclear. Acoustic neurinomas have a relatively clear genetic character. Individuals with the 
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familial, autosomal dominant cancer syndrome neurofibromatosis (NF) are at high risk for 
acoustic neurinoma development. Patients with NF type 2 typically develop bilateral acoustic 
neurinomas [WHO, 2000a]. In patients with NF type 1, however, peripheral rather than 
central neurinomas are prevalent [Wrensch et al., 2002; Preston-Martin and Mack, 1996; 
Inskip et al., 1995].  
Several other risk factors have been discussed throughout the last decades. These include head 
and noise trauma, dental x-rays, and mobile phone use [Christensen et al., 2004; Lonn et al., 
2004; Hardell et al., 2003; Preston-Martin et al., 1989]. Hay fever and allergies to several 
substances were reported to increase the risk for acoustic neurinoma development in a 
hospital-based case-control study [Brenner et al., 2002].  
Most of the results, however, were based on small numbers and, in addition, most of the 
hypotheses are based on one single study and, if more studies had been conducted, the results 
between the different studies are inconclusive. Therefore, further research is needed to 
identify additional etiological pathways leading to acoustic neurinoma. 
 
1.4.3 Diagnosis, Therapy and Prognosis 
Since schwannomas favor sensory nerve roots, motor symptoms are uncommon. Patients with 
acoustic neurinoma develop tinnitus, hearing impairments, vertigo and facial palsy [WHO, 
2000b]. MRI and CT are the best methods of imaging these tumors [Grisold et al., 2000].  
The preferred therapy is a complete surgical resection of the neoplasm, eventually followed 
by craniospinal irradiation.  
Patients with this benign tumor have a chance of 100% to survive 5 years after diagnosis 
[Preston-Martin, 1996]. Hence, although complications during therapy such as hearing losses 
or facial paresis are frequent, patients have a normal life expectancy after complete removal.  
Acoustic neurinomas rarely undergo malignant transformation. However, patients with the 
rarely occurring malignant acoustic neurinoma (ICD-10 code C72.4) have a relatively poor 
prognosis [Grisold et al., 2000]. 
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(B) Virological Background 
1.5 The Family of Herpesviruses 
Herpesviruses are ubiquitous DNA viruses infecting humans and several vertebrates. Today, 
approximately 100 different herpesviruses have been detected.  
 
1.5.1 Taxonomy 
The family of herpesviruses consists of three subfamilies, which are classified according to 
their pathogenicity, their target cells and their replication characteristics (alpha [α]-, beta [ß]-, 
and gamma [γ]-herpesviruses; Tab. 4). 
 
Table 4: The family of herpesviruses in humans 
Family Subfamily Genus Species Designation 
     
Herpesviridae     
     
 α-herpesviridae Simplexvirus Herpes simplex virus 1 HHV-1 
   Herpes simplex virus 2 HHV-2 
  Varicellavirus Varicella-zoster virus HHV-3 
     
 ß-herpesviridae Cytomegalovirus Human cytomegalovirus HHV-5 
  Roseolovirus  HHV-6 
    HHV-7 
     
 γ-herpesviridae Lymphocryptovirus Epstein-Barr virus HHV-4 
  Rhadinovirus Kaposi’s sarcoma  
associated herpesvirus 
HHV-8 
     
HHV, human herpesvirus 
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The subfamily of α-herpesviruses is characterized by a variable host range, a short replication 
cycle and a rapid spread in culture. In vivo, they usually but not exclusively persist in 
ganglions. In contrast to α-herpesviruses, ß-herpesviruses have a restricted host range and a 
long replication cycle in cultured cells. Latency occurs in secretory glands, lymphoreticular 
cells, kidneys, and other tissues. Infected cells become typically enlarged (cytomegalia). The 
last subfamily, the γ-herpesviruses, typically infects either B- or T-lymphocytes. They, too, 
are species-specific. Latent virus is frequently demonstrated in lymphoid tissues [Modrow, 
2002; Roizman and Pellet, 2001]. 
Besides the common names α-, ß-, and γ-herpesviruses, the Committee on Taxonomy of 
Viruses designates herpesviruses in the chronological order of their discovery [Modrow, 
2002; Mocarski, Jr. and Courcelle, 2001; Roizman and Pellet, 2001] 
 
1.5.2 Structure 
Inclusion in the family of herpesviridae is based on the structure of the virion. A herpesvirion 
typically has a diameter of approximately 150 to 200 nm and consists of the following: 
1. a core containing a linear, double-stranded DNA with a size of up to 230 kbp, 
2. an icosadeltahedral capsid, containing 162 capsomeres, 
3. an amorphous tegument surrounding the capsid, and 
4. an envelope with viral glycoprotein spikes on its surface. 
The size of herpesvirions varies between 120 nm and 300 nm. The core of the mature virion 
contains the viral DNA in form of a torus. The capsid, containing the pentameric capsomeres, 
is approximately 100-110 nm in diameter. The thickness of the herpesvirus-specific tegument 
depends on the location of the virion in the infected cell. This tegument is an unstructured 
protein matrix containing 20 viral proteins. There is evidence that the amount of tegument is 
more likely to be determined by the virus than by the host. The envelope is the outer 
membrane of the virus. This lipid membrane contains numerous spikes consisting of 
glycoproteins, which vary in number and relative amount [Modrow, 2002; Roizman and 
Pellet, 2001]. The genome range of the linear, double-stranded DNA varies approximately 
from 125 to 248 kbp. It circularizes immediately upon release from capsid into the nucleus of 
an infected cell [Modrow, 2002; Roizman and Pellet, 2001].  
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1.5.3 Replication 
Herpesviruses can infect the host cell in two different ways. First, herpesviruses can build 
virions and cause a lytic infection, i.e., the host cell is killed by the virus. The most interesting 
property of all herpesviruses, however, is their ability to establish a so-called latent infection 
without virion production and host cell destruction [Modrow, 2002]. In latency, herpesviruses 
are able either to establish an antigenically silent form of latent infection or to impair the 
antigen-processing capacity of lytically infected cells (see below)  
 
1.5.3.1 Lytic Infection 
Generally, herpesvirus replication is accompanied by irreversible destruction of the infected 
host cell. For this so-called “lytic infection”, the adsorption of herpesvirions to the host cell 
occurs on the cell surface where viral envelope proteins bind to cell surface receptors. 
Attachment is followed by penetration. Viral nucleocapsids quickly make their way to the 
nucleus pores to deliver the viral DNA to the nucleus. Upon entry, the genome typically 
circularizes and integrates in the host cell DNA.  
Gene expression can be divided based on time of gene synthesis after infection: immediate 
early (α), early (ß) and late (γ). Immediate early (IE) proteins are important for ongoing 
infection. No prior viral protein synthesis is required for their expression. They act as 
transcriptional trans-activators for the expression of early proteins (early antigens, EA), 
whose expression is totally independent of viral DNA synthesis. Late proteins (late antigens, 
LA) are transcribed during DNA synthesis, which is coincident with cellular DNA replication. 
LAs are responsible for the coding of glycoproteins, which are important for the assembly of 
nucleocapsid, tegument and covering membrane. DNA packaging follows formation of 
capsids. Thereafter, progeny virions acquire an envelope from the inner nuclear membrane, 
are transported in vesicles via the endoplasmatic reticulum and the Golgi apparatus to the cell 
surface and get released via an exocytotic pathway [Landolfo et al., 2003; Modrow, 2002; 
Mocarski, Jr. and Courcelle, 2001; Roizman and Pellet, 2001].  
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1.5.3.2 Latent Infection 
Latency is a characteristic feature of all herpesviruses. The viral genome remains with its host 
for life after primary infection [Modrow, 2002; Roizman and Pellet, 2001].  
The sites of latency differ between the herpesvirus subfamilies. α-herpesviruses most 
commonly persist in ganglions. ß-herpesviruses remain in secretory glands, lymphoreticular 
cells, kidneys, and other tissues, and latent γ-herpesviruses are usually demonstrated in 
lymphoid tissues [Modrow, 2002; Roizman and Pellet, 2001]. During latency, no virus 
replication and no cell destruction occurs. However, the viruses can be reactivated in case of 
immunosuppression such as infections, pregnancy, malignancies, stress and other medical 
conditions, and the lytic cycle may be started. 
 
1.5.4 Transmission 
Transmission of herpesviruses is cell-associated, and occurs by direct or indirect person-to-
person contact. In contrast to most other infectious diseases, the presence of acquired 
antibodies does not prevent infection.  
Because of the relative lability of all herpesviruses after exposure to common environmental 
conditions such as heat and drying, close or even intimate contact is required for its horizontal 
spread. Sources of virus include oropharyngeal secretions, urine, cervical and vaginal 
excretions, semen, breast milk, tears, feces and blood. Without producing clinical disease, 
virus excretion persists for years after acquired infections, being responsible for an extensive 
spread of herpesviruses in susceptible populations [Modrow, 2002; Roizman and Pellet, 
2001].  
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1.6 Human Cytomegalovirus 
Human cytomegalovirus (HCMV; also 
designated HHV-5) is a member of the 
herpesvirus subfamily of ß-herpesviridae. 
Characteristically, these viruses produce 
cell enlargement with intranuclear 
inclusions, a fact that led to the early 
designation of the term “cytomegalic 
inclusion disease” (CID), thereby giving 
this virus its name [Britt and Alford, 1996]. 
 
The HCMV genome is the largest of all herpesviruses, containing approximately 248 kbp, 
with slight differences in size between the different strains. So far, the DNA of the AD169 
laboratory strain is the only completely sequenced HCMV genome [Landolfo et al., 2003]. 
 
1.6.1 Epidemiology 
HCMV is a ubiquitous virus widespread in the human population. According to the Robert 
Koch Institute (RKI), Germany [2000a], the prevalence in the German adult population is 
between 40% and 80%. Another publication assessed a prevalence of 42% in 20-39 year-old 
persons in the Freiburg area in Southern Germany [Krech, 1973]. The worldwide prevalence 
has been estimated to vary between 40% in developed countries and higher socioeconomic 
status (SES) and up to 100% in developing countries and low SES. Immunosuppression, SES 
and promiscuity are general factors promoting seroconversion [Modrow, 2002; Pass, 2001; de 
Jong et al., 1998].  
 
                                                          
§ from University of Birmingham www.biosciences.bham.ac.uk 
 
Figure 5: Electron micrograph of a CMV virion§ 
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HCMV can be transmitted intrauterinely. Up to 2% of infants in developed countries are 
infected in utero, with approximately 10-15% of them exhibiting long-term neurologic 
sequelae following this infection. Hence, HCMV is the most common congenital infection in 
humans. In addition, it is the leading infectious cause of CNS maldevelopment (e.g. 
hydrocephalus and microcephaly) in children.  
Generally, HCMV is transmitted through body fluids, such as semen, blood, cervical and 
vaginal excretions, breast milk, tears, urine and feces [Landolfo et al., 2003; Pass, 2001]. 
Before puberty, less than 40% become infected; afterwards, the percentage of infected 
persons increases only about 1% per year. Two peaks can be observed in HCMV 
seroprevalence analogous to its transmission pathways. A first increase in seroprevalence 
occurs during the first three years of life (close physical contact) and a second peak is reached 
in early adulthood due to sexual contacts [Landolfo et al., 2003].  
 
1.6.2 Pathogenesis 
Following oral transmission, HCMV characteristically infects ductal epithelial cells of the 
salivary glands. The parotidoid gland is most frequently infected. Typically, HCMV-infected 
cells can be seen with multiple prominent intranuclear inclusions surrounded by a clear halo. 
These inclusions have given rise to the term “owl’s eyes inclusions”.  
A first replication in the salivary glands is followed by hematogenous, cell-associated 
viremia, where the virus spreads throughout the body to several organs [Sinzger and Jahn, 
1996]. Gastrointestinal involvement as well as involvement of the respiratory tract is 
frequently seen, mainly in immunocompromised individuals. Other sites susceptible for 
HCMV infection are spleen, kidney, liver, myocard, brain, and bone marrow [Landolfo et al., 
2003; Modrow, 2002; Pass, 2001; Ho, 1982]. After primary infection, HCMV may develop 
latency in macrophage-granulocyte progenitors in the bone marrow and in peripheral 
monocytes, and can be reactivated under certain conditions [Landolfo et al., 2003]. However, 
the sites of latency are still largely undefined [Pass, 2001; de Jong et al., 1998].  
An important issue for HCMV viremia and disease is the immunological status of the infected 
person, as described below [Landolfo et al., 2003; de la Hoz et al., 2002].  
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1.6.3 Clinical Features 
HCMV has an incubation period of 4 to 8 weeks. As mentioned above, the immunological 
status of the infected person is of high importance for the clinical outcome of the disease.  
 
1.6.3.1 Immunocompetent Persons 
In immunocompetent persons, HCMV infection usually leads to a clinically inapparent 
infection. Infrequently, the development of a mononucleosis-like syndrome occurs, which is 
clinically indistinguishable from an infection with Epstein-Barr virus; about 8% of all 
mononucleosis cases are caused by HCMV [Pass, 2001]. Cervical adenopathy, myalgia and 
nonspecific constitutional syndromes are typical, as is persistent fever during 2-5 weeks 
[Landolfo et al., 2003; Modrow, 2002; Ho, 1982].  
 
1.6.3.2 Congenital Infection 
HCMV infection is the most common congenital viral infection in humans. On average, 1% 
of all newborns are infected with this virus, with geographical differences (0.2% in Europe, 
and up to 2.2% in the US according to Pass, 2001).  
Approximately 0.1% of all children are congenitally damaged by HCMV infection [Modrow, 
2002], resulting in mental retardation, hearing impairments, hepatosplenomegaly, jaundice, 
pneumonia, microcephaly, seizures and thrombocytopenia [Landolfo et al., 2003]. Affected 
children develop permanent damages in 90% of the cases, mainly neurologic abnormalities. 
Interestingly, the incidence of hearing loss in otherwise asymptomatically infected newborns 
is 5-15%. It has been shown that multiple organs of congenitally infected children become 
infected, with the major target organs being the lung, the pancreas, the kidneys and the liver 
[Bissinger et al., 2002; de Jong et al., 1998].  
The presence of maternal immunity is highly correlated with fetal outcome. 8-10% of primary 
maternal infections lead to a clinically apparent infection, whereas women with 
preconceptional immunity rarely deliver symptomatic infants [Modrow, 2002; Pass, 2001].  
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1.6.3.3 Immunocompromised Individuals 
In immunocompromised persons, mainly allograft recipients and persons infected by human 
immunodeficiency virus (HIV), HCMV infection is a dreaded condition. In fact, HCMV 
pneumonia is the leading cause of death in HIV-infected patients and bone marrow allograft 
recipients [Modrow, 2002].  
Primary infection of allograft recipients through a seropositive graft can cause a severe 
mononucleosis syndrome. In the worst case, primary HCMV infection can lead to 
inflammation or even rejection of the graft. However, even in seropositive recipients, HCMV 
can be reactivated through treatment-induced immunosuppression, and then lead to manifest 
HCMV disease [Modrow, 2002; de la Hoz et al., 2002; Pass, 2001]. Fortunately, improved 
prophylaxis and preemptive antiviral therapy led to a decrease in the incidence of HCMV 
disease in graft recipients in the past years [de Jong et al., 1998].  
In general, immunomodulation is thought to alter the risk for HCMV infection or reactivation 
[Landolfo et al., 2003; Pass, 2001]. For instance, either the occurrence or the treatment of 
cancer may cause the necessary immunosuppression [Pass, 2001; Sinclair and Sissons, 1996].  
Reactivation of a latent HCMV infection is the major cause for severe disease in HIV-infected 
individuals rather than primary infection, leading to a manifest mononucleosis syndrome. 
There is a clear correlation between the severity of HIV immunodeficiency and the 
development of HCMV disease. Clinically syndromes in affected patients include disease in 
almost every organ system, e.g. gastrointestinal ulcerations, chorioretinitis, severe pneumonia, 
and encephalitis [Modrow, 2002; Pass, 2001; de Jong et al., 1998].  
 
1.6.4 Diagnosis 
Clinical symptoms are usually unspecific if any are present in immunocompetent persons. 
Therefore, laboratory analyses are required for adequate diagnostics. Diagnostic methods for 
the detection of HCMV infection include serological methods (detection of anti-HCMV IgG 
and IgM antibodies in sera of the patients), measurement of pp65 antigen in leucocytes, virus 
isolation from several body fluids, histology of tissue sections and detection of viral nucleic 
acids, generally by polymerase chain reaction (PCR; Pass, 2001; de Jong et al., 1998).  
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1.6.5 Management of HCMV Infection 
In the management of HCMV disease, four different strategies can be distinguished [de Jong 
et al., 1998]: 
1. Prophylactic, 
2. preemptive, 
3. suppressive, and 
4. antiviral treatment. 
Prophylaxis is defined as treatment in the absence of detectable virus to prevent primary 
infection or reactivation of the virus (e.g. prior to an organ transplantation). Preemptive and 
suppressive treatments aim at limiting treatment to individuals at higher risk of developing a 
manifest HCMV disease. In this case, virus is detectable, but without causing any clinical 
symptoms.  
Currently available drugs for antiviral treatment are virus polymerase inhibitors like 
gancyclovir, foscarnet and cidofovir, which inhibit HCMV replication. However, these drugs 
have severe side effects. Efforts to develop an HCMV vaccine are being made since several 
decades to reduce morbidity and mortality in individuals affected by HCMV, but so far, no 
effective HCMV vaccine has been developed [Landolfo et al., 2003; Pass, 2001; de Jong et 
al., 1998].  
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1.7 Herpes Simplex Virus  
Of all human herpesviruses, herpes 
simplex viruses (HSV) were the first to be 
discovered. They are members of the 
herpesviruses subfamily of α–
herpesviridae, containing a genome of 
approximately 152 kbp.  
Two species exist, herpes simplex virus 1 
(HSV-1, also designated HHV-1), which 
causes orolabial lesions, and herpes 
simplex virus 2 (HSV-2, also designated 
HHV-2), infecting the genital tract.  
The virus has been named in reference to the spreading nature of the visualized skin lesions 
(Greek herpein: creep or crawl; Whitley, 1990).  
 
1.7.1 Epidemiology 
HSV, like all herpesviruses, is a ubiquitous virus widespread in the human population with 
the ability to develop latency in the host.  
As for other herpesviruses, incidence is strongly associated with the socioeconomic status of 
the population. Frequency of direct person-to-person contact, indicative of crowding 
encountered with lower SES, appears to be the major mediator of infection, followed by 
immunosuppression and promiscuity [Whitley, 1990]. HSV-2 is in fact one of the most 
prevalent sexually transmitted infectious agents worldwide [Smith and Robinson, 2002]. 
Generally, individuals from lower SES populations have an HSV-1 seroprevalence of 75-90% 
by the end of the first decade of life. In contrast, in middle or high SES populations, the 
proportion is only 30-40% by the middle of the second decade of life [Whitley, 1990].  
                                                          
** University of Leeds, UK, www.bmb.leeds.ac.uk/mbiology 
 
Figure 6: Electron micrograph of herpes simplex 
virus** 
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In Germany, the seroprevalences of IgG antibodies to HSV-1 was reported to be 64% for men 
and 71% for women in the age group 15-39 years. Above the age of 40 years, prevalences are 
83% and 85%, respectively (Rabenau et al., 2002; Frankfurt am Main area). Hellenbrand et al. 
[2001] compared seroprevalences of antibodies to HSV-1 in West and East Germany. In the 
western part of Germany, a seroprevalence of 85% (95%CI 83-87%) compared to 89% 
(95%CI 87-90%) in the eastern part has been reported.  
For HSV-2, a seroprevalence of 13% (95%CI 11-14%) in West Germany and 16% (95%CI 
14-18%) in East Germany, respectively, was estimated [Hellenbrand et al., 2001]. A similar 
seroprevalence of IgG antibodies to HSV-2 of 13% (95%CI 12-14%) was reported for a 
population of blood donors and hospital patients in the Frankfurt am Main area, Germany 
[Wutzler et al., 2000]. 
 
1.7.2 Pathogenesis 
Herpes simplex virus infection requires intimate, personal contact of a seronegative person 
with an individual excreting the virus.  
Infection is initiated when HSV comes into contact with mucosal surfaces or small skin 
lesions. At the site of infection, a first viral replication takes place including intense 
inflammatory response and the formation of vesicles containing infectious virus. Through 
retrograde axonal transport, HSV virions arrive at the dorsal root ganglia, where the virus 
establishes latency. HSV may become systemic, infecting multiple organs, e.g. in neonatal 
HSV infection (resulting in herpes neonatorum) and in immunocompromised persons. 
An important issue for HSV viremia and disease is the immunological status of the infected 
person. Immunosuppression and stress are clearly correlated with reactivation from latent 
status. However, as with primary infection, reactivation may occur in the absence of clinical 
symptoms [Modrow, 2002; Whitley, 1990].  
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1.7.3 Clinical Features 
The pathologic changes induced by HSV are similar for primary and recurrent infection. 
Although HSV-1 and HSV-2 are transmitted by different routes and involve different areas of 
the body, the manifestations of infections caused by HSV are coincident [Whitley, 1990].  
 
1.7.3.1 Oropharyngeal Disease 
Infection with HSV-1 may induce HSV-1-specific oropharyngeal disease (“infection above 
the belt”), the so-called “herpes labialis”. However, asymptomatic infection is the rule.  
The mean incubation period is 4 days. Primary infection in children lasts from two to three 
weeks, usually including fever, edema, lymphadenopathy, sore throat, gingivostomatitis, and 
lesions within the mouth evolving from vesicles. These lesions are followed by ulcerations 
and erythemas, which progress slowly to healing.  
Later in life, primary infection is associated with pharyngitis and a mononucleosis-like 
syndrome. Recurrent infections start with pain, burning, or itching, followed by vesicles that 
commonly occur at the vermilion border of the lip. These lesions usually progress to a 
pustular or ulcerative and crusting stage. Subsequent healing is rapid, generally being 
complete in 8-10 days [Modrow, 2002; Whitley, 1990]. 
 
1.7.3.2 Genital Disease 
Genital herpes (“herpes genitalis”, “infection below the belt”) is caused by HSV-2. Again, 
asymptomatic infection is the rule. However, primary genital herpetic infection may cause 
severe clinical disease. Symptoms include fever, dysuria, localized lymphadenopathy, 
macules and papules, followed by painful vesicles, pustules, and ulcers. Systemic spread is 
common, especially in women, approaching approximately 70% of all cases, with the most 
common being aseptic meningitis (10%) and other extragenital lesions. Recurrent disease is 
associated with a limited number of lesions and an approximate duration of 7-10 days. 
Neurologic or systemic complications are uncommon [Modrow, 2002; Whitley, 1990]. 
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1.7.3.3 Other Clinical Manifestations 
Other clinical manifestations of an infection with HSV include 
1. neonatal HSV infection, 
2. HSV keratoconjunctivitis, 
3. skin infections, 
4. infections of the immunocompromised host, and 
5. infections of the CNS. 
 
1.7.4 Diagnosis 
Diagnosis is based on the clinical disease and on the serological determination of anti-HSV 
IgG and IgM antibody concentrations. If lesions are present, a scraping of skin vesicles should 
be made with subsequent virus isolation. In case of doubtful results, viral DNA can be 
amplified by PCR methods. A distinction between HSV-1 and HSV-2 is possible by 
determining specific antibodies or via PCR [Modrow, 2002; Whitley, 1990].  
 
1.7.5 Management of HSV Infection 
HSV infections can be treated locally or systemically using the virus polymerase inhibitor 
acyclovir. Exclusive local treatment is recommended only for the treatment of recurrent, 
circumscribed lesions. Viruses can develop resistance during treatment, but fortunately, 
resistant viruses are epidemiologically not relevant to date [Modrow, 2002]. 
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1.8 Varicella-Zoster Virus 
 
Varicella-zoster virus, like HSV, 
belongs to the herpesvirus subfamily of 
α-herpesviridae.  
Among these, VZV is unique in its T-
cell tropism, which allows dissemination 
of the virus to the skin. Its chronological 
designation is HHV-3 [Arvin, 2001].  
 
1.8.1 Epidemiology 
VZV is a ubiquitous virus, producing annual varicella (chickenpox) epidemics during winter 
and spring in temperate climates. Epidemic years are usually followed by years with a lower 
incidence. In contrast, reactivation (resulting in shingles) exhibits no seasonal pattern.  
Without immunization, the incidence of chickenpox has a peak in early childhood. The IgG 
seroprevalence to VZV is increasing with increasing age. In temperate climates, only 
approximately 5% of all individuals remain susceptible for primary VZV infection at the age 
of 30 years [Arvin, 2001]. Wutzler et al. investigated in the seroprevalence of IgG antibodies 
to VZV in the German population. They found that from an age of 11 years, more than 90% 
of the study subjects were positive for VZV IgGs [Wutzler et al., 2001]. Data from the RKI, 
Germany, confirm these findings; 95% of the study participants were reported to have been 
VZV antibody-seropositive already at the age of 17 years. At the age of 40 years, 
seropositivity reaches 100% [RKI, 2000c]. Interestingly, only about 50% of seropositive 
individuals give a clinical history of varicella, indicating either asymptomatic or mild disease 
or misdiagnosis [Arvin, 2001].  
                                                          
†† Image by Dr Frank Fenner, Australian National University, Canberra, http://online.anu.edu.au/ 
Figure 7: Electron micrograph of VZV†† 
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Given the high incidence of VZV infection, most adults are at risk for VZV reactivation, 
which leads to herpes zoster (shingles). Increased age is strongly correlated with the 
occurrence of shingles. A population-based, prospective cohort study reported that incidence 
continued to rise after the age of 60 years, such that the lifetime risk to develop shingles is as 
high as 50% among those who survive to 85 years [Schmader et al., 1998]. 
 
1.8.2 Pathogenesis 
Primary infection is presumed to start with inoculation of respiratory mucosa, and a 
subsequent first viral replication in regional lymph nodes. This is followed by a primary 
viremia during which VZV is transported to cells of the reticuloendothelial system, and a 
subsequent second phase of replication. Acute illness occurs at the start of a second viremia, 
during which VZV is disseminated to cutaneous epithelial cells. Cell-associated viremia 
continues after the initial skin lesions develop. Cellular tropism of VZV includes T-
lymphocytes, skin cells and cells of the dorsal root ganglia. Although infectious virus has 
rarely been detected from nasopharyngeal secretions during the preeruptive phase, VZV must 
also be transported back to respiratory mucosa because it can already be transmitted prior to 
the occurrence of cutaneous lesions. Direct contact with cutaneous lesions provides another 
mechanism for VZV transmission. After primary infection, epidermal cells become the major 
target for further replication of the virus, and the typical lesions (liquid-filled, small vesicles) 
occur. In immunocompromised persons, disseminated infections are seen, including lung, 
liver, CNS, and other organs.  
Primary infection is followed by latency in the dorsal root ganglia, but it is still unknown how 
the virus reaches this site. Reactivation leads to the so-called shingles (herpes zoster), a 
vesicular rash usually involving the dermatomal distribution of a single sensory nerve. 
Pathologic changes include inflammatory necrosis of the dorsal root ganglia, motor and 
sensory root degeneration, neuritis, and segmental myelitis. In immunocompromised 
individuals, reactivated VZV disease is similar to progressive varicella [Modrow, 2002; 
Arvin, 2001; RKI, 2000c].  
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1.8.3 Clinical Features 
1.8.3.1 Varicella 
Primary infection of the host leads to varicella, commonly called chickenpox. This is a highly 
contagious, febrile illness characterized by a generalized, pruritic vesicular rash, which is 
most prevalent in childhood where it represents the most common preventable infectious 
disease in Germany [RKI, 2000c].  
After an incubation period of 10-21 days, typical varicella exanthemas begin on the scalp, 
face, or trunk, followed by progression to macules and fluid-filled vesicles, which are usually 
intensely pruritic. Lesions of mucous membranes are common. The number of days of new 
lesion formation ranges from 1-7 days followed by final crusting and healing. In children, the 
most common complications are caused by secondary infections with staphylococcus aureus 
and streptococcus pyogenes whereas in healthy adults, varicella pneumonia as well as the 
hemorrhagic form of chickenpox is a serious concern. Generally, immunocompromised 
persons are at higher risk for progressive varicella than healthy persons [Modrow, 2002; 
Arvin, 2001]. 
 
1.8.3.2 Shingles 
Reactivation of VZV leads to herpes zoster, commonly called shingles. Clinically 
symptomatic varicella disease is not necessary for a reactivation of the virus. Furthermore, 
shingles can also occur in patients vaccinated against varicella [RKI, 2000c].  
Herpes zoster, which is usually observed in elderly or immunocompromised individuals, is a 
vesicular rash restricted to a dermatomal distribution of one or more adjacent sensory nerves. 
Cutaneous lesions are often accompanied by pain, acute neuritis, and pruritus, and they may 
progress to confluent lesions with involvement of the whole dermatome. Final crusting and 
healing occurs approximately after 2 weeks but may require up to 4-6 weeks.  
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In the elderly, the most common complication is postherpetic neuralgia, a severe, invalidating, 
chronic pain. VZV reactivation in immunocompromised individuals leads to a progressive 
form of shingles whereas complications in younger patients are rare [Modrow, 2002; Arvin, 
2001].  
 
1.8.4 Diagnosis 
Usually, there is no need for specific diagnostic analyses because the clinical picture is typical 
for chickenpox or shingles [RKI, 2000c].  
If laboratory methods are required, detection of viral proteins, viral isolation in tissue culture 
and detection of DNA using PCR can be performed. A scraping of skin vesicles with 
subsequent virus isolation is necessary for a definitive diagnosis. Further processes include 
the serological determination of anti-VZV IgG and IgM antibody concentrations using 
enzyme immunoassays [Modrow, 2002; Arvin, 2001]. 
 
1.8.5 Management of VZV Infection 
The nucleoside analog acyclovir has been proven to be an effective drug for the treatment of 
primary VZV infection or its reactivation, in healthy as well as in immunocompromised 
patients. Other nucleoside analogs, which are licensed for treatment of shingles, are 
famciclovir and valaciclovir [Modrow, 2002; Arvin, 2001]. Preventing VZV transmission is 
difficult as infected persons are contagious prior to the onset of varicella. Passive IgG 
antibody preparations are administered to people at risk for serious varicella, but studies are in 
disagreement about their efficacy [Arvin, 1996].  
However, VZV is the first human herpesvirus for which a vaccine has been developed. The 
burden of disease can be diminished by this immunization using a live attenuated varicella 
vaccine, which successfully protects against primary infection [Asano, 1996; Arvin and 
Gershon, 1996]. Furthermore, this vaccine has the potential to lower the risk to develop 
herpes zoster [Gershon et al., 1996]. 
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1.9 Epstein-Barr Virus 
Tony Epstein and Yvonne Barr were 
the first to find Epstein-Barr virus 
(EBV) in Burkitt’s lymphoma in the 
1950s, thereby identifying EBV as 
the first candidate human tumor 
virus [Rickinson and Kieff, 2001].  
Belonging to the herpesvirus 
subfamily of γ-herpesviridae, genus 
lymphocryptovirus, its formal 
designation is HHV-4.  
 
1.9.1 Epidemiology 
Like all herpesviruses, EBV is a ubiquitous virus, which is widespread in the human 
population. Its site of latency are resting memory B cells [Cohen, 2000].  
In developing countries, most people become infected within the first three years of life, and 
EBV antibody seroprevalences reach up to 100% within the first decade of life. In the 
developed Western world, however, only approximately 50% are seropositive within the first 
decade of life. They become infected later in life through intimate oral contact, and only about 
5% of adults in developed countries remain EBV-uninfected [Berger, 2003; Rickinson and 
Kieff, 2001]. These seronegative individuals constitute a population from which rare cases of 
classic infectious mononucleosis are drawn [Rickinson and Kieff, 2001].  
Reviewed by Cohen [2000], IgG antibodies to EBV have a worldwide seroprevalence of more 
than 90% in the adult population.  
 
 
 
 
Figure 8: Epstein-Barr virus (dark sphere; Travis, 2002) 
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1.9.2 Pathogenesis 
The incubation period for infectious mononucleosis is 4-6 weeks, but little is known about 
what happens after oral transmission of EBV. One theory is that primary replication takes 
place at a specialized oropharyngeal site, with a subsequent transfer into the B cell system. An 
alternative hypothesis is that EBV primarily targets B cells infiltrating the oropharyngeal 
mucosa, followed by viremia to permissive epithelium. However, EBV infection is not 
necessarily associated with disease, and even long-term carriers with no history of infectious 
mononucleosis secrete low levels of infectious virus.  
B cells are the site of latency of EBV. Therefore, reactivation can occur at any mucosal site 
with a B cell infiltrate. After primary infection, EBV-positive B cells remain detectable even 
in asymptomatic carriers. So far, the complexity of EBV strategies is not fully understood and 
any current attempt to map EBV pathogenesis must be regarded as preliminary [Rickinson 
and Kieff, 2001]. 
 
1.9.3 Clinical Features 
EBV has been linked to several medical conditions for decades, but frequently, its clinical 
importance for onset of certain diseases or malignancies is only assumed [Rickinson and 
Kieff, 2001; Okano, 1998; Gaffey and Weiss, 1992].  
 
1.9.3.1 Infectious Mononucleosis 
Infectious mononucleosis occurs in rare cases during primary infection with EBV. This 
disease is more prevalent in adolescents and adults whereas children very rarely develop 
infectious mononucleosis [Cohen, 2000]. Symptoms can range from mild fever to several 
weeks of pharyngitis, lymphadenopathy and general malaise [Gaffey and Weiss, 1992]. In 
about half of the cases, splenomegaly occurs [Modrow, 2002]. However, there is evidence 
that these symptoms may occur due to immunopathological events (activation of cytokines) 
rather than be the result of viral replication [Rickinson and Kieff, 2001]. 
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1.9.3.2 Burkitt’s Lymphoma 
There are three different kinds of Burkitt’s lymphoma; (i) an endemic form that was first 
described by Denis Burkitt in Africa, (ii) a sporadic form causing rare childhood lymphomas, 
and (iii) a form, which appears in HIV-infected individuals.  
The endemic form shows the strongest association with EBV. Endemic Burkitt’s lymphoma is 
a common childhood cancer in Africa that is more common in males than in females. In 
contrast to other lymphomas, Burkitt’s lymphoma occurrs at extranodal sites. This 
malignancy occurs mainly in the jaw in association with molar tooth development. Other sites 
include the orbit, abdomen, or CNS. To date, c-myc expression and EBV infection are the 
best documented etiological factors of endemic Burkitt’s lymphoma, for which a multistep 
pathogenesis is accepted [Rickinson and Kieff, 2001; Gaffey and Weiss, 1992]. 
 
1.9.3.3 Lymphomas in Immunodeficient Patients 
The clearest evidence for the oncogenicity of EBV in its natural host comes from the fatal B 
cell lymphoproliferations that are seen in immunocompromised persons with impaired T cell 
immunity, therefore being unable to control the proliferation of EBV-infected B cells [Cohen, 
2000]. EBV-associated lymphomas (especially CNS lymphomas) occur in congenitally 
immunodeficient patients as well as after transplantations and in HIV-infected individuals, in 
which the incidence can be as high as 60% [Modrow, 2002; Rickinson and Kieff, 2001].  
 
1.9.3.4 Hodgkin’s Disease 
EBV is frequently found in Hodgkin’s lymphomas’ tumor cells. Several studies reported a 
clearly increased risk for Hodgkin’s disease in individuals with a history of infectious 
mononucleosis. However, a variety of these tumors are EBV-negative and the proportion of 
EBV to be present in Hodgkin’s disease varies between the different histologic types from 
very few to 80% [Rickinson and Kieff, 2001]. So far, the pathogenetic role of EBV in 
Hodgkin’s disease still remains controversial [Gaffey and Weiss, 1992].  
Virological Background 
 
40
1.9.3.5 Nasopharyngeal Carcinoma 
Nasopharyngeal carcinomas are seen all over the world, with an age-adjusted incidence in 
Europe of less than 0.5 per 100 000 per year. The regular presence of the EBV genome in 
cells of this type of tumor, and higher antibody titers in tumor patients lead to the suggestion 
that EBV might be involved in nasopharyngeal carcinoma pathogenesis [Rickinson and Kieff, 
2001]. However, there is increasing evidence that this tumor type arises independently of 
EBV, because the tumor usually occurs in the fourth decade of life or later, and EBV infection 
is known to occur prior to adulthood in more than 90% of the population [Cohen, 2000].  
However, although ongoing studies are still controversial, this possible relation is used as a 
diagnostic and prognostic tool in disease monitoring. Since patients with nasopharyngeal 
carcinomas in contrast to healthy persons have elevated anti-EBV IgA, these tumors can be 
detected at an early stage by screening for these antibodies [Rickinson and Kieff, 2001]. 
 
1.9.4 Diagnosis 
During primary infection, the immune system of the host produces detectable IgG, IgM and 
IgA antibodies to early antigens of EBV. The detection of IgM and IgA antibodies is 
indicative for an acute infection whereas IgG antibodies point at a previous infection. Another 
diagnostic method is the detection of viral DNA in B cells of the patients [Modrow, 2002].  
 
1.9.5 Management of EBV Infection 
Acyclovir used to be the choice treatment of EBV infection, since it was able to inhibit viral 
replication in vitro. However, clinical use did not show any effect on the clinical outcome of 
EBV infection [Cohen, 2000]. Therapy of EBV infection is restricted to therapy of 
malignancies caused by this virus. Burkitt’s lymphomas show a good respond rate to 
chemotherapy [Modrow, 2002; Cohen, 2000]. So far, no vaccinations are available for the 
prevention of primary EBV infection [Modrow, 2002; Rickinson and Kieff, 2001]. 
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2 Material and Methods  
The following section describes the recruitment of the study population between December 
2002 and April 2004 as well as the samples available for analyses.  
 
Blood samples for PCR 
and IHC analyses
n=71
Tumor tissues for IHC analyses
n=72
Completed interview
n=54
No interview; reason:
•Failure to contact (n=16)
•Deceased (n=1)
•Refusal (n=5)
5 patients did not provide
a blood sample
4 samples were not large enough
for a formaldehyde probe
Tumor tissues for PCR analyses
n=76
Study
Participants
N=76
7 patients
excluded
Patients, total
n=83
 
Figure 9: Study design, recruitment of the study population and material available for analyses 
* brain tumor diagnosed prior to the present study period (prevalent cases); 
   PCR, polymerase chain reaction; IHC, immunohistochemistry 
Blood samples for PCR and 
ELISA 
71 
*
4 samples were too small to 
prepare paraffin slides 
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2.1 Study Design and Recruitment of the Study Population 
The present study included patients, who underwent surgery of primary brain tumors at the 
Department of Neurosurgery, University of Heidelberg, between December 2002 and April 
2004. Inclusion in the study was not dependent on patients’ age or residence.  
The reference date for all analyses performed was the date of surgery.  
Of the tumor samples collected from December 2002 to May 2003, ten were collected 
anonymously; information was only obtained about histology, gender and year of birth. 
Inclusion in the study of these samples without informed consent, however, is in concordance 
with the national ethics commission [Zentrale Ethikkommission Deutschland, 2003]. 
Surgical specimens were collected from 83 brain tumor patients. Only persons with incident 
primary brain tumors were included. Therefore, seven patients (4 gliomas, 2 meningiomas, 1 
medulloblastoma) had to be excluded from the study, because their tumors were diagnosed 
prior to the study period. As described above, brain tumors are unequivocally no homogenous 
group of cancer. Therefore, all analyses were stratified by tumor type (e.g., gliomas, 
meningiomas, and acoustic neurinomas), and only some analyses were additionally pooled. 
The study finally included 76 brain tumor patients. Patients gave informed consent after they 
received adequate verbal or written clarification. 
 
Study Participants
N=76
Tumor tissue DNA
n=76
Tumor tissues paraffin slides
n=72
Blood sample DNA
n=71
Completed interview
n=54
Gliomas n=37
Meningiomas n=29
Acoustic neurinomas n=6
Gliomas n=23
Meningiomas n=26
Acoustic neurinomas n=5
Gliomas n=34
Meningiomas n=31
Acoustic neurinomas n=6
Gliomas n=39
Meningiomas n=31
Acoustic neurinomas n=6
 
Figure 10: Samples available for study analyses, stratified by tumor type 
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2.2 Questionnaire  
Interviews were performed directly after brain tumor surgery in the hospital if possible. 
Otherwise, patients were contacted by letter, followed up by up to four more letters and 
several phone calls if necessary, and telephone interviews were performed.  
The standardized questionnaire included questions about previous herpesvirus and common 
infections, hereditary diseases, previous cancers and other medical conditions. Furthermore, 
vaccinations as well as contact to animals, a complete occupational history and demographic 
data were assessed, all of which are controversially discussed as putative risk factors for 
either brain tumor development or HCMV infection or reactivation.  
To exclude that reported seizures, hearing impairments and tinnitus were early symptoms of 
the present primary brain tumor, these conditions were only taken into account if they 
occurred two years and more prior to the present tumor.  
The question on tinnitus addressed its role as an early symptom of acoustic neurinoma. At 
first place, only patients affected by acoustic neurinoma were asked about the occurrence of 
tinnitus. Later on in the study, however, all patients were asked to answer that question. 
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2.3 Laboratory Material 
2.3.1 Brain Tumor Samples 
With informed consent of the patients (except of those, who were collected anonymously, cf. 
above), samples of glioma, meningioma, and acoustic neurinoma were obtained from the 
Department of Neurosurgery, University of Heidelberg, between December 2002 and March 
2004. One part of the sample was immediately stored at -80°C and in addition, if enough 
tumor tissue was available, a piece was put in formaldehyde for further preparation.  
Altogether, 76 primary brain tumor samples were collected (39 gliomas, 31 meningiomas, 6 
acoustic neurinomas).  
Of the 76 tumor samples, 72 (94.7%) were large enough to prepare a formaldehyde-fixed 
sample for the preparation of paraffin slides (37 gliomas, 29 meningiomas, 6 acoustic 
neurinomas).  
Furthermore, four of the brain tumor samples were prepared for cell culture, grown in short-
term cultures (see below) and frozen in liquid nitrogen.  
 
2.3.2 Blood Samples 
In addition to the brain tumor samples, a heparinized or EDTA blood sample (3-7 ml) was 
provided from 71 (93.4%) of the patients at the time of surgery or two days after surgery at 
the latest, yet prior to chemotherapy or irradiation (34 gliomas, 31 meningiomas, 6 acoustic 
neurinomas). Blood clot and serum were separated and stored at -80°C.  
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2.3.3 Equipment 
Centrifuge for Eppendorf tubes 5415   Eppendorf, Hamburg 
Electrophoresis chamber, horizontal   Life Technologies, Gaithersburg, USA 
(Horizon 11•14)  
Hood: Template TM Tamer     Q•Biogene, Heidelberg 
Image Master® VDS      Amersham Biosciences, Freiburg 
Laboratory scale 1216     MP Sartorius, Göttingen 
Measuring cylinder 50-500 ml    VIT LAB, Seeheim-Jugenheim 
Microwave 600W      Bosch, Lohr 
Nalgene TM Laptop Cooler     Bender & Hobein AG, Zürich, CH 
Picofuge       Stratagene, Amsterdam 
Pipettes (Eppendorf)      Eppendorf, Hamburg 
Pipettes (Finnpipette)     Labsystems, Helsinki 
PTC-100 Programmable Thermal Cycler   MJ Research Inc. California, USA 
Table centrifuge Biofuge 13R    Kendro Laboratory Systems, USA 
Table centrifuge Sigma 1-15K    Sigma, Osterode am Harz 
Vortex Genie 2TM      Bender & Hobein AG, Zürich, CH 
Power supply      Biotech-Fischer, Pittsburgh, USA 
 
2.3.4 Consumables 
Eppendorf tube 0.5; 1.5; 2 ml    Eppendorf, Hamburg 
Erlenmeyer flask 250 ml     Schott, Mainz 
Falcon tubes 15 ml      Becton/Dickinson, Franklin Lakes, USA 
Measuring cylinder     Bürkle, Lörrach 
Parafilm “M”       American National Can., Chicago 
Pipette tips, unsterile     Greiner Bio-one, Frickenhausen 
RNAse-free pipette tips 10/100/1000 µl  Nerbe-Plus, Winsen-Luhe 
Tumbler       Schott, Mainz 
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2.3.5 DNA Extraction 
REDExtract N-AmpTM Blood PCR Kit Sigma-Aldrich Chemie GmbH, Taufkirchen 
High Pure PCR Template Preparation Kit Roche, Mannheim 
Isopropanol     Merck, Darmstadt 
 
2.3.6 PCR and Gel Electrophoresis 
2.3.6.1 Oligonucleotides 
All Oligonucleotides were obtained from Sigma-Ark GmbH, Darmstadt. 
Name    Sequence (5’-3’) 
GAPDH1   TTA ACT CTG GTA AAG TGG ATA TTG TTG CCA 
GAPDH2   TAT TTG GCA GGT TTT TCT AGA CGG CA 
EL    TAA CGG GTA CTG TGG GTG TTG G 
ER    ACC AAG TAC CCC TAT CGC GTG T 
IL    CTG CCC AGC AGA TAA GTG GTG T 
IR    ATC ATC TGC ACC TCG ATG AAG C 
EXTL    CGA GGC TAC GCT TCC TAC AC  
EXTR    GCG TAC GAG GAA CTC TTT GC 
INTL    GAC GAC CCT TTC GAT GAG TG 
INTR    GCC CAA CAA CTG GTG GTA AC 
IEN1    ACA TCT TTC TCG GGG TTC TCG TTG C 
IEN2    GTC CTC TGC CAA GAG AAA GAT GGA C 
IEN3    TTG AGG GAT TCT TCG GCC AAC TCT G 
IEN4    TCT CCT GTA TGT GAC CCA TGT GCT T 
EXT_F   TCC AAC ACC CAC AGT ACC CGT 
EXT_R   CGG AAA CGA TGG TGT AGT TCG 
INT_F    CGC CGC GGC AGC ACC TGG CT 
INT_R    GTA AAC CAC ATC ACC CGT GGA 
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2.3.6.2 Reagents and Buffers 
Agarose      Life Technologies, Eggenstein 
Aqua ad injectabila     Braun, Melsungen 
DNA 100 bp Ladder     Life Technologies, Gaithersburg, USA 
DNA agarose gel 0.3-2% (w/v)   agarose 
50x electrophoresis buffer 
2 M Tris, pH 7.8 
0.25 M sodium acetate 
0.05 M EDTA 
Electrophoresis buffer  ammonium formate buffer; 0.05 M; pH 4.0: 
  ammonia, concentrated; 2.9 ml 
formic acid, 98%; 2.0 ml 
distillated water ad 1000 ml 
adjust pH-value with concentrated formic 
acid to pH ≤4.0  
Ethidium bromide     Sigma, Deisenhofen 
10 mg EtBr/ml H2O, stored dark at 4 °C 
Gene Ruler 100 bp DNA Ladder   MBI Fermentas, St. Leon-Rot 
Loading Dye Solution (6x)    MBI Fermentas, St. Leon-Rot 
       50% sucrose 
0.15% bromine phenol blue 
0.1% SDS, in H2O 
Oligonucleotides    Sigma-Ark GmbH, Darmstadt 
PCR Supermix     Life Technologies, Eggenstein 
22 mM Tris-HCl, pH 8.4 
5 mM  KCl 
1.65 mM MgCl2 
220 µM dGTP 
220 µM dATP 
220 µM dTTP 
220 µM dCTP 
22 U/ml Taq-Polymerase 
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2.3.7 Cell Culture, Cell Fixation 
PBS      8.0 g  NaCl 
      0.2 g KH2PO4  
      1.2 g Na2HPO4 
      0.2 g  KCl  
ad 100 ml H2O, pH 7.2-7.5 
Dulbecco’s Modified Eagle’s Medium Sigma, Deisenhofen 
(DMEM) 
Fetal Calf Serum    Sigma, Deisenhofen 
(FCS) 
Penicillin/Streptomycin   Gibco, Invitrogen Corporation, Karlsruhe 
(Pen/Strep) 
Trypsin EDTA    Gibco, Invitrogen Corporation, Karlsruhe 
DMEM+     DMEM  
10% FCS 
1% Pen/Strep 
Methanol     Merck, Darmstadt 
Aceton     Merck, Darmstadt 
Dimethylsulfoxide    Sigma, Deisenhofen 
(DMSO) 
Freezing medium for cells   60% DMEM  
10% DMSO  
30% FCS 
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2.3.8 Immunohistochemistry 
Paraffin sections were prepared from formaldehyde-fixed tumor tissue samples at the 
Division Cellular and Molecular Pathology, DKFZ. 
 
2.3.8.1 Antibodies  
anti-Cytomegalovirus, Early Antigen  Novocastra, Newcastle upon Tyne, UK 
NCL-CMV-EA 
mouse monoclonal antibody 
anti-Cytomegalovirus, pp65 antigen   Novocastra, Newcastle upon Tyne, UK 
        NCL-CMVpp65 
        mouse monoclonal antibody 
anti-Cytomegalovirus, IE-1 antigen   Chemicon, Temecule, USA  
MAB810 
mouse monoclonal antibody  
2.3.8.2 Chemicals 
AEC+ Substrate-Chromogen    Dako Cytomation, Carpinteria, USA 
Antigen Retrieval Accessory Kit   Biogenex, San Ramon, USA 
Antigen Retrieval Citra Solution   Biogenex, San Ramon, USA 
Aquatex® aqueous mounting medium  Merck KGaA, Darmstadt  
Avidin-Biotin Blocking Kit    Biogenex, San Ramon, USA 
Common Antibody Diluent    Biogenex, San Ramon, USA 
Ethanol, absolute     Riedel-de Haen, Seelze 
Negative Control for Mouse Antibody  Biogenex, San Ramon, USA 
Peroxide Block     Biogenex, San Ramon, USA 
Super Sensitive HRP Label    Biogenex, San Ramon, USA 
Super Sensitive Mouse Link    Biogenex, San Ramon, USA 
TRIZMA® Pre-set crystals    Sigma, Saint Louis, USA 
Xylene      Sigma-Aldrich, Seelze 
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2.3.9 ELISA Reagents 
Enzygnost® System (Dade Behring, Marburg): 
IgG Detection     IgM Detection 
Enzygnost Anti-CMV/IgG test plate   Enzygnost Anti-CMV/IgM test plate 
Anti-CMV Reference P/P 
Anti-CMV Reference P/N    Anti-CMV Reference P/N 
Enzygnost Anti-VZV/IgG test plate    Enzygnost Anti-VZV/IgM test plate 
Anti-VZV Reference P/P 
Anti-VZV Reference P/N    Anti-VZV Reference P/N 
Enzygnost Anti-HSV/IgG test plate    Enzygnost Anti-HSV/IgM test plate 
Anti-HSV Reference P/P 
Anti-HSV Reference P/N     Anti-HSV Reference P/N 
Enzygnost Anti-EBV/IgG test plate    Enzygnost Anti-EBV/IgM test plate 
Anti-EBV Reference P/P 
Anti-EBV Reference P/N     Anti-EBV Reference P/N    
Anti-Human-IgG/POD Conjugate    Anti-Human-IgM/POD Conjugate 
Sample Buffer POD     Sample Buffer POD 
Conjugate Buffer Microbiol.    Conjugate Buffer Microbiol. 
RF Absorbent 
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2.4 Methods 
2.4.1 Sample Preparation 
2.4.1.1 Brain Tumor Samples  
Brain tumor samples were obtained in isotonic sodium chloride (0.9%) immediately after 
surgery at the Department of Neurosurgery, University of Heidelberg. All brain tumors were 
histologically diagnosed at the Pathological Institute, University of Heidelberg. The samples 
were stored at -80°C for further preparation. In case the sample was large enough, one part 
was stored in formalin (4%) for preparation of paraffin sections. For analyses to validate the 
methods performed, short-term cultures were prepared from four of the collected tumors from 
which suitable material was available (two gliomas, two meningiomas; cf. below).  
 
2.4.1.2 Cell Culture 
Cell lines provide a useful system for further understanding the biology of certain tissues, e.g. 
neoplasms. Furthermore, the availability of unlimited numbers of cells and the possibility of 
performing multiple, repeated experiments over long time intervals provide a valuable 
resource for studies on pathogenesis or therapy of malignancies.  
 
2.4.1.2.1 Preparation of Short-term Cultures 
Surgical specimens of primary brain tumors were obtained immediately after surgery. In this 
study, two meningiomas WHO grade I, one astrocytoma WHO grade III and one glioma with 
unknown grading were prepared for short-term culture. For this, one part of the tissue sample 
was minced to small pieces. Afterwards, hackled tissue was prepared as a fine cell suspension 
Material and Methods 
 
52
by digestion with trypsin/EDTA for 5 minutes at room temperature. Cells were washed with 
DMEM+ (DMEM containing 10% FCS and 1% Penicillin/Streptavidin), and transferred into 
culture flasks containing DMEM+. All short-term cultures were incubated at 37°C in a 
humidified atmosphere of 5% CO2. At the time the cells reached confluence, they were 
washed with phosphate buffered saline (PBS), treated with trypsin/EDTA and then transferred 
into new flasks containing DMEM+.  
 
2.4.1.2.2 Cultivation of Human Skin Fibroblasts 
Human skin fibroblasts were kindly provided by PD Dr. Tomakidi, Medical Faculty, 
University of Heidelberg.  
Cultivation of these fibroblasts took place at 37°C in a humidified atmosphere of 5% CO2. 
DMEM+ was applied. When confluence was achieved, the medium was removed, cells were 
briefly washed in PBS and the monolayer was removed using trypsin/EDTA at 37°C. 
Afterwards, cells were transferred into new culture flasks in a ratio of 1:10.  
 
2.4.1.2.3 Freezing and Thawing of Cells 
For permanent storing in liquid nitrogen, cells were removed from the culture flask by 
treatment with trypsin/EDTA, and resuspended in DMEM+. Afterwards, the cell count was 
determined, cells were centrifuged at 1000 rpm for 10 min and the supernatant was removed. 
Cells were resuspended in 1 ml of freezing medium on ice and filled into kryo vials. These 
were enveloped by several tissue plies to assure a slow freezing process. After 24 h in -80°C, 
kryo vials were taken into liquid nitrogen.  
For reculturing, cells were taken out of the liquid nitrogen, resuspended in DMEM+ and 
centrifuged at 1000 rpm for 10 min. After removal of the supernatant, cells were transferred 
into a culture flask containing DMEM+ and incubated at 37°C in a humidified atmosphere of 
5% CO2.  
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2.4.1.2.4 Cell Fixation on Cover Glasses for Immunohistochemistry 
Trypsinized cells were transferred into 6-well plates containing two cover glasses each at a 
concentration of 1x105 cells per well. When confluence was achieved, DMEM+ was removed 
and fixation of the cells grown on the cover glasses took place by incubation in methanol (10 
min at -20°C). Afterwards, methanol was removed and cells were incubated in acetone for 10 
min at -20°C. After removal of the acetone, fixated cells were stored at -80°C until further 
analyses.  
 
2.4.1.2.5 HCMV Infection of Human Skin Fibroblasts 
For HCMV infection, medium was removed and virus suspended in DMEM was inoculated to 
the cell layer at a MOI (multiplicity of infection) of one infectious unit per cell. Fibroblasts 
were incubated at 37°C (humidified atmosphere, 5% CO2) for 1.5 h. Afterwards, the virus was 
removed thoroughly by washing the cells thrice with PBS. Finally, DMEM+ was added, and 
cells were stored at 37°C in a humidified atmosphere of 5% CO2.  
Fig. 11 shows typically enlarged fibroblasts (cytomegalia) 5 days after HCMV infection, 
which served as positive controls, and mock-infected fibroblasts, which served as negative 
controls for immunohistochemical analyses.  
 
A B
 
Figure 11: Human skin fibroblasts 5 days after HCMV infection (MOI 1). (A) showing typical cytomegalia 
and inclusions. In contrast, mock-infected fibroblasts did not show any cytomegalia (B). 
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2.4.1.3 Blood Samples 
3-7 ml of blood samples containing EDTA or heparin were provided by 71 (93.4%) of the 
brain tumor patients. The samples were centrifuged at 1000 rpm for 10 min. Serum and blood 
clot were separated, and stored in kryo vials at -80°C for further analyses.  
 
2.4.2 DNA Extraction from Tumor Tissue 
DNA isolation took place using the “High Pure PCR Template Preparation Kit”. With this 
method, tissue is lysed by a specific buffer, followed by a short incubation with proteinase K 
in the presence of chaotropic salts that immediately inactivate all nucleases. Nucleic acids 
bind to a glass fiber fleece and remain bound, while several washing steps remove 
contaminating small molecules. Finally, remaining DNA is removed by a low salt elution.  
First, minced tissue was taken into a mix of lysis buffer and proteinase K, and incubated at 
55°C overnight until all tissue was solubilized. Binding buffer was added and incubation took 
place at 72°C for 10 min in a prewarmed water bath. After addition of isopropanol, the 
solution was pipetted into a glass fiber-covered filter tube, centrifuged for 2 min at 8000 rpm 
and the flowthrough was discarded. Twice adding washing buffer and centrifugation as 
described above followed this step. Finally, DNA was eluted with twice the recommended 
amount of elution buffer to increase the final volume of DNA. Now, extracted tissue DNA 
could directly be used for PCR analyses or stored at 4°C.  
 
2.4.3 DNA Extraction from Blood Samples  
DNA isolation was performed using the “REDExtract-N-AmpTM Blood PCR Kit”. First, 20 µl 
lysis buffer were pipetted in Eppendorf tubes, and 10 µl of the whole blood sample were 
added. After incubation for 5 min at room temperature, 180 µl of neutralization buffer was 
added and resuspended thoroughly. Finally, extracted DNA could be stored at 4°C or directly 
used in PCR analyses (as described below). 
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2.4.4 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) is a method for in vitro-amplification (multiplication) 
of specific DNA fragments. The American chemist K. B. Mullis, who received the Nobel 
price for chemistry for this work in 1993, developed this method. With this very sensitive 
technique, a defined double-stranded DNA fragment can be amplified (i.e., multiplied) a 
million times out of a certain double stranded DNA fragment within a few hours.  
A template DNA (i.e., DNA that has to be amplified), the thermo-stable taq-polymerase 
(isolated from the thermo-stable bacterium Thermus aquaticus), specific primers and 2’-
desoxynucleosid-5’-triphosphates (dNTPs) for synthesizing new DNA strands are needed for 
PCR. In addition, free cations (commonly magnesium chloride, MgCl2) are added and a 
buffer, which keeps the pH-value constantly at 7.0-7.2.  
The principle of this method is as follows: 
First, the double-stranded template DNA is denaturated. After that, the specific primers added 
attach to their complementary sequences on the single-stranded DNA (‘annealing’). The DNA 
polymerase starts to synthesize new double strands starting from both primers with the aid of 
dNTPs (‘extension’). This cycle is repeated 30-40 times. At the end, a multitude of amplified 
template DNA is available. This amplified DNA can now be identified according to its size 
(measured in base pairs=bp) after electrophoretic separation via agarose gel.  
For increasing specificity, PCR products can be blotted and hybridized following PCR. For 
increasing sensitivity and proving specificity, the so-called nested PCR (nPCR) can be 
performed, in which the first product is amplified again in a second PCR with primers that lay 
within the first primer pair.  
PCR in all protocols used in this study (except the protocol according to Mangano et al., 
1992) was performed using Supermix (Invitrogen), which contains tris-salt acid, potassium 
chloride, MgCl2, dNTPs and taq polymerase. The basic mix for the first PCR contained 45 µl 
Supermix, 0.2 µl per primer and 2 µl template DNA. For nested PCR, 1 µl PCR product was 
used instead of template DNA. In GAPDH PCR, 5 µl of template DNA were applied.  
In the protocol according to Mangano et al. [1992], 10 µl of Readymix (Sigma-Aldrich), 7.6 
µl double-distilled water, 0.2 µl per primer and 2 µl template DNA (and 1 µl PCR product in 
the nested PCR, respectively) were used.  
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Along with the samples being amplified, a positive control (HCMV DNA and HeLa DNA, 
respectively, for GAPDH PCR) and a negative control (Aqua ad injectabilia) were run to 
control for contamination and successful DNA amplification.  
 
Primers and temperature protocols of all PCRs performed are described in more detail in the 
following sections. The same PCR temperature protocols were used for first and second DNA 
amplification in nested PCR analyses. Amplified DNA fragments were segregated by agarose 
gel electrophoresis and visualized under UV light.  
Primers used for the detection of HCMV DNA were synthesized from HCMV strain AD169. 
Numbers in brackets state the position of each oligonucleotide within the genome of HCMV. 
All primers are given in 5’Æ 3’ direction. 
 
2.4.4.1 Quality Assessment in Brain Tumor DNA 
GAPDH is an enzyme of glycolysis, which exists in every human cell. A negative GAPDH 
PCR result would indicate that the isolated DNA is insufficient for PCR detection or that 
inhibitors of the PCR are present in the sample. The amplified PCR product with the primers 
chosen has a length of 670 .  
 
Table 5: PCR protocol and primers for the detection of GAPDH in brain tumor DNA 
 
Primers Sequences 
GAPDH1 TTA ACT CTG GTA AAG TGG ATA TTG TTG CCA 
GAPDH2 TAT TTG GCA GGT TTT TCT AGA CGG CA 
 
Reaction Mix 
 Supermix 45 µl 
 Primers, each 0.3 µl 
 Template DNA 5.0 µl 
 
Temperature Protocol 
 Initial Denaturation 94°C 3 min 
 Denaturation 94°C 45 s  
 Annealing 53°C 45 s 40 cycles 
 Extension 72°C 1 min  
 Final extension 72°C 10 min 
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2.4.4.2 HCMV DNA Amplification in Brain Tumor DNA 
2.4.4.2.1 Protocols for the Detection of HCMV-specific gB (UL55) Gene Sequences 
PCR was performed to detect sequences of the HCMV-specific gB (UL55) gene, which 
encodes for one of the most highly conserved herpesvirus-common proteins [Chee et al., 
1989].  
The primers EL, ER, IL and IR amplify a segment of gB (UL55) gene. The first PCR product 
has a length of 419 bp; the second of the nPCR has a length of 167 bp. To confirm PCR 
results obtained by the first protocol, an alternative PCR was carried out with a subset of the 
brain tumor DNA samples to detect the HCMV-specific gB (UL55) gene as described by 
Cobbs et al. [2002]. The primers EXT_F, EXT_R, INT_F and INT_R recognize a segment of 
gB (UL55) gene. The external primers EXT_F and EXT_R amplified a 268 bp fragment 
within the coding region of gB (position 655-922). The internal primers INT_F and INT_R 
amplified sequences of the gB gene from position 704 to 825 (Tab. 6).  
 
Table 6: PCR primers and protocols used for the detection of two different sequences 
of the HCMV-specific gB (UL55) gene 
 
1st Protocol: 
   
Primers Sequences Genome Position 
EL TAA CGG GTA CTG TGG GTG TTG G (83747-83768) 
ER ACC AAG TAC CCC TAT CGC GTG T (84165-84124) 
IL CTG CCC AGC AGA TAA GTG GTG T (83933-83912) 
IR ATC ATC TGC ACC TCG ATG AAG C (84099-84078) 
 
Reaction Mix 
 Supermix 45 µl 
 Primers, each 0.2 µl 
 Template DNA / 
Product from 1st PCR 
2.0 µl / 
1.0 µl 
 
Temperature Protocol 
 Initial Denaturation 94°C 2 min 
 Denaturation 94°C 30 s 
 Annealing 67°C 45 s 35 Cycles 
 Extension 72°C 45 s 
 Final extension 72°C 10 min 
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Table 6 continued 
2nd Protocol (according to Cobbs et al., 2002): 
   
Primers Sequences Genome Position 
EXT_F TCC AAC ACC CAC AGT ACC CGT (634-655)  
EXT_R CGG AAA CGA TGG TGT AGT TCG (922-943) 
INT_F CGC CGC GGC AGC ACC TGG CT (684-704) 
INT_R GTA AAC CAC ATC ACC CGT GGA (825-845) 
 
Reaction Mix 
 Supermix 45 µl 
 Primers, each 0.2 µl 
 Template DNA / 
Product from 1st PCR 
2.0 µl / 
1.0 µl 
 
Temperature Protocol 
 Initial Denaturation 94°C 5 min 
 Denaturation 94°C 30 s 
 Annealing 60°C 45 s 30 Cycles 
 Extension 72°C 45 s 
 Final extension 72°C 10 min 
 
 
2.4.4.2.2 Protocol for the Detection of HCMV-specific IE-1 Gene Sequences 
Additional PCRs were performed to detect sequences of the HCMV-specific IE-1 gene using 
two different protocols (see Tab. 7).  
 
Table 7: PCR primers and protocols used for the detection of the HCMV-specific IE-1 gene 
 
1st PCR Protocol: 
   
Primers Sequences Genome Position 
EXTL CGA GGC TAC GCT TCC TAC AC (172687- 172626) 
EXTR GCG TAC GAG GAA CTC TTT GC (172932- 172912) 
INTL GAC GAC CCT TTC GAT GAG TG (172711 – 172732) 
INTR GCC CAA CAA CTG GTG GTA AC (172887 – 172868) 
 
Reaction Mix 
 Supermix 45 µl 
 Primers, each 0.2 µl 
 Template DNA / 
Product from 1st PCR 
2.0 µl / 
1.0 µl 
 
Temperature Protocol 
 Initial Denaturation 94°C 2 min 
 Denaturation 94°C 30 s 
 Annealing 64°C 45 s 30 Cycles 
 Extension 72°C 45 s 
 Final extension 72°C 10 min 
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Table 7 continued 
2nd PCR Protocol (according to Mangano et al., 1992): 
   
Primers Sequences Genome Position 
IEN1 ACA TCT TTC TCG GGG TTC TCG TTG C (172000 – 172424) 
IEN2 GTC CTC TGC CAA GAG AAA GAT GGA C (172736 – 172760) 
IEN3 TTG AGG GAT TCT TCG GCC AAC TCT G (172461 – 172485) 
IEN4 TCT CCT GTA TGT GAC CCA TGT GCT T (172606 – 172630) 
 
Reaction Mix 
 Readymix 10 µl 
 dd H2O 7.4 µl 
 Primers, each 0.2 µl 
 Template DNA / 
Product from 1st PCR 
2.0 µl / 
1.0 µl 
 
Temperature Protocol 
 Initial Denaturation 94°C 5 min 
 Denaturation 94°C 1 min 
 Annealing 67°C 2 min 35 Cycles 
 Extension 72°C 1 min 
 Final extension 72°C 7 min 
 
 
The primers EXTL, EXTR, INTL and INTR recognize a segment of the Immediate Early-1 
(IE-1) gene. The first PCR product has a length of 246 bp; the second of the nested PCR has a 
length of 177 bp. A subset of DNA samples was amplified using an alternative PCR protocol 
published by Mangano et al. [1992]. The primers IEN1, IEN2, IEN3 and IEN4 recognize a 
segment of the IE-1 (UL123) gene. The first PCR product has a length of 350 bp; the second 
of the nested PCR has a length of 170 bp.  
 
2.4.4.3 HCMV DNA Detection in Blood Sample DNA 
To exclude the possibility that positive results in brain tumor tissue were due to a 
contamination of the tissues with HCMV DNA-positive blood cells, nested PCR of 
corresponding blood samples of 71 brain tumor patients was carried out, using the protocols 
published by Cobbs et al. [2002] and Mangano et al. [1992] as described in Tab. 6 and 7.  
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2.4.5 Agarose Gel Electrophoresis 
Agarose gel electrophoresis is a method to identify the size of a DNA strand. Agarose is a 
linear polysaccharide forming a lattice in polymerized condition. By using gels with different 
concentrations of agarose, one can resolve different sizes of DNA fragments. Higher 
concentrations of agarose facilitate the separation of small DNA fragments, while low agarose 
concentrations allow resolution of larger DNA fragments. Amplified DNA strands migrate 
through an agarose gel in an electrophoresis chamber towards the anode according to their 
size (measured in base pairs=bp) and the amplified DNA strand can be identified after 
comparison with the size of a defined DNA fragment (e.g. “DNA ladder”). 
For analyses in the present study, 2.25 g of agarose were weighed out in an Erlenmeyer flask 
and 150 ml of electrophoresis buffer were added, meeting a gel of 1.5%. Afterwards, the 
Erlenmeyer flask was microwaved until total solution of agarose. Boiling retardation was 
refilled with electrophoresis buffer. After a short cooling, 10 µl of ethidium bromide (EtBr), 
which attaches to DNA double strands during electrophoresis and emits a visible light under 
UV exposure, were added. The liquid agarose was poured into a horizontal electrophoresis 
chamber containing a slot-forming comb.  
After the gel had solidified, the chamber was filled with electrophoresis buffer and the comb 
was extracted. 5 µl of loading buffer, containing a fluid with high density (e.g. glycerol) to 
allow the sample to "fall" into the slots, were added to each PCR product (except for PCR 
products that were amplified with ‘REDExtract-N-AmpTM Blood PCR Kit’, which already 
contained loading dye). 20-25 µl of the PCR product containing loading dye were pipetted 
into the slot. An electric current was applied to the chamber, starting with 80V for 5 minutes, 
then 60V for about 1.5-2 hours. The negatively charged DNA strands migrated towards the 
anode. In addition, a so-called “DNA ladder”, which shows bands of defined sizes (generally 
multiples of 50 or 100 bp), and can therefore be used to determine the size of the separated 
DNA fragments, was added into one of the gel slots. After electrophoresis, the gel was 
exposed to UV light at 254 nm for visualization of the bands, and photographed for 
documentation using a Polaroid camera. 
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2.4.6 Immunohistochemistry Using the Streptavidin-Biotin Method 
Prior to applying immunohistochemical methods, the tissues have to be fixed and embedded 
in paraffin, cut in sections of 8-10 µm and to be applied to a microscope slide.  
The principle of immunohistochemical analyses is as follows:  
After tissue preparation, the primary antibody is added. A biotinylated second antibody (so-
called ‘Link’) is attached followed by incubation with a conjugate (‘Label’) of streptavidin 
and an enzyme (horseradish peroxidase or alkaline phosphatase). Afterwards, a chromogen 
binds to the enzyme, leading to a specific staining of the target antigens in the tissue.  
Streptavidin isolated from ‘Streptomyces avidinii’ has many advantages compared to other 
methods of microchemistry. First, streptavidin has no carbon hydrate side chains that 
unspecifically bind to lectin-like substances in the tissue. Furthermore, the isoelectric point of 
streptavidin is near the neutral pH-value. Therefore, streptavidin conjugates show no 
unspecific binding in contrast to avidin conjugates or avidin complexes.  
 
2.4.6.1 HCMV Protein Detection in Brain Tumor Tissue Sections 
The occurrence of false negative results in PCR is common for the detection of HCMV. 
Several publications reported that great discrepancies can occur in results obtained by PCR 
and immunohistochemistry [Knosel et al., 2004; Cobbs et al., 2002; Gass et al., 1993]. 
Therefore, the presence of HCMV-specific proteins in brain tumor samples was further 
investigated using immunohistochemistry. 72 surgical specimens (94.7%; 32 gliomas, 29 
meningiomas, 6 acoustic neurinomas) obtained in paraffin blocks, which were cut (8 µm) and 
mounted on SuperFrost®Plus slides (Menzel Gläser, Braunschweig, Germany), were available 
for these analyses.  
Test conditions were optimized for each monoclonal antibody (see below) and all 
immunohistochemical analyses were performed blinded for tumor type. An anti-pp65, anti-
EA, and anti-IE antibody were used for analyses. The monoclonal anti-pp65 antibody 
recognizes an HCMV-specific immediate early (IE) protein, which is an important target for 
cytotoxic T-lymphocytes. Analysis of this protein is recommended by the Robert-Koch-
Institute, Germany, for early detection of reactivation or primary HCMV infection prior to 
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seroconversion [RKI, 2000a]. The anti-IE-1 antibody detects reactivation of HCMV as well as 
latent infection. During infection, IE proteins are responsible for the regulation of Early 
Antigen (EA) expression. Thus, EA are detected later in the viral replication cycle after the 
expression of IE proteins. 
Because no HCMV-positive brain tissues or cells could be obtained, HCMV-positive human 
lung (Dako) and HCMV-infected fibroblasts, respectively, were stained in parallel as positive 
controls. In addition, a negative control (uninfected lung tissue and uninfected fibroblasts, 
respectively) was run.  
 
2.4.6.1.1 pp65 Antigen 
In order to assess the possible presence of the HCMV-specific pp65, immunohistochemistry 
was performed using a monoclonal anti-pp65 antibody.  
Paraffin slides were deparaffinized in xylol for 3x10 min. Afterwards, rehydration took place 
through a decreasing alcohol series (100%, 95%, and 70% ethanol, each for 2x5 min). 
Remaining ethanol was removed with double distilled water. Endogenous enzyme activity 
was blocked by incubation with 3% peroxidase for 10 min to prevent background staining that 
would lead to false positive results, followed by washing in TBS for 3x5 min. Antigen 
retrieval took place by heating the slides in citrate buffer pH 6.0 (microwave oven, 180 W for 
10 min). This treatment increases the specific intensity of the staining and reduces 
background staining. Avidin-biotin-blocking followed a washing step in TBS (3x5 min). First, 
slides were incubated with avidin for 15 min, washed with TBS 3x5 min, incubated with 
biotin for 15 min and again washed with TBS 3x5 min. Then, the monoclonal primary 
antibody was added (NCL-CMVpp65, Novocastra) in a dilution of 1:200, and incubated at 
4°C overnight. After a wash for 3x5 min in TBS, a biotinylated secondary antibody (goat anti-
mouse) was applied for 45 min at room temperature. The secondary antibody was removed by 
washing (TBS, 3x5 min), and incubation with streptavidin-conjugated horseradish peroxidase 
took place at room temperature for 30 min. After a wash in TBS for 3x5 min, a substrate 
containing the chromogen AEC (3-Amino-9-Ethylcarbazol) was applied and incubated for 7-
10 min. Remaining chromogen was removed with double-distilled water, sections were 
counterstained in hemalaun, washed with water and mounted using an aqueous medium.  
Material and Methods 
 
63
2.4.6.1.2 IE-1 Antigen and Early Antigen 
Additional immunohistochemistry was performed using a monoclonal anti-IE-1 antibody and, 
in another protocol, a monoclonal anti-EA antibody. Paraffin slides were deparaffinized, 
blocked with 3% peroxidase and treated with citrate buffer as described above.  
Afterwards, the primary antibody (NCL-CMV-EA, Novocastra, and MAB810, Chemicon, 
respectively) was added in a dilution of 1:100, and incubated at room temperature for 2 h. 
After a wash for 3x5 min in TBS, a biotinylated secondary antibody (goat anti-mouse) was 
applied for 30 min at room temperature. This secondary antibody was removed by washing 
(TBS, 3x5 min), and incubation with streptavidin-conjugated horseradish peroxidase took 
place for 30 min at room temperature. After an additional washing step (TBS for 3x5 min), a 
substrate containing the chromogen AEC was applied and incubation took place for 7-10 min. 
Remaining chromogen was removed with double-distilled water and tissue sections were 
counterstained in hemalaun, washed again with water and mounted using an aqueous medium.  
 
2.4.6.2 HCMV Protein Detection in Cultured Brain Tumor Cells 
To control for efficiency of the method and to exclude that the presence of paraffin or other 
factors in brain tumor tissues interfered with the detection of HCMV in 
immunohistochemistry, short-term cultures derived from four of the primary brain tumors 
(two meningiomas, two gliomas) were prepared and fixed as described above. 
For immunohistochemistry, cells were first washed for 3x5 min in TBS. Primary antibody 
(monoclonal anti-pp65 antibody) was diluted 1:200 and cells were incubated overnight at 4°C 
in a humidified atmosphere. Following a wash in TBS (3x5 min), cells were incubated with a 
biotinylated secondary antibody (goat anti-mouse) for 30 min at room temperature, and 
incubation with streptavidin-conjugated horseradish peroxidase took place for 30 min at room 
temperature. After an additional washing step (TBS for 3x5 min), a substrate containing the 
chromogen AEC was applied for 5-10 min at room temperature. Afterwards, cells were 
thoroughly washed with double-distilled water and mounted with an aqueous medium.  
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2.4.7 Serological Analyses Using the BEP-III®-System 
Additional to the evaluation of HCMV molecules in brain tumor tissues and corresponding 
blood samples, the serological status of the study participants concerning previous or acute 
infection with HCMV, HSV, EBV and VZV was determined.  
Serum samples were obtained from 71 (93.4%) of the 76 study participants. Five glioma 
patients did not provide a blood sample. 
Patients’ sera were analyzed for the presence of IgM and IgG antibodies to HCMV, HSV, 
EBV, and VZV, using an enzyme-linked immunosorbent assay (ELISA) at the Department of 
Virology, University of Heidelberg (PD Dr. P Schnitzler). Analyses were carried out using a 
fully automated measuring system. This so-called BEP-III®-system (Dade-Behring) is an 
ELISA for detection and quantitative determination of human antibodies to viruses in serum. 
The performance characteristics of the BEP-III®-system according to the manufacturer are 
listed in Tab. 8. 
 
Table 8: Sensitivities and specificities of the BEP-III®-system according to the manufacturer 
 Detection of IgG antibodies  
Detection of 
IgM antibodies 
 Sensitivity  (%) 
Specificity  
(%)  
Sensitivity  
(%) 
Specificity  
(%) 
      
CMV 99.3 98.2  95.0 100 
HSV 100 100  92.0 95.8 
EBV 92.0 100  97.3 99.5 
VZV 99.3 100  98.5 100 
      
Ig, immunoglobulin; CMV, cytomegalovirus; HSV, herpes simplex virus; VZV, varicella-zoster 
virus; EBV, Epstein-Barr virus 
 
In analyses performed with the BEP-III®-system, specific antigens for the determination of 
anti-HCMV antibodies are derived from HCMV-infected human fibroblasts. For 
determination of anti-HSV antibodies, antigens derived from permanent simian kidney cells 
infected with HSV are used. VZV-infected cells not further specified by the manufacturer 
serve as antigens for determination of anti-VZV antibodies, and to state anti-EBV antibody 
levels, lymphoblastoid cells infected with EBV are used.  
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2.4.7.1 IgG Detection 
Virus-specific IgG antibodies in the test sample bind to the antigen in the wells of the test 
plate. Afterwards, a conjugate of anti-human IgG and peroxidase binds to this complex. The 
enzyme component of the conjugate catalyzes a chromogen solution (tetramethylbenzidine, 
TMB), which produces a blue color. This reaction is determined by addition of a stopping 
solution, and color changes to yellow, which is measured at 450 nm. The intensity of the 
yellow color is proportional to the amount of the virus-specific IgG antibodies contained in 
the sample.  
 
2.4.7.2 IgM Detection 
The principle for IgM determination corresponds to the method for the detection of IgG 
antibodies. The only difference is that a rheumatoid factor absorbent not further specified by 
the manufacturers is added to the serum sample for 15 minutes prior to the test. This 
absorbent binds to any rheumatoid factor (which is an IgM antibody present during several 
non-target diseases), thereby minimizing the occurrence of false positive results. This effect 
enhances the specificity of the analyses. Afterwards, virus-specific IgM antibodies bind to the 
antigen in the wells of the test plate and antibody detection continues as described above. 
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2.4.8 Statistical Analyses 
2.4.8.1 Prevalence Estimation 
Prevalence is defined as the proportion of occurrence of a disease, condition or characteristic 
in a certain population at a particular point in time. More precisely, this measure is called the 
point prevalence.  
Point prevalence = 
 timeofpoint  same at the population in the people of No.
in timepoint  oneat  population in  the cases existing of No.  
As it is impossible for practical reasons to get the true prevalence in the population, the 
calculated prevalence can only be an estimate of the true proportion. More precisely, the 
estimated point prevalence ( p ) is given as 
 p  = 
n
a  
with a being the number of cases in the sample, and 
  n being the number of people in the sample. 
The point in time to which it refers must always be specified [dos Santos Silva, 1999]. 
In the present study, overall prevalences as well as prevalences for the occurrence of IgM and 
IgG antibodies to HCMV, HSV, EBV, and VZV stratified by 20-year age groups and tumor 
type, respectively, were estimated. The particular point in time refers to the blood withdrawal, 
which occurred during surgery or two days after surgery at the latest.  
Furthermore, prevalences of several variables stratified by tumor type were obtained by 
telephone or direct interviews and subsequently compared to population prevalences, where 
possible.  
All prevalences were computed using the FREQ procedure of the statistical software package 
SAS. 
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2.4.8.2 Confidence Intervals 
As mentioned above, it is difficult to get the true prevalences in all brain tumor patients in 
Germany. Therefore, a subset of this population is drawn, which has to be representative for 
all patients with primary brain tumors.  
The inferential statistics involved in the construction of confidence intervals (CI) are based on 
standard error, which reflects the sampling fluctuation of the statistic. In general, the larger 
the sample size the smaller the standard error and the narrower the confidence interval. 
The standard error of a sampling distribution of a proportion p is given by  
SE ( p ) = 
n
pp )1( −  
 
with p  being the estimated point prevalence a/n, and 
 n  being the sample size. 
Assuming a normal distribution of the prevalence, the 95% confidence interval (95%CI) 
represents the range of values that has an approximately 95% probability of containing the 
true and unknown proportion being estimated.  
The approximate limits of the 95%CI are given as:  
95%CI = )(96.1 pSEp ×±  
That means that before drawing a sample, there is an approximately 95% chance that the 
proportion for the subset of brain tumor patients would lay within 1.96 standard errors of the 
true population value [dos Santos Silva, 1999]. 
For small numbers of cases (a<20) or sample sizes (n<40), however, this formula is 
insufficient and should not be used. Instead, it is better to calculate exact CIs for the binomial 
proportion using the F distribution method given by Leemis and Trivedi [1996] and also 
described in Collett [2002]. In the present study, exact 95%CIs for calculated prevalences 
were computed using the FREQ procedure of the statistical software package SAS. 
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2.4.9 Evaluation of the Questionnaire 
A questionnaire was developed to control for factors indicative for previous infections, 
especially for any possible infection with or reactivation of herpesviruses. Furthermore, the 
questionnaire addressed the role of several medical conditions as well as the suggestive role 
of high-level person-person or person-animal contact in brain tumor pathogenesis.  
The present study included fast-growing as well as slow-growing tumors with different 
latency periods. Therefore, with the exception of the questions addressing epilepsy, hearing 
impairments and tinnitus, which are also considered being early symptoms of brain tumors, 
no latency period was taken into account for all variables evaluated. 
Prevalences of all variables addressed were estimated as described in Chapt. 2.4.8.1. 
 
2.4.9.1 Exclusion of a Selection Bias in the Interviewed Participants 
Of the 66 patients in the present study, who could be contacted, 81.2% were willing to 
complete the questionnaire. Ten samples were collected anonymously and therefore, the 
patients could not be contacted (cf. above). 
In total, 54 of the 76 participants completed the questionnaire, resulting in a participation rate 
of 71.1%, which was mainly due to the part-time anonymous collection of the samples. The 
subset of subjects willing to complete the interview, though, could differ from those who were 
not interviewed, and this could cause much stronger associations between any risk factor and 
the respective tumor type, but it is also possible that this causes biased results. The main study 
intentions were related to the histological type of the present brain tumor. Therefore, 
heterogeneity between those participating in the interview and those not interviewed was 
tested according to the histological distribution in either group.  
Usually, χ2-testing is applied to measure the extend to which the observed data (or data from 
the subset) differ from those expected (i.e., from the whole study population) if the two 
populations were equal. However, for small sample sizes and if the expected value in any of 
the cells is less than 5, which was the case for the present study, Fisher’s exact test will be the 
appropriate statistical test [dos Santos Silva, 1999].  
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The heterogeneity of the patients completing the questionnaire and those who could not be 
interviewed was tested at a significance level of α=0.05 focusing on the distribution of the 
histological types of the tumors in either population. P-values show the probability that in 
both subsets the found differences occurred by random where in truth the populations were 
equal [Kreienbrock and Schach, 2000]. 
WHO grade III-IV gliomas differ in their clinical and histological behaviors by being more 
aggressive than any other brain tumors included in the present study. These malign neoplasms 
may lead to a reduced ability to complete the questionnaire by causing severe disease (or 
death), and thus are suspected to introduce the most important selection bias. Therefore, these 
tumors were taken as an extra group, resulting in four groups for this analysis:  
o low-grade gliomas (WHO I and II),  
o gliomas WHO grade III and IV,  
o meningiomas, and  
o acoustic neurinomas. 
Analyses were performed using the FREQ procedure of the statistical software package SAS.  
 
2.4.9.2 Determination of the Socioeconomic Status 
For all participants, the SES was determined according to advises from the “Deutsche 
Arbeitsgemeinschaft für Epidemiologie” (DAE) for measurement and quantification of 
sociodemographic characteristics in epidemiologic studies (Tab. 9; DAE, 1997).  
In this model, education and training are taken into account, and the SES is categorized in 
eight classes with category 1 counting for low SES and category 8 counting for high SES. 
Education is defined as the highest graduation in categories of the national educational 
system, whereas training is identified according to the national training system (the 
underlying scheme is shown in Tab. 9). 
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Table 9: Educational achievement in combination with training level and corresponding 
categorizing index (taken from the DAE guidelines for evaluation of socioeconomic status, 1997) 
 Education:    
 No 
education 
8th/9th 
grade * 
10th 
grade ** 
Abitur*** Miscellaneous
Training:      
No training 1 2 3 6 1 
Apprenticeship 3 3 4 6 3 
Technical school - 4 5 6 4 
FH - - 7 7 7 
University - - 8 8 8 
Miscellaneous - - 4 7 3 
*Hauptschulabschluß;   **Realschulabschluß;   ***Gymnasialabschluß 
FH, Fachhochschule; DAE, Deutsche Arbeitsgemeinschaft für Epidemiologie 
 
The social stratification is characterized by smooth transitions between the single classes. 
Therefore, the advices for this SES grading scheme do not determine further categorizations 
into low, intermediate and high SES. However, in the present study, the SES categories of the 
DAE were categorized into low SES (DAE category 1-3), intermediate SES (DAE category 4-
5) and high SES (DAE category 6-8) for a better interpretation and comparison of the data 
with published results.  
For Germany, problems may occur due to the differences in the education and training 
systems between the Eastern and Western part of Germany. However, this difference was not 
taken into account in the present study since all participants had grown up in the Western part 
of Germany.  
 
2.4.9.3 Occupational History 
Complete occupational histories from leaving school to the date of interview were obtained 
from all brain tumor patients completing the questionnaire (n=54). All employments in which 
a participant was involved for more than one year were taken into account. Exposure 
assessment included the job title as well as the precise characterization of the occupational 
activity and its duration in years.  
Due to the small sample size, no cumulative working time was calculated. If the subject 
changed the working place but not the occupational activity, it was considered that other 
exposures were present at the new place and the occupational category was counted twice in 
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the analyses. Similarly, a subject could belong to different categories, depending on the 
activities during its occupational life.  
Two separate analyses were performed and evaluated separately: 
(1) First, all job titles and occupational activities were coded according to the International 
Standard Classification of Occupation [ISCO, 2003]. Subsequently, activities of similar 
profile were classified into 16 a priori defined categories based on exposure criteria 
(such as chemicals, metals, farming, etc.) as described by Schlehofer et al. [1990]. 
(2) Additional separate analyses were performed to evaluate the main hypothesis of this 
study, which refers to a possible causal relationship between neuro-oncogenic infections 
and the development of primary brain tumors. Therefore, occupational activities were 
classified into activities with potential high level contact to humans or animals as a 
measurement of possible transmission of neuro-oncogenic infections as described by 
Menegoz et al. [2002]. For instance, people working as physicians, teachers, nurses, 
hairdresser and trained retail sales clerk were considered to have high levels of contact 
with humans or human tissues. Similar, farmers and cooks were considered to have 
potential high-level contact to animals or animal tissue. Subjects working for a catering 
service, in gastronomy (serving and cooking) or as trained retail sales clerk at butchery 
were considered to have high-level exposure to both, humans and animals. Therefore, 
these subjects were defined as an extra category.  
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3 Results 
The reference date in the present study for all analyses performed refers to the date of surgery.  
(A) Questionnaire Data 
3.1 Characteristics of Participants Completing the Questionnaire 
A questionnaire was developed to control for risk factors of infection with herpesviruses prior 
to diagnosis and additional putative risk factors controversially discussed in the literature. 
Interviews were performed after brain tumor surgery in the hospital if possible. Otherwise, 
patients were contacted by letter, followed up by up to four more letters and several phone 
calls if necessary, and telephone interviews were performed.  
Of the 76 participants, 54 persons completed the questionnaire either by direct (n=26) or by 
telephone interview (n=28). The participation rate was 71.1%. Reasons for nonparticipation 
included refusal (n=5; 6.6%), death (n=1; 1.3%), and failure to contact the study subjects 
(n=16; 21.1%; percentage due to the part-time anonymous collection of the tumor samples as 
described above). Among those not interviewed were 16 gliomas (one with unknown grading, 
one WHO II, five WHO III, nine WHO IV), five meningiomas (four WHO I, one WHO II), 
and one acoustic neurinoma (WHO I). 
To exclude a selection bias in the subset of patients completing the questionnaire, Fisher’s 
exact test was applied to determine whether there was a difference concerning the distribution 
of the histological findings in those interviewed and those not interviewed. Considering a 
significance level of α=0.05, no statistically significant heterogeneity in the distribution of 
tumor types was detected (p=0.09), and the null hypothesis that the two groups were 
homogenous could not be rejected. 
One meningioma patient could not be interviewed because of severe disease; therefore, his 
son completed the interview (proxy interview). Furthermore, one patient with glioblastoma 
multiforme did not want do perform an interview because of amblyacousia (hardness of 
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hearing). Instead, his wife was interviewed, but the study subject remained besides her during 
the interview and answered the questions if the proxy was not able to (partly proxy interview). 
Two meningioma and one glioma patient were interviewed prior to brain tumor surgery. In 
patients interviewed after brain tumor surgery, the mean time period between the time of 
surgery and the interview was 53 days in glioma patients, 111 days in meningioma patients, 
and 87 days in acoustic neurinoma patients.  
At surgery, glioma patients had a median age of 54.0 years with a range from 9 to 80 years; of 
these patients, 57% were male. In meningioma patients, 15% were male; the median age was 
51.5 years with a range from 36-83 years. Acoustic neurinoma patients were slightly younger 
with a median age of 46 years (range 34-66 years). The proportion of men was 80% (Tab. 10).  
The distribution of age and gender in subjects completing the questionnaire did not differ 
significantly from that of the overall study population as described in Chapt. 3.5.  
 
Table 10: Distribution of age and gender in brain tumor patients who completed the 
questionnaire (N=54) 
 n  Age  Gender 
   Median Age 
Age  
Range  Male Female 
Patients with   (years) (years)  n (%) n (%) 
          
Glioma  23  54.0 9-80  13 (56.5) 10 (43.5) 
Meningioma  26  51.5 36-83  4 (15.4) 22 (84.6) 
ACN  5  46.0 34 - 66  4 (80.0) 1 (20.0) 
          
ACN, acoustic neurinoma 
 
For the participants completing the questionnaire, the socioeconomic status (SES) was 
calculated taking into account educational and training levels (Tab. 11).  
Secondary level (Hauptschulabschluß, 8th/9th class) was the most common educational level in 
all patients, independent of the type of tumor. Glioma patients had the smallest proportion of 
subjects completing Gymnasium and Fachhochschule, respectively. Two of the glioma 
patients and one meningioma patient reported to have no education. 
In training levels, apprenticeship was the most common level for all patients. None of the 
participants went to Fachhochschule, and only five of all 54 interviewed participants went to 
university. 
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Table 11: Education and training level in patients with primary brain tumors completing the 
questionnaire according to DAE guidelines for evaluation of socioeconomic status [DAE, 1997] 
 Glioma  
patients  
(n=23) 
Meningioma 
patients  
(n=26) 
ACN 
patients  
(n=5) 
 n % n % n % 
       
Education Level       
No education 2 8.7 1 3.8 - - 
8th/9th class (Hauptschule) 13 56.5 12 46.2 4 80.0 
10th class (Realschule) 5 21.7 6 23.1 - - 
12th/13th class (Abitur/FH-level) 3 13.0 7 26.9 1 20.0 
Miscellaneous - - - - - - 
       
Training Level       
No training 4 17.4 8 30.8 - - 
Apprenticeship 16 69.6 13 50.0 4 80.0 
Technical school 2 8.7 1 3.8 1 20.0 
FH - - - - - - 
University 1 4.3 4 15.4 - - 
Miscellaneous - - - - - - 
       
ACN, acoustic neurinoma; FH, Fachhochschule 
 
According to the DAE categorizing index, the most frequent SES category in brain tumor 
patients was category 3, indicating a low SES (Tab. 12). The highest SES category was 
present only in one glioma and four meningioma patients. 
 
Table 12: Socioeconomic status in brain tumor patients who completed 
the interview according to DAE guidelines [DAE, 1997] 
Category 
Glioma  
patients  
(n=23) 
Meningioma 
patients  
(n=26) 
ACN 
patients  
(n=5) 
 n % n % n % 
       
1 3 13.0 1 4.2 - - 
2 2 8.7 6 25.0 - - 
3 10 43.5 7 29.2 4 80.0 
4 4 17.4 4 16.7 - - 
5 1 4.3 1 4.2 - - 
6 2 8.7 3 12.5 1 20.0 
7 - - - - - - 
8 1 4.3 4 16.7 - - 
ACN, acoustic neurinoma 
 
low SES 
high SES 
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The majority of the study participants completing the questionnaire was married or living 
with a partner (66.7%). Of all 54 persons, four were widowed (7.4%) and one participant was 
divorced (1.9%). 24.1% of the subjects completing the questionnaire were single.  
In meningioma and acoustic neurinoma patients, 77% and 80%, respectively, were married. In 
glioma patients, the proportion being married was 52% (Tab. 13).  
 
Table 13: Marital status of participants completing the questionnaire (N=54) 
 
Glioma  
patients  
(n=23) 
Meningioma 
patients  
(n=26) 
ACN 
patients 
(n=5) 
 n % n % n % 
       
Single 9 39.1 3 11.5 1 20.0 
Married/partner 12 52.2 20 76.9 4 80.0 
Divorced - - 1 3.9 - - 
Widowed 2 8.7 2 7.7 - - 
       
ACN, acoustic neurinoma 
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3.2 Medical History 
The questionnaire addressed information on medical factors possibly indicating an infection 
or reactivation of herpesviruses as well as on putative medical risk factors for the 
development of primary brain tumors.  
 
3.2.1 Distribution of Previous Infections 
Previous herpesvirus and common infections were assessed using a standardized 
questionnaire (Tab. 14).  
More than 50% of all brain tumor patients reported to have had chicken pox (primary 
infection with VZV). Five glioma and three meningioma patients could not remember if they 
ever had this disease. One of those glioma patients who could not remember a history of 
chickenpox, though, reported the occurrence of shingles 30 years prior to the present tumor. 
Of the other glioma patients with a positive shingles history, one did not remember at what 
age this condition occurred; one reported shingles 4 and one 20 years prior to the present 
tumor. One meningioma patient reported the occurrence of shingles without any history of 
chickenpox, but could not remember at what age shingles occurred. The second meningioma 
patient with a history of chickenpox reported its occurrence 14 years prior to the present 
tumor. 
In total, shingles, which is caused by reactivation of VZV, was more common in glioma 
patients (17%) than in meningioma patients (8%), and absent in all acoustic neurinoma 
patients. The recurrence rates, i.e., the proportion of shingles in individuals with a history of 
chickenpox, were 25% for glioma (3 out of 12) and 5.9% for meningioma patients (one out of 
17), respectively.  
Mononucleosis (EBV infection) was not reported by any of the patients. Only two subjects 
(one meningioma and one glioma patient) remembered to have had roseola (‘exanthema 
subitum’, HHV-6 infection). More than 20% of the patients were suffering from an HSV 
infection (oropharyngeal disease), and more than 20% reported regular common infections 
like flu, colds and sore throat.  
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Common infections were distinctly more frequent in meningioma patients (69%) than in 
glioma patients (25%). In none of the patients, an HCMV titer had been determined 
previously.  
 
Table 14: Distribution of previous herpesvirus and common infections (e.g. flu, 
sore throat) in brain tumor patients (N=55) 
 Glioma  
patients  
(n=23) 
Meningioma 
patients  
(n=26) 
ACN 
patients  
(n=5) 
 n % n % n % 
       
Chicken pox       
Yes 12 52.2 17 65.4 4 80.0 
No 6 26.1 6 23.1 1 20.0 
Do not know 5 21.7 3 11.5 - - 
       
Shingles       
Yes 4 17.4 2 7.7 - - 
No 18 78.3 23 88.5 5 100 
Do not know 1 4.3 - - - - 
Missing* - - 1 3.8 - - 
       
Mononucleosis       
Yes - - - - - - 
No 19 82.6 25 96.2 5 100 
Do not know 2 8.7 - - - - 
Missing* 2 8.7 1 3.8 - - 
       
Roseola       
Yes 1 4.3 1 3.8 - - 
No 21 91.3 23 88.5 5 100 
Do not know 1 4.3 1 3.8 - - 
Missing* - - 1 3.8 - - 
       
Herpes simplex       
Yes 7 30.4 12 46.2 1 20.0 
No 16 69.7 14 53.8 4 80.0 
Do not know - - - - - - 
       
Infections       
Yes 6 26.1 18 69.2 1 20.0 
No 17 73.9 8 30.8 4 80.0 
Do not know - - - - - - 
       
HCMV titer       
Yes - - - - - - 
No 18 78.3 22 84.6 5 100 
Do not know 5 21.7 4 15.4 - - 
       
* Missing, patient did not respond to the question; 
ACN, acoustic neurinoma; HCMV, human cytomegalovirus 
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The self-reported history of previous herpesvirus infections was compared to the results of the 
serological analyses, which are described in more detail in chapter 3.10 (see Tab. 15).  
The single meningioma patient and two of three glioma patients, who reported the occurrence 
of both chickenpox and shingles, were anti-VZV antibody positive. All other glioma patients 
with a positive history of both did not provide a blood sample.  
 
Table 15: Self-reported history of herpesvirus diseases compared to the serological status concerning these 
herpesviruses in brain tumor patients providing a blood sample and completing the questionnaire (n=52) 
 
Glioma  
patients 
(n=21*) 
Meningioma  
patients 
(n=26) 
ACN  
patients 
(n=5) 
    
IgG IgG IgG Self-reported 
history of** positive negative positive negative positive negative 
 n % n % n % n % n % n % 
             
HCMV             
Yes - - - - - - - - - - - - 
No 7 33.3 9 42.9 13 50.0 9 34.6 3 60.0 2 40.0 
             
Herpes simplex 
(HSV)             
Yes 7 33.3 - - 12 46.1 - - 1 20.0 - - 
No 12 57.1 1 4.8 8 30.8 6 23.1 2 40.0 1 20.0 
             
Mononucleosis 
(EBV)             
Yes - - - - - - - - - - - - 
No 15 71.4 2 9.5 22 84.6 3 15.4 5 100 - - 
             
Chickenpox and/ 
or Shingles 
(VZV) 
            
Yes 9 42.9 2 9.5 16 61.5 2 7.7 4 80.0 - - 
No 5 23.8 - - 6 23.1 - - 1 20.0 - - 
             
*2 glioma patients did not provide a blood sample;  
**patients missing to the overall number of individuals did not know whether they had the respective disease; 
ACN, acoustic neurinoma; HCMV, human cytomegalovirus; HSV, herpes simplex virus; EBV, Epstein-Barr 
virus; VZV, varicella zoster virus; IgG, immunoglobulin G 
 
 
 
Results 
 
79
3.2.2 Distribution of Vaccinations 
The proportions of patients being vaccinated against 14 different diseases were evaluated. 
One glioma patient refused to answer the question about vaccinations (Tab. 16).  
 
Table 16: Distribution of vaccinations against several diseases in brain tumor patients (N=54) 
 Glioma  
patients 
(n=23*) 
Meningioma  
patients 
(n=26) 
ACN  
patients 
(n=5) 
 n % n % n % 
       
Diphtheria       
Ever 10 43.5 12 46.2 3 60.0 
Never 10 43.5 11 52.3 2 40.0 
Do not know 2 8.7 3 11.5 - - 
       
Tetanus       
Ever 18 78.3 23 88.5 4 80.0 
Never 3 13.1 2 7.7 1 20.0 
Do not know 1 4.3 1 3.8 - - 
       
Pertussis       
Ever 4 17.4 2 7.7 2 40.0 
Never 15 65.2 23 88.5 3 60.0 
Do not know 3 13.1 1 3.8 - - 
       
Poliomyelitis       
Ever 12 47.8 17 65.4 4 80.0 
Never 8 34.8 9 34.6 1 20.0 
Do not know 3 13.1 - - - - 
       
Tuberculosis       
Ever 5 21.7 7 26.9 2 40.0 
Never 11 47.8 16 61.5 3 60.0 
Do not know 6 26.1 3 11.6 - - 
       
Rubella       
Ever 3 13.0 7 26.9 - - 
Never 16 69.6 16 61.5 5 100 
Do not know 3 13.0 3 11.6 - - 
       
Mumps       
Ever 3 13.0 3 11.5 - - 
Never 17 73.9 19 73.1 5 100 
Do not know 2 8.7 4 15.4 - - 
       
Measles       
Ever 3 13.0 3 11.5 - - 
Never 17 73.9 20 76.9 5 100 
Do not know 2 8.7 3 11.6 - - 
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Tab. 16 continued 
 Glioma  
patients 
(n=23*) 
Meningioma  
patients 
(n=26) 
ACN  
patients 
(n=5) 
 n % n % n % 
       
MMR       
Ever - - 2 7.7 - - 
Never 20 87.0 23 88.5 5 100 
Do not know 2 8.7 1 3.8 - - 
       
Hepatitis A       
Ever 4 17.4 5 19.2 - - 
Never 17 73.9 20 76.9 5 100 
Do not know 1 4.3 1 3.9 - - 
       
Hepatitis B       
Ever 4 17.4 3 11.5 - - 
Never 17 73.9 22 84.6 5 100 
Do not know 1 4.3 1 3.9 - - 
       
Rabies       
Ever - - 2 7.7 - - 
Never 21 91.3 24 92.3 5 100 
Do not know 1 4.3 - - - - 
       
FSME       
Ever 2 8.7 3 11.5 - - 
Never 18 78.3 23 88.5 5 100 
Do not know 2 8.7 - - - - 
       
Influenza       
Ever 3 13.1 10 38.5 1 20.0 
Never 18 78.3 16 61.5 4 80.0 
Do not know 1 4.3 - - - - 
       
* one glioma patient refused to answer the question on vaccinations; 
ACN, acoustic neurinoma; MMR, measles-mumps-rubella combination; FSME, tick-borne encephalitis 
 
44% to 60% of the patients had been vaccinated against diphtheria and more than 78% of the 
study subjects were vaccinated against tetanus. For polio, the proportion was 48% for glioma, 
65% for meningioma and 80% for acoustic neurinoma patients. Two to four of the patients in 
each histological subgroup were vaccinated against pertussis. For tuberculosis, mumps, 
measles, and hepatitis A and B, the proportions were similar. The use of a combination 
vaccine (measles, mumps, rubella; MMR) was rarely reported.  
Of the patients with meningioma, only 8% had been vaccinated against rabies compared to 
none of the other participants. The proportion of vaccinated subjects against rubella and tick-
borne encephalitis (FSME) in meningioma patients was higher as those in glioma patients. 
The proportion for influenza was 13% in glioma, 39% in meningioma and 20% in acoustic 
neurinoma patients.  
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3.2.3 Medical History of the Participants’ Children as an Indicator for 
Parental HCMV Infection 
HCMV transmission from mother to child during pregnancy can lead to various diseases in 
the newborn, becoming apparent during the 1st year of life. Therefore, the questionnaire 
addressed the occurrence of frequent symptoms of prenatal HCMV infection (e.g. anemia, 
icterus, pneumonia, gastrointestinal diseases, and malformations/hereditary diseases). 
Fifteen glioma, twenty-one meningioma, and two acoustic neurinoma patients reported to 
have children. The mean number varied from 0.8 to 1.7 in the different tumor types (Tab. 17). 
 
Table 17: Parity in brain tumor patients with offspring (N=54) 
 Glioma  
patients  
(n=23) 
Meningioma  
patients  
(n=26) 
ACN 
patients  
(n=5) 
Parity n % n % n % 
       
0 8 34.8 5 19.2 3 60.0 
1 2 8.7 8 30.8 - - 
2 9 39.1 6 23.1 2 40.0 
3 2 8.7 5 19.2 - - 
4 2 8.7 2 7.7 - - 
Mean N° 1.5 1.7 0.8 
Total N° 34 43 4 
       
ACN, acoustic neurinoma 
 
For analyzing the occurrence of hereditary diseases, malformations and diseases during the 
offspring’s first year of life, and for better handling of the data, patients having offspring with 
one of the addressed conditions were serially numbered (see Tab. 18). 
Patients with acoustic neurinoma did not report any of the diseases in their offspring. 
Furthermore, none of the study subjects reported anemia in their children.  
The most frequent disease was jaundice. One glioma patient had a child affected by jaundice; 
one offspring of another glioma patient was affected by hereditary amblyopia. In meningioma 
patients, the occurrence of malformations, hereditary or other addressed diseases was reported 
by 10 out of 21 meningioma patients with offspring.  
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Table 18: Numbers of children affected by medical conditions being suspect for HCMV transmission from 
brain tumor patients to their offspring, and occurrence of IgG antibodies to HCMV  
 
Total  
N° of  
kids 
N° of  
kids 
affected 
Malformation / 
hereditary 
disease 
Anemia Icterus Pneu-monia 
Chronic  
GI 
disease 
IgGs to 
HCMV 
in parent 
         
Glioma patients 
1) 2 1 - - 1 - - No 
2) 2 1 Amblyopia - - - - No 
         
Meningioma patients 
3) 1 1 - - 1 - - Yes 
4) 3 1 - - 1 - - No 
5) 1 1 Neurodermatitis - - - - Yes 
6) 2 1 - - 1 - - Yes 
7) 1 1 - - 1 - - No 
8) 3 2 - - 2 1 - No 
9) 1 1 Neurodermatitis,Asthma - - - 1 No 
10) 2 1 Asthma - - - - No 
11) 2 1 Amblyopia - - - - Yes 
12) 3 1 Intestinal obstruction - - 1 - No 
         
GI, gastro-intestinal; IgG, immunoglobulin G; HCMV, human cytomegalovirus 
 
The child of subject (9) was affected by two hereditary conditions and by gastrointestinal 
disease. Intestinal obstruction in combination with pneumonia was reported in one child of 
patient (12). Pneumonia and jaundice occurred in one child of patient (8); another one of the 
three children of patient (8) was affected by jaundice, too.  
None of the glioma patients with affected children was seropositive for anti-HCMV IgG. In 
contrast, four meningioma patients with affected children were seropositive for anti-HCMV 
IgG.  
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3.2.4 Distribution of Immunosuppressive Conditions 
Immunosuppressive conditions (such as stress, intake of specific drugs, organ transplantation, 
etc.) may lead to a reactivation of herpesviruses. Self-reported immunosuppression was taken 
into account only if it occurred at least two years prior to the present brain tumor surgery. 
Therefore, one glioma and one meningioma patient each, reporting a blood transfusion less 
than 2 years prior to the present tumor, had to be excluded.  
None of the glioma and acoustic neurinoma patients and only one meningioma patient 
reported immunosuppressive conditions more than 2 years prior to the present tumor, which 
were due to an intake of immunosuppressive drugs (namely carboplatin chemotherapy during 
breast cancer therapy 5 years prior to the present tumor). This single patient reporting 
immunosuppressive conditions was HCMV-seronegative. None of the study subjects reported 
organ transplantation or infectious diseases leading to an immunosuppression. 
HCMV transmission frequently occurs through blood transfusions. Therefore, the occurrence 
of blood transfusions at least 2 years prior to the present brain tumor surgery was evaluated in 
all patients. Only six individuals of the total study population reported a blood transfusion for 
different reasons. One meningioma, one acoustic neurinoma and four glioma patients reported 
having received a transfusion (Tab. 19). Of the four affected glioma patients, two were 
seropositive for HCMV IgG. The meningioma and the acoustic neurinoma patients who ever 
received a blood transfusion were HCMV-seropositive, too.  
 
Table 19: Distribution of blood transfusions and immunosuppressive 
conditions in brain tumor patients at least 2 years prior to brain tumor 
surgery (N=54) 
 Glioma  
patients  
(n=23) 
Meningioma 
patients  
(n=26) 
ACN 
patients  
(n=5) 
 n % n % n % 
       
Blood Transfusion      
Ever 4 17.4 1 3.8 1 20.0 
Never 19 82.6 25 96.2 4 80.0 
       
Immunosuppressive Conditions    
Yes - - 1 3.8 - - 
No 23 100 25 32.5 5 100 
       
ACN, acoustic neurinoma 
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3.2.5 Distribution of Previous Cancers 
The occurrence of malignancies prior to brain tumor diagnosis in the present study was 
assessed to control for previous immunosuppression and for hereditary diseases associated 
with an increased risk for the development of primary brain tumors (such as 
neurofibromatosis or tuberous sclerosis).  
None of the study subjects reported to be affected by either of these two hereditary diseases.  
Seven of the 54 patients reported one previous neoplasm (13.0%) and four (7.4%) reported 
two previous cancers each (Tab. 20). None of participants with acoustic neurinoma was 
affected by previous malignancies. 
Stratified by brain tumor type, 9% and 19% of the glioma and meningioma patients, 
respectively, reported one cancer diagnosis before the present brain tumor. Two previous 
cancers were diagnosed in 9% of the glioma and 8% of the meningioma patients. In glioma 
patients, the most common cancer was breast cancer. Meningioma patients most often 
reported previous myoma, followed by breast and thyroid gland cancer.  
Altogether, eight out of eleven patients with a positive cancer history were HCMV-
seropositive (75.0% of the glioma and 71.4% of the meningioma patients). 
 
Table 20: Distribution of neoplasms prior to the present study in those with a positive cancer history (n=11)  
Present neoplasm 1st previous tumor 2nd previous tumor IgGs to 
Tumor Type Age at Onset Tumor Type 
Age at 
Onset Tumor Type 
Age at 
Onset HCMV 
Glioma patients      
GBM IV 62 Myoma 48 Breast cancer 61 No 
GBM IV 66 Kidney cancer 57 - - Yes 
GBM IV 79 Breast cancer 75 Breast cancer 76 Yes 
GBM IV 59 Breast cancer 22 - - Yes 
       
Meningioma patients      
Meningioma I 36 Fibroadenoma 25 - - Yes 
Meningioma I 53 Myoma 49 - - Yes 
Meningioma I 62 Myoma 35 - - Yes 
Meningioma I 48 Thyroid gland cancer 45 - - Yes 
Meningioma I 41 Thyroid gland cancer 40 - - Yes 
Meningioma I 44 Breast cancer 39 Breast cancer  43 No 
Meningioma I 47 Myoma 24 Ovarian cancer 41 No 
       
GBM IV, glioblastoma multiforme WHO grade IV; IgG, immunoglobulin G; HCMV, human cytomegalovirus 
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3.2.6 Distribution of Allergic Conditions 
Allergic conditions are controversially discussed to be associated with brain tumors. In total, 
allergic conditions were reported rarely by all participants (Tab. 21).  
The simultaneous occurrence of hay fever, eczema and other allergies was reported by one 
acoustic neurinoma patient. Asthma did not occur.  
One glioma and one meningioma patient reported the occurrence of asthma. The prevalence 
of hay fever was higher in glioma (13%) than in meningioma patients (8%). Reported eczema 
distribution was similar in glioma and meningioma patients (17% and 15%, respectively).  
35% of all meningioma patients and 22% of all glioma patients reported to have at least one 
other allergy (such as pollen or dust mite).  
 
Table 21: Distribution of allergic conditions in brain tumor patients (N=54) 
 Glioma  
patients  
(n=23) 
Meningioma 
patients  
(n=26) 
ACN 
patients  
(n=5) 
 n % n % n % 
       
Asthma       
Yes 1 4.3 1 4.8 - - 
No 22 95.7 25 96.2 5 100 
       
Hay fever       
Yes 3 13.0 2 7.7 1 20.0 
No 20 87.0 24 92.3 4 80.0 
       
Eczema       
Yes 4 17.4 4 15.4 1 20.0 
No 19 86.7 22 84.6 4 80.0 
       
Other Allergies      
Yes 5 21.7 9 34.6 1 20.0 
No 18 78.3 17 65.4 4 80.0 
       
ACN, acoustic neurinoma 
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Overall, nine out of 23 glioma patients (39.1%) were suffering from at least one allergic 
condition. This proportion was 38.5% in meningioma (n=10) and 20% (n=1) in acoustic 
neurinoma patients (Tab. 22)  
 
Table 22: Number of allergic conditions (asthma, hay fever, eczema, 
other allergies) reported by brain tumor patients (N=54) 
N° of allergic 
conditions 
Glioma  
patients  
(n=23) 
Meningioma 
patients  
(n=26) 
ACN 
patients  
(n=5) 
 n % n % n % 
       
1 5 21.7 4 15.4 - - 
2 4 17.4 6 23.1 - - 
3 - - - - 1 20.0 
       
At least 1 9 39.1 10 38.5 1 20.0 
(95%CI)  (20, 61)  (20, 59)  (1, 72) 
       
ACN, acoustic neurinoma; CI, confidence interval 
 
3.2.7 Distribution of Hearing Impairments and Tinnitus 
Hearing impairments and tinnitus could be indicators for prenatal HCMV infection, which 
should be evaluated in the present study. Furthermore, they are also frequently reported as 
early clinical symptoms of brain tumors. Therefore, their occurrence was only taken into 
account if it occurred at least two years prior to the present tumor surgery, and three acoustic 
neurinoma patients had to be excluded from the analyses. At the beginning of the present 
study, this question addressed only acoustic neurinoma patients, resulting in a high proportion 
of missing data in glioma and meningioma patients.  
None of the patients reported to be affected by tinnitus. Hearing impairments occurred in two 
of the five acoustic neurinoma patients, in one glioma and in three meningioma patients, who 
had answered that question, respectively (Tab. 23).  
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Table 23: Hearing impairments and tinnitus occurring at least 2 years prior to the 
present study (N=54) 
 Glioma  
patients  
(n=23) 
Meningioma 
patients  
(n=26) 
ACN 
patients  
(n=5) 
 n % n % n % 
       
Hearing impairments      
Ever 1 4.3 3 11.5 2 40.0 
Never 20 87.0 23 88.5 3 60.0 
Missing 2 8.7 - - - - 
       
Tinnitus       
Ever - - - - - - 
Never 10 43.5 17 65.4 5 100 
Missing 13* 56.5 9* 34.6 - - 
       
*question was taken up for glioma and meningioma patients later during the study period;  
ACN, acoustic neurinoma 
 
Concerning the serological status, three of the six patients with a positive history of hearing 
impairments were HCMV seropositive (one glioma and two meningioma patients).  
 
3.2.8 Distribution of Epilepsy 
An association between epilepsy and the occurrence of brain tumors has been suggested in 
several studies. Therefore, the prevalence of seizures in brain tumor patients was evaluated.  
As the possible etiology in brain tumor development was addressed in the present study and 
as seizures are a frequent first clinical symptom of these tumors, epilepsy occurring at least 
two years prior to brain tumor surgery was taken into account. Therefore, one glioma and two 
meningioma patients had to be excluded from this analysis.  
None of the other study participants reported the occurrence of seizures two years and more 
prior to the present tumor.  
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3.3 Assessment of Occupational History 
Tab. 24 shows the distribution of the brain tumor patients in the different occupational 
categories according to Schlehofer et al. [1990]. Multiple classifications of the subjects to 
different categories were possible.  
None of the participants was working in category “food”, and only one person with 
meningioma was working in the “agriculture” category. In glioma and meningioma patients, 
most study subjects had worked in jobs belonging to the “office” category (74% and 62%, 
respectively), and the “service” category (44% and 92%, respectively). All acoustic 
neurinoma patients reported to have been involved in the “service” category. Working in the 
“health system” was most common in meningioma patients (65%) whereas working in 
electrical/electronically industry was most often found in acoustic neurinoma patients (40%). 
No considerable increase in occurrence in the other categories was seen in either subgroup.  
 
Table 24: Distribution of 54 brain tumor patients in 16 Occupational categories 
(according to Schlehofer et al., 2005) 
Occupational 
category* 
Glioma  
patients  
(n=23) 
Meningioma 
patients  
(n=26) 
ACN 
patients 
(n=5) 
 n % n % n % 
       
Chemical - - 3 11.5 1 20.0 
Metal 5 21.7 5 19.2 - - 
Office 17 73.9 16 61.5 1 20.0 
Health system 3 13.0 17 65.4 1 20.0 
Electrical/electronic 5 21.7 7 26.9 2 40.0 
Construction 2 8.7 - - - - 
Transport - - - - 1 20.0 
Sales/trade - - - - - - 
Food - - - - - - 
Service 10 43.5 24 92.3 5 100 
Agriculture - - 1 3.8 1 20.0 
Textile 1 4.3 9 34.6 - - 
Wood/paper 2 8.7 2 7.7 - - 
Glass/ceramic 3 13.0 - - - - 
Painters 2 8.7 - - - - 
Artists - - - - - - 
       
* Multiple assignments possible, percentage related to the respective total numbers of 
study participants;  
ACN, acoustic neurinoma 
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3.4 Assessment of High-level Contact to Animals and/or Humans  
According to the literature, zoonotic as well as immunologic factors are suggested to be 
involved in the development of brain tumors [Khuder et al., 1998; Musicco et al., 1988]. 
Therefore, patients’ self-reported occupational as well as private contact to animals or pets 
was evaluated (Tab. 26). 
In addition, patients were classified according to a potential high-level contact to humans 
and/or animals or the respective tissues during work (Tab. 25). This separate analysis was 
performed according to the classification of Menegoz et al. [2002].  
Teachers, sales clerks, traders, and people working in the health system were considered to 
have had high-level contact to humans or human tissues, whereas farmers and cooks were 
considered to have had high-level contact to animals or animal tissues. Patients working as 
sales clerk at a butchery and gastronomists doing both service and cooking were considered to 
have had high-level contact to both animals and humans. 
Differences between self-reported occupational contact to animals (Tab. 26) and potential 
occupational high-level contact to animals (Tab. 25) are determined by the fact that animal 
tissues were considered as high-level contact to animals, although the subject would not have 
reported any vocational contact to animals. For example, a butcher would be considered as 
having had potential high-level contact to animals (tissue) according to Menegoz et al. [2002] 
although the subject did not report vocational animal contact.  
 
Table 25: Distribution of 54 brain tumor patients working in occupations with 
suggested occupational high-level contact to humans or animals (according to the 
categorization of Menegoz et al., 2002) 
Glioma  
patients  
(n=23) 
Meningioma 
patients  
(n=26) 
ACN 
patients 
(n=5) Potential high-level 
contact to* n % n % n % 
       
Humans 13 56.5 23 88.5 4 80.0 
Animals 1 4.3 6 23.1 - - 
Humans and animals - - 6 23.1 - - 
None 39 - 42 - 8 - 
       
* Multiple assignments possible, percentage related to the respective total numbers of 
study participants;  
ACN, acoustic neurinoma 
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Potential high-level contact to people at work was distributed in the range from 57% to 89% 
in the different brain tumor types. Only one of the glioma patients had potential high-level 
contact to animals, whereas the proportion was 23% (n=6) in meningioma patients. 
Meningioma patients were the only subjects with occupational activities at potential high-
level contact to both animals and humans (23%). Four of the acoustic neurinoma patients 
were considered to have had occupational high-level contact to humans (Tab. 25).  
Self-reported private contact frequently occurred in all study subjects; it was reported by 70% 
and more of all patients. Occupational contact to animals was reported by 4% of glioma and 
12% of meningioma patients (Tab. 26).  
 
Table 26: Distribution of self-reported private or occupational contact to 
animals in brain tumor patients (N=54) 
 Glioma  
patients  
(n=23) 
Meningioma 
patients  
(n=26) 
ACN 
patients 
(n=5) 
 n % n % n % 
       
Private       
Ever 16 69.6 19 73.1 4 80.0 
Never 7 30.4 7 26.9 1 20.0 
       
Occupational       
Ever 1 4.3 3 11.5 - - 
Never 22 95.7 23 88.5 5 100 
       
ACN, acoustic neurinoma 
 
For analyses stratified by animal type, private and vocational contacts were analyzed together 
(Tab. 27), because it was defined as unimportant whether the possible transmission of a 
neuro-oncogenic infection took place during leisure time or at work. 
The period of time between first contact to any animal and the present surgery was 22.2 years 
(range 8-53 years) in glioma patients, 29.0 years (range 4-58 years) in meningioma patients 
and 27.3 years (range 18-35 years) in acoustic neurinoma patients 
Almost 50% of the patients reported having a dog. Fewer subjects reported contact to cats. 
Contact to rodents (guinea pigs, rats, hamsters), rabbits and birds (budgerigars, poultry, zebra 
finch) was also frequently reported. Contact to farm animals was commonest in meningioma 
patients; eight of them reported contact to either pigs or ruminants (goats, sheep, cattle), 
whereas in other subjects, only two glioma patients reported contact to ruminants.  
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Table 27: Private and occupational contact to animals stratified by animal species (N=54) 
Contact to* 
Glioma  
patients  
(n=23) 
Meningioma 
patients  
(n=26) 
ACN 
patients  
(n=5) 
 n % n % n % 
       
Dog 11 47.8 12 45.2 2 40.0 
Cat 11 47.8 9 34.6 1 20.0 
Horse 2 8.7 3 11.5 - - 
Rodent 4 17.4 2 7.7 2 40.0 
Rabbit 3 13.0 6 23.1 2 40.0 
Bird 4 17.4 7 26.9 2 40.0 
Ruminant 2 8.7 5 19.2 - - 
Pig - - 3 11.5 - - 
Fish 1 4.3 - - - - 
Turtle - - 1 3.8 1 20.0 
Cheetah - - 1 3.8 - - 
       
* Multiple assignments possible, percentage related to the respective total numbers of study 
participants;  
ACN, acoustic neurinoma 
 
First contact to animals took place at a median age of 5.0 years (range 0-28 years) in acoustic 
neurinoma patients, at 31.0 years (range 0-59 years) in glioma patients and 20.0 years (range 
0-48 years) in meningioma patients. The mean number of animals to which the study 
participants had contact varied between 1.7 and 2.0 (Tab. 28) 
 
Table 28: Number of animals to which the study participants completing the 
questionnaire had contact prior to the present study (N=54) 
Glioma  
patients  
(n=23) 
Meningioma  
patients  
(n=26) 
ACN 
patients  
(n=5) 
Number of 
Animals 
n % n % n % 
       
       
0 5 21.7 4 15.4 1 20.0 
1 6 26.1 7 26.9 1 20.0 
2 6 26.1 4 15.4 - - 
3 4 17.4 10 38.5 3 60.0 
4 1 4.3 1 3.8 - - 
5 1 4.3 - - - - 
Mean N° 1.7 1.9 2.0 
       
ACN, acoustic neurinoma 
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(B) Laboratory Results 
3.5 Characteristics of Participants Providing Biological Samples 
For laboratory analyses, 39 glioma, 31 meningioma and 6 acoustic neurinoma patients were 
recruited. At the time of surgery, all patients had a median age of 53.5 years (range 9 to 83 
years). The median ages were similar for meningioma and glioma patients; acoustic 
neurinoma patients had a median age of 42 years. 67% of acoustic neurinoma and 56% of 
glioma patients were male. The majority in meningioma patients was female (Tab. 29).  
 
Table 29: Distribution of age and gender in 76 brain tumor patients included in the study 
 N  Age  Gender 
   Median  Age 
Age  
Range  Male Female 
Patients with   (years) (years)  n (%) n (%) 
          
Glioma  39  55.0 9-80  22 (56.4) 17 (43.6) 
Meningioma  31  53.0 32-83  5 (16.1) 26 (83.9) 
ACN  6  42.0 34 - 66  4 (66.7) 2 (33.3) 
          
ACN, acoustic neurinoma 
 
 
3.6 Analyses of the Presence of HCMV DNA Sequences in Blood 
Samples of the Brain Tumor Patients 
To exclude a possible contamination of brain tumor tissues by HCMV DNA positive blood 
cells, PCR of corresponding blood samples of 71 brain tumor patients was carried out. From 
five glioma patients, no blood sample was available. 
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3.6.1 Prevalence of DNA Sequences of the HCMV-specific 
GlycoproteinB (UL55) Gene 
DNA from patients’ blood samples was amplified by nested PCR using primers for the 
detection of sequences of the HCMV-specific gB (UL55) gene as described by Cobbs et al. 
[2002]. No viral DNA sequences were detected in any of the corresponding blood samples 
(Fig. 12). 
 
PC NC102327 1126 1819 17 1220D
 
Figure 12: Agarose gel after PCR for the detection of HCMV-
specific gB gene as described by Cobbs et al. [2002] in 10 blood 
samples from patients with primary brain tumor (as an example for 
71 blood samples tested); D, DNA ladder (size marker); PC, positive 
control; NC, negative control 
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3.6.2 Prevalence of DNA Sequences of the HCMV-specific Immediate 
Early-1 (UL123) Gene 
Another nested PCR protocol was carried out for the detection of DNA sequences of the IE-1 
gene as published by Mangano et al. [1992] to validate the results obtained with nested PCR 
using primers specific for sequences of the gB (UL55) gene. HCMV-specific IE-1 gene 
sequences were not detected in any of the blood samples (Fig. 13).  
 
PC NC62 61 58 5560 59 545657D
 
Figure 13: Agarose gel after PCR for the detection of HCMV-
specific IE-1 gene as described by Mangano et al. [1992] in 9 blood 
samples from patients with primary brain tumor (as an example 
for 71 blood samples tested); D, DNA ladder; PC, positive control; 
NC, negative control 
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3.7 Polymerase Chain Reaction in Brain Tumor Tissues 
3.7.1 Quality Assessment (GAPDH Detection) in Brain Tumor DNA 
All brain tumor samples were examined for the presence of amplifiable cellular DNA by a 
GAPDH PCR to control for successful DNA extraction. Cellular GAPDH DNA sequences 
could be amplified in all brain tumor samples, demonstrating that no inhibitors of the PCR 
were present in the sample. A positive result was defined as a band of 670 bp (Fig. 14).  
 
Amplified brain tumor DNA
Amplified brain tumor DNAPC
PC
D
D ifie
ifie
NC
NC
 
Figure 14: Agarose gel after GAPDH PCR to control for 
successful DNA extraction of primary brain tumors 
(representative for 76 brain tumor samples tested); D, DNA 
ladder; PC, positive control; NC, negative control 
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3.7.2 Analyses of the Presence of HCMV DNA Sequences in Primary 
Brain Tumor Tissues 
To evaluate the role of HCMV in brain tumor development as previously suggested by Cobbs 
et al. [2002], the presence of HCMV DNA was assessed in 76 primary brain tumors using 
different nested PCR protocols.  
 
3.7.2.1 Detection of Sequences of the HCMV-specific Glycoprotein B (UL55) 
Gene 
No HCMV-specific gB (UL55) gene sequences were detected in the tumor samples using two 
different PCR protocols (Fig. 15). Nested PCR was performed using primers synthesized from 
HCMV strain AD169 for the detection of gB (UL55) gene and, in a subset of DNA samples, 
using a protocol as published by Cobbs et al. [2002] to exclude possible measurement errors.  
 
PC NC59 58 56 5357 55 54 52D
 
Figure 15: Agarose gel after gB (UL55) PCR for the detection of 
HCMV-specific gB gene using primers as described in Chapt. 
2.4.4 in 8 brain tumor samples (as an example for 76 neoplasms 
tested); D, DNA ladder; PC, positive control; NC, negative 
control 
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3.7.2.2 Detection of Sequences of the HCMV-specific Immediate Early-1 Gene 
Sequences of the HCMV-specific IE-1 gene were not found in any of the 76 primary brain 
tumors investigated using two different PCR protocols (Fig. 16). Primers for the detection of 
sequences of the IE-1 gene were synthesized from HCMV strain AD169 and, in a subset of 
DNA samples to control for false negative results, primers as published by Mangano et al. 
[1992] were used for the detection of such HCMV DNA sequences in brain tumor tissues.  
 
PC NC59 58 56 5357 55 54 52D
 
Figure 16: Agarose gel after PCR for the detection of IE-1 gene 
using primers as described in Chapt. 2.4.4 in 8 primary brain 
tumors as an example for 76 brain tumors tested; D, DNA ladder; 
PC, positive control; NC, negative control 
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3.8 Prevalence of HCMV Proteins in Primary Brain Tumors 
Because of published discrepancies between results obtained from PCR and 
immunohistochemical analyses, the presence of HCMV-specific proteins in brain tumor 
samples as well as in short-term cultures derived therefrom was investigated additionally.  
 
3.8.1 Detection of the HCMV-specific Phosphoprotein 65 Antigen  
No immunoreactivity was detected in sections of 72 primary brain tumors and in four short-
term cultures tested by using anti-pp65 monoclonal antibodies. In contrast, the positive 
controls (HCMV-positive lung tissue and HCMV-infected fibroblasts, respectively) showed 
clear intracytoplasmatic and intranuclear antigen staining with the protocols used (Fig. 17).  
 
3.8.2 Detection of the HCMV-specific Immediate Early-1 Antigen  
Immunohistochemistry was performed using a monoclonal anti-IE-1 antibody to validate the 
results obtained for pp65. No HCMV-specific IE-1 protein was detected in the brain tumor 
sections. In contrast, clear intracytoplasmatic and intranuclear antigen staining was seen in 
HCMV-positive lung tissue and in HCMV-infected fibroblasts, which served as positive 
controls (Fig. 17). 
 
3.8.3 Detection of the HCMV-specific Early Antigen  
To investigate the possibility that EA can be detected in the absence of expression of IE 
proteins, an immunohistochemical protocol was carried out for the detection of HCMV EA. 
Again, no immunoreactivity was detected in paraffin slides of brain tumors in contrast to a 
clear positive staining observed in the positive control (Fig. 17).  
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Figure 17: Immunohistochemistry for HCMV detection in brain tumor sections. Tissue types and anti-
HCMV antibodies used (pp65, IE1, EA), are indicated in the respective micrograph. Typical enlarged cells 
can be seen in the positive controls (HCMV-infected lung tissue and HCMV-infected fibroblasts, 
respectively) with HCMV-immunoreactivity (red staining) in both, cytoplasm and nucleus (column A). 
The lack of immunoreactivity in brain tumor tissue sections (first, second, and third row) and 
corresponding short-term cultures (last row) is visible in columns B and C.  
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3.9 Summary of Analyses for the Detection of HCMV Macromolecules 
in Brain Tumor Tissues and Blood Samples 
Summarizing the results obtained with immunohistochemistry and PCR of brain tumor tissues 
and obtained with PCR of corresponding blood samples, HCMV macromolecules could be 
detected neither in the primary brain tumors nor in patients’ blood. The results of all analyses 
performed as well as the histology of all primary brain tumors included in the present study 
are compiled in Tab. 30. 
 
Table 30: Lack of detection of HCMV molecules in brain tumor tissue and corresponding blood samples using 
different methods (number of positive samples out of the number of samples tested) 
 n 
 PCR  
tumor tissue
(n=76) 
 
IHC 
tumor tissue 
(n=72)* 
 
PCR  
blood samples
(n=71)** 
Tumor 
type   
 Primers 
specific for  
Monoclonal 
antibodies to  
Primers 
specific for 
   gB IE1  pp65 IE EA  gB IE1 
            
Glioblastoma multiforme IV 23  0/23 0/23  0/22 0/22 0/22  0/22 0/22 
Gliosarcoma IV 1  0/1 0/1  0/1 0/1 0/1  0/1 0/1 
Anaplastic oligodendroglioma III 4  0/4 0/4  0/4 0/4 0/4  0/2 0/2 
Astrocytoma II/III 2  0/2 0/2  0/1 0/1 0/1  0/1 0/1 
Diffuse astrocytoma II 3  0/3 0/3  0/3 0/3 0/3  0/3 0/3 
Oligodendroglioma II 1  0/1 0/1  0/1 0/1 0/1  0/1 0/1 
Glioma (not further specified) 5  0/5 0/5  0/5 0/5 0/5  0/4 0/4 
            
Transitional meningioma I 10  0/10 0/10  0/9 0/9 0/9  0/10 0/10 
Meningothelial meningioma I 5  0/5 0/5  0/5 0/5 0/5  0/5 0/5 
Microcystic meningioma I 2  0/2 0/2  0/2 0/2 0/2  0/2 0/2 
Fibrous meningioma I 2  0/2 0/2  0/2 0/2 0/2  0/2 0/2 
Psammomatous meningioma I 1  0/1 0/1  0/0 0/0 0/0  0/1 0/1 
Secretory meningioma I 2  0/2 0/2  0/2 0/2 0/2  0/2 0/2 
Meningioma I 6  0/6 0/6  0/6 0/6 0/6  0/6 0/6 
Atypical meningioma II 3  0/3 0/3  0/3 0/3 0/3  0/3 0/3 
            
Acoustic neurinoma I 5  0/5 0/5  0/5 0/5 0/5  0/5 0/5 
Acoustic neurinoma II 1  0/1 0/1   0/1 0/1 0/1  0/1 0/1 
            
Tumors in total 76  0/76 0/76  0/72 0/72 0/72  0/71 0/71 
*no paraffin slides available of 2 glioma and 2 meningioma;  
**no blood samples available for 5 glioma patients; 
gB, glycoproteinB; IE, immediate early; pp65, phosphoprotein 65; EA, early antigen; IHC, immunohistochemistry 
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3.10 Prevalences of IgG and IgM Antibodies in Serum Samples 
To estimate the seroprevalences of antibodies to four herpesviruses (HCMV, HSV, EBV, 
VZV), serum samples of 71 (93%) of the 76 brain tumor patients included in the present study 
were examined by an automated Enzyme Immunoassay (BEP-III®-system, Dade-Behring).  
 
3.10.1 Prevalences of IgM Antibodies to HCMV, HSV, EBV, and VZV 
At the time of surgery, none of the primary brain tumor patients’ sera was positive for IgM 
antibodies to HCMV, HSV, EBV, and VZV, indicating that none of them had an acute 
herpesvirus infection or reactivation of these viruses at the time of surgery. 
 
3.10.2 Prevalences of IgG Antibodies to HCMV, HSV, EBV, and VZV 
The presence of IgG antibodies is an indicator for a previous exposure to the corresponding 
antigen. To investigate the possible role of previous infections with HCMV, HSV, EBV, and 
VZV in brain tumor development, the prevalence of anti-herpesvirus IgGs was determined. 
 
Table 31: Overall seroprevalences of IgG antibodies to 
HCMV, HSV, EBV and VZV in 71 brain tumor patients 
 Brain tumor patients  (N=71) 
 IgG positive (n) 
Prevalence 
(%) (95%CI) 
    
HCMV 45 63.4 (51, 75) 
HSV 61 85.9 (76, 93) 
EBV 63 88.7 (79, 95) 
VZV 65 91.6 (83, 97) 
    
HCMV, human cytomegalovirus; HSV, herpes simplex virus; 
EBV, Epstein-Barr virus; VZV, varicella-zoster virus; CI, 
confidence interval 
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Overall prevalences (Tab. 31 and Fig. 
18) as well as prevalences stratified 
by 20-year age groups and tumor type 
(Tab. 32; Fig. 19; Tab. 34) and the 
corresponding 95%CI of IgG 
antibodies to HCMV, HSV, EBV and 
VZV were evaluated. Additionally, 
gliomas were stratified according to 
Wrensch et al. [2001] into WHO 
grade I-III and WHO grade IV 
gliomas for additional analyses (Tab. 
33). 
 
3.10.2.1 IgG Antibodies to HCMV 
For all brain tumor patients, the seroprevalence of antibodies to HCMV was 63% (95%CI 
51%-75%; Tab. 31). Stratified by age, a clear increase in seroprevalence was observed from 
50% in the youngest age group (20-39 years) to 73% in the oldest age group (60-84 years; 
Tab. 32), which could also be observed in analyses stratified by tumor type, though less 
conspicious (Tab. 34). Stratification of the gliomas by WHO grading did not show any 
perceivable differences (Tab. 33). 
 
3.10.2.2 IgG Antibodies to HSV 
The overall seroprevalence of antibodies to HSV was 86% (95%CI 76%-93%; Tab. 31). An 
increase in the prevalence from 79% (95%CI 49%-95%) in the youngest to 88% (95%CI 
70%-98%) in the oldest age group was observed (Tab. 32), which was still present in 
meningioma and acoustic neurinoma patients in tumor type stratified analyses (Tab. 34). 
Stratification by WHO grading did not show any perceivable differences (Tab. 33). 
HCMV IgG HSV IgG EBV IgG VZV IgG
IgG antibodies
Prevalences in %
20
40
60
80
100
 
Figure 18: Overall seroprevalences and corresponding 
95%CI of IgG antibodies to HCMV, HSV, EBV and 
VZV in 71 brain tumor patients 
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Table 32: Seroprevalences and corresponding 95% 
confidence intervals (95%CI) of IgG antibodies to HCMV, 
HSV, EBV and VZV in 71 brain tumor patients  
Age Groups  Brain tumor  patients 
 n Prevalence (%) (95%CI) 
    
HCMV    
20-39y 14 50.0 (23, 77) 
40-59y 31 61.3 (42, 78) 
60-84y 26 73.1 (52, 88) 
    
HSV    
20-39y 14 78.6 (49, 95) 
40-59y 31 87.1 (70, 96) 
60-84y 26 87.5 (70, 98) 
    
EBV    
20-39y 14 100 (77, 100) 
40-59y 31 90.3 (74, 98) 
60-84y 26 80.8 (61, 93) 
    
VZV    
20-39y 14 78.6 (49, 95) 
40-59y 31 100.0 (89, 100) 
60-84y 26 88.5 (70, 98) 
    
HCMV, human cytomegalovirus; HSV, herpes simplex virus; 
EBV, Epstein-Barr virus; VZV, varicella-zoster virus; CI, 
confidence interval; y, years 
 
3.10.2.3 IgG Antibodies to EBV 
The overall seroprevalence for anti-EBV IgGs was 89% (95%CI 79%-95%; Tab. 31). In age-
stratified analyses, the seroprevalence decreased from 100% (95%CI 77%-100%) in the 
youngest age group to 81% (95%CI 61%-93%) in patients over 60 years of age (Tab. 32). A 
similar trend was found only for meningioma patients after stratification by tumor type (Tab. 
34). Compared to subjects with gliomas WHO grade I-III, glioblastoma patients had a 
decreased seroprevalence of IgG antibodies to EBV (Tab. 33). 
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Figure 19: Seroprevalences and corresponding 95%CI of IgG antibodies to HCMV, HSV, EBV, and 
VZV in brain tumor patients stratified by 20-year age groups (71 serum samples tested) 
 
 
Table 33: Seroprevalences in 34 glioma patients stratified by WHO grading 
Glioma patients in the present study 
Prevalences of 
IgGs to 
All  
(n=34)* 
GBM IV ** 
(n=23) 
WHO I-III  
(n=11) 
    
HCMV 58% 57% 64% 
 (41-75%) (35-77%) (31-89%) 
    
HSV 91% 91% 91% 
 (76-98%) (72-99%) (59-100%) 
    
EBV 85% 83% 91% 
 (69-95%) (61-95%) (59-100%) 
    
VZV 91% 91% 91% 
 (76-98%) (72-99%) (59-100%) 
    
*5 glioma patients did not provide a blood sample;  
**1 GBM patient with did not provide a blood sample; 
WHO, World Health Organization; IgG, immunoglobulin G; GBM, glioblastoma 
multiforme; HCMV, human cytomegalovirus; HSV, herpes simplex virus; EBV, Epstein-
Barr virus; VZV, varicella zoster virus 
Epstein-Barr virus 
Human cytomegalovirus 
Varicella-zoster virus 
Herpes simplex virus
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3.10.2.4 IgG Antibodies to VZV 
Overall, the seroprevalence of IgG antibodies to VZV was 92% (95%CI 83%-97%; Tab. 31). 
Stratified by age, no age-dependent trend was seen (Tab. 32). Patients aged from 40-59 years 
showed a peak seroprevalence of 100% (95%CI 89%-100%), which was also observed after 
stratification for tumor type (Tab. 34). In glioma patients, the prevalences did not differ 
between the different WHO grades (Tab. 33). 
 
Table 34: Seroprevalences of IgG antibodies to HCMV, HSV, EBV, and VZV, stratified by tumor type 
and 20-year age groups 
  
 IgG antibody-positive patients with 
 Glioma (n=34**) Meningioma (n=31) ACN (n=6) 
Virus   
         age  n SP (%) (95%CI) n SP (%) (95%CI) n SP (%) (95%CI) 
          
HCMV          
20-39y 7 42.9 (10, 82) 4 75.0 (19, 99) 3 33.3 (1, 91) 
40-59y 12 58.3 (28, 85) 17 58.8 (33, 82) 2 100 (16, 100) 
60-84y 15 66.7 (38, 88) 10 80.0 (44, 97) 1 100 (3, 100) 
all 34 58.8 (41, 75) 31 67.7 (49, 83) 6 66.7 (22, 96) 
          
HSV          
20-39y 7 85.7 (42, 100) 4 75.0 (19, 99) 3 66.7 (9, 99) 
40-59y 12 100 (74, 100) 17 76.5 (50, 93) 2 100 (16, 100) 
60-84y 15 86.7 (60, 98) 10 90.0 (56, 100) 1 100 (3, 100) 
all 34 91.2 (76, 98) 31 80.7 (63, 93) 6 83.3 (36, 100) 
          
EBV          
20-39y 7 100 (59, 100) 4 100 (40, 100) 3 100 (29, 100) 
40-59y 12 83.3 (52, 98) 17 94.1 (71, 100) 2 100 (16, 100) 
60-84y 15 86.7 (52, 96) 10 80.0 (44, 97) 1 100 (3, 100) 
all 34 85.3 (69, 95) 31 85.7 (70, 95) 6 100 (54, 100) 
          
VZV          
20-39y 7 85.7 (42, 100) 4 50.0 (7, 93) 3 100 (29, 100) 
40-59y 12 100 (74, 100) 17 100 (80, 100) 2 100 (16, 100) 
60-84y 15 86.7 (60, 98) 10 90.0 (56, 100) 1 100 (3, 100) 
all 34 91.2 (76, 98) 31 91.4 (77, 98) 6 100 (54, 100) 
          
**no serum sample available for five glioma patients; 
HCMV, human cytomegalovirus; HSV, herpes simplex virus; EBV, Epstein-Barr virus; VZV, varicella-zoster 
virus; SP, seroprevalence; CI, confidence interval; y, years; IgG, immunoglobulin G 
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4 Discussion 
4.1 Ethical Justification for the Part-time Anonymous Sample 
Collection 
In the present study, laboratory as well as questionnaire data were evaluated. During 
collection of the brain tumor samples, organizational problems occurred and ten of the 
samples had to be collected anonymously. This may have been in conflict with ethical issues. 
However, according to the central ethics commission, it is appropriate to use samples without 
informed consent of the patients if the following premises are provided [Zentrale 
Ethikkommission Deutschland, 2003]: 
(1) Analyzing the sample will no longer be useful for the respective person (e.g. for 
diagnostics), 
(2) the samples are fully anonymized, 
(3) no individual gene analyses will be performed, 
(4) the results of the study will be of no individual use for the respective person or its 
family members, 
(5) no controversial issues are under research, 
(6) there are no hints for a potential refusal of the concerned patient, and 
(7) the informed consent can only be obtained with extraordinary efforts. 
In the present study, the respective samples were anonymized in such way that only data on 
gender and year of birth were obtained. Therefore, the persons could never be traced back.  
Furthermore, the study investigated putative etiological pathways in brain tumor development 
and therefore, as persons were already affected by a brain malignancy, the outcome of the 
study was of no individual prognostic interest. Similarly, this is true for family members.  
Gene analyses were not performed, and there are also no hints that affected persons are not 
willing to help to ascertain the development of their disease. 
Therefore, the use of the ten anonymized samples in the present study is justifiable.  
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(A) Questionnaire Data 
A questionnaire was developed to control for factors indicative of previous infections, 
especially with herpesviruses, and to control for any possible reactivation of herpesviruses, 
which previously had been suggested to lead to cancers [Cinatl, Jr. et al., 2004; Michaelis et 
al., 2004; Roizman and Pellet, 2001; Chan et al., 1999; zur Hausen, 1975; Gahrton et al., 
1971].  
In addition, the role of several medical conditions as well as the suggestive role of high-level 
contact to humans or animals in brain tumor development, which are controversially 
discussed in the literature, were addressed [Ohgaki and Kleihues, 2005; Khuder et al., 1998; 
Preston-Martin and Mack, 1996]. 
 
4.2 Characteristics of Participants Completing the Questionnaire  
The present study comprises two parts. First, laboratory analyses were performed to confirm 
the results of Cobbs et al. [2002] indicating a possible role of HCMV in brain tumor 
pathogenesis and second, a questionnaire was developed to control for factors indicative of 
previous infections and for other variables (cf. above).  
Unfortunately, 22 of the 76 study participants in the present study did not complete the 
questionnaire for different reasons, mainly because of the part-time anonymous tumor 
collection, which could not be avoided during the collection period. Therefore, heterogeneity 
between patients not interviewed and the subset of patients completing the interview was 
tested.  
Putative risk factors (mainly factors related to infections) were reported to be rather associated 
to tumor grading than to factors like gender or age. Therefore, and due to the small sample 
size in this study, WHO grading was determined to be the most important factor for analyses, 
and the test for heterogeneity between those completing and those not completing the 
questionnaire focused on the histological distribution of the tumors in these groups.  
No heterogeneity at a significance level of α=0.05 between those patients completing the 
questionnaire and those not interviewed was detected using Fisher’s exact test. Therefore, it 
was presumed for the present study that the subset of interviewed persons was probably 
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representative for the whole study population, although, of course, this result may not have 
been obtained in a larger study population or if the comparison would have been done by 
methods of equivalence testing. Therefore, the results in the present study have to be 
interpreted with care. 
 
Demographic Factors 
In the present study, the tendency of both age and gender distribution in glioma and 
meningioma patients was similar to published descriptive epidemiology. There were more 
males having glioma and obviously more women were affected by meningioma. Therefore, 
the study participants affected by glioma and meningioma are a representative subset of brain 
tumor patients. 
Generally, astrocytoma and glioblastoma have a peak in incidence at the age of 65-74 years 
and oligodendroglioma at the age of 35-44 years. Males are more often affected than females 
[Wrensch et al., 2002; Davis et al., 1999; Preston-Martin and Mack, 1996]. In meningioma, 
the incidence rate increases with increasing age [Bondy and Ligon, 1996]. A peak occurrence 
can be seen between 50-70 years of age [WHO, 2000b], and females are significantly more 
affected [Wrensch et al., 2002; Davis et al., 1999; Inskip et al., 1995].  
Gender and age distribution in acoustic neurinoma patients, though, differed from that 
reported in the literature as they usually occur in people aged 50 years and above [Lanser et 
al., 1992] without any association with gender [Muscat et al., 2002]. However, this 
observation is likely to be due to the small number of acoustic neurinoma patients included in 
the present study.  
 
Socioeconomic Status 
An association between the socioeconomic status and brain tumor development was reported 
in several studies. Therefore, in the present study, the socioeconomic status was evaluated 
according to guidelines of the “Deutsche Arbeitsgemeinschaft für Epidemiologie”[DAE, 
1997], taking into account educational and training level of each subject. Most subjects were 
grouped in category 3, indicating a low social class for most study subjects in either tumor 
type subgroup. This is in contrast to previous studies reporting a positive correlation between 
social class and all brain tumor types combined [Preston-Martin and Mack, 1996]. In 
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stratified analyses, higher social class seemed to be positively associated with glioma, 
meningioma and acoustic neurinoma [Faggiano et al., 1997; Preston-Martin et al., 1993; 
Preston-Martin, 1989]. Other studies, however, found a negative association between high 
social class (evaluated by assessing years of schooling) and the occurrence of glioma 
[Schlehofer et al., 2005; Preston-Martin et al., 1998].  
In the present study, few people were on higher social classes in either histological type of 
brain tumor. For glioma, this corresponds to some of the published results. For meningioma 
and acoustic neurinoma, however, the present results differ from literature, which may be due 
to the small number of patients included in the present study.  
A case-control study has been conducted by Inskip et al. [2003] to evaluate the association of 
sociodemographic indicators and the risk of brain tumors. Being single at the time of 
diagnosis was associated with a significantly reduced risk for meningioma and glioma, but not 
for acoustic neurinoma. Similarly, most participants in the present study were married or 
living with a partner. In analyses stratified by tumor type, the proportion of all patients being 
single was less to those being married or having a partner. An explanation for this reported 
distribution might be that spouses recognize brain tumor symptoms earlier than affected 
persons, and force them to seek medical advice. Similar results were reported by Goodwin et 
al. [1987]. Unmarried persons had a poorer prognosis and they were more likely to be 
diagnosed at a regional or distant stage as persons living with a partner. Therefore, the results 
of the present study are in the line with published results.  
 
4.3 Association between Medical History and Primary Brain 
Tumors 
4.3.1 Previous Infections 
In the present study, histories of previous infections in brain tumor patients were addressed 
for two reasons. On the one hand, previous infections with herpesviruses were evaluated to 
control for a possible involvement of these viruses in brain tumor development. On the other 
hand, there is strong evidence that common infections like colds and flu may play a decisive 
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role in brain tumor pathogenesis (see below). Furthermore, the correlation between self-
reported history of herpesvirus disease and occurrence of IgGs was evaluated.  
As mentioned above, human herpesviruses have been suggested to be involved in the 
pathogenesis of several tumors. For EBV it is evident that it plays a role in specific lymphoma 
and sarcoma pathogenesis. In addition, its part in the development of nasopharyngeal 
carcinoma has become clear during the last years [Rickinson and Kieff, 2001]. HCMV has 
been linked to several neoplasms, including tumors of cervix, prostate, colon, and brain 
[Samanta et al., 2003; Cobbs et al., 2002; Harkins et al., 2002; Ho, 1982]. Being a sexually 
transmitted disease, HSV has been discussed as co-factor for cervical carcinoma 
pathogenesis, though the results are still inconsistent [Whitley, 1990]. The occurrence of 
chickenpox (primary VZV infection) and shingles (reactivation of latent VZV) has been 
reported to be less prevalent in glioma patients than in population-based controls [Wrensch et 
al., 1997b]. Another case-control study in a similar study population by Wrensch et al. [2001] 
showed a reduced prevalence of IgG antibodies to VZV in glioma patients with a significant 
inverse correlation for glioblastoma cases. This was additionally confirmed in another study 
population, taking into account the levels of anti-VZV IgG [Wrensch et al., 2005]. 
This section first focuses on the distribution of infectious diseases in the study subjects, 
followed by a discussion of the self-reported history of disease and the serological result. 
 
Common Infections 
In the present study, meningioma patients were more often affected by common infections 
than all other patients were. Frequent occurrence of infectious diseases was reported by 69% 
of them, in contrast to 26% in glioma patients and 20% in acoustic neurinoma patients.  
Common infections are suggested to be involved in cancer development since several years. 
In previous studies addressing brain tumors and common infections prior to tumor diagnosis, 
decreased risks were consistently seen for glioma patients. Decreased tumor risks for people 
with a history of common infections such as colds and gastroenteric influenza were found by 
Abel et al. [1991] and subsequently supported by several studies. Schlehofer et al. [1999] 
reported that population-based controls were more likely to have common infections than 
glioma and meningioma cases in an international population-based case-control study on 
brain tumors. Other investigators could not find statistically significant associations, though 
the trend of the odds ratios for brain malignancies and infectious diseases were also indicative 
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for an inverse association between common infections and brain tumors [Cicuttini et al., 
1997]. This observed correlation, however, is not yet understood. Immunologic factors 
triggering the immune system are suggested to alter the tumor risk.  
A major problem concerning this subject is that “common disease” is a very subjective 
variable. In the present study, an inverse association with infectious diseases and brain tumor 
development is likely to be apparent in glioma patients if any is present. The proportion in 
meningioma patients, though, seems to be elevated, and would therefore rebut previous 
studies reporting higher prevalences of common infections in healthy individuals (cf. above).  
However, there is no comparative literature available about the prevalence of common 
diseases in the general population. Therefore, and due to the small sample size, the 
distribution of infectious diseases in the different tumor types of the present study has to be 
interpreted with care. 
 
Mononucleosis 
Mononucleosis is caused by EBV, which has been proven to be an oncogenic virus 
[Rickinson and Kieff, 2001]. Furthermore, it has been shown in vitro that EBV is able to 
infect astrocytes [Menet et al., 1999]. The seroprevalence of anti-EBV antibodies has been 
investigated, suggesting previous EBV to be involved in brain tumor pathogenesis [Wrensch 
et al., 2005; Wrensch et al., 2001]. However, none of the subjects in the present study 
reported previous mononucleosis disease. 
 
Exanthema Subitum 
Only one glioma and one meningioma patient reported previous roseola infantum (exanthema 
subitum), which occurs after infection with HHV-6 and leads to a generally benign rash 
illness of infants. This disease is characterized by fever occurring in newborns [Maschke, 
1967], which is often not recognized as this specific condition.  
Few of the present study’s participants knew this disease, mostly those with small children. 
This might be the reason for the low prevalence in the present study, possibly introducing a 
high recall bias. For this reason, it is difficult to make a statement about the occurrence of 
roseola infantum in brain tumor patients in this study.  
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Herpes Labialis 
30% of glioma patients, 46% of meningioma patients and one patient with acoustic neurinoma 
(20%) reported to be affected by vesicles occurring at the vermilion border of the lip, 
resulting from a reactivation of HSV.  
Reviewed by Whitley [1990], the recurrence rate of herpes labialis is approximately 33% 
(range from 16% to 38%) with a higher frequency in the upper social classes. Although this 
virus has been suggested to be involved in tumor pathogenesis, interestingly, an oncolytic 
(cancer killing) property of HSV has also been seen, and modified HSV may provide a tool 
for the treatment of malignant gliomas [Shah et al., 2003].  
In the present study, there seems to be an elevated number of meningioma patients affected by 
herpes simplex lesions, especially after considering the low SES in these patients. However, 
to the author’s knowledge, there are no clear-cut prevalence data about recurrent orolabial 
herpes disease and there is no report suspecting HSV disease to cause primary brain tumors. 
Thus, and due to the small sample size, results have to be interpreted carefully and further 
research is needed to evaluate the role of HSV in the etiology of brain malignancies.  
 
Chickenpox and Shingles 
In the present study, 52% of glioma, 65% of meningioma, and 80% of acoustic neurinoma 
patients reported previous chickenpox. The occurrence of shingles was reported by 17% of 
glioma and 8% of meningioma patients, resulting in recurrence rates (i.e., the proportion of 
shingles in individuals with a positive history of chickenpox) of 25% and 6%, respectively.  
In a population-based case-control study, Wrensch et al. [1997b] reported an inverse 
correlation between glioma cases and self-reported history of chickenpox and shingles. 
However, although these findings were confirmed using serological analyses by the same 
investigators [Wrensch et al., 2005; 2001], no plausible biological explanation has yet been 
found for this observation. Immunological factors might have an influence on glioma 
pathogenesis, either by preventing cancer development or by killing existing cancer cells. A 
decreased risk for histories of common infections and allergies and the development of brain 
tumors has been reported, supporting this hypothesis (cf. above).  
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Unfortunately, no prevalence data for chickenpox and shingles in the overall German 
population are available. An incidence of 42.2 per 10 000 per year was reported for the 
country city of Ansbach (Bavaria) in 1996 [Paul and Thiel].  
Furthermore, results of the present study may not be comparable with that of previous 
publications since these probably included individuals vaccinated against varicella in recent 
years and prevented the disease. In contrast, varicella vaccination was unlikely in the present 
study population because of the median age of the patients and the fact that this vaccination 
was first recommended by the German Permanent Immunization Committee (Ständige 
Impfkommission, STIKO) after the present study period. Considering the results of the 
present study and the hypothesis of frequent infections triggering the immune system and 
preventing cancer, low prevalences of VZV disease would have been expected, especially for 
reactivation of the virus (i.e., shingles). Therefore, VZV could be suggested to be involved in 
glioma etiology because of the low prevalence of chickenpox, and in meningioma 
pathogenesis, for these reported low proportions of shingles.  
On the other hand, it has been reported that cancer is associated with a higher risk for shingles 
[Arvin, 2001; Whitley, 1990], but it has also been found that herpes zoster in healthy persons 
is not associated with an increased risk for neoplasms [Ragozzino et al., 1982].  
Hence, no definite conclusion can be drawn and further research may be needed to evaluate a 
potential role of VZV in the pathogenesis of primary brain tumors. 
 
Correlation between Self-reported Disease and Occurrence of IgG Antibodies 
Self-reported histories of herpesvirus infections in the present study, however, do not reflect 
the serological status of the persons concerning anti-herpesvirus antibodies, as these 
infections are frequently inapparent. Therefore, the seroprevalence of IgG antibodies to 
HCMV, HSV, EBV, and VZV was evaluated and compared to the self-reported history of the 
respective diseases. The seroprevalences are discussed in more detail in Chapt. 4.7.  
Only few of the patients reporting a negative history of either disease were seronegative for 
the respective IgG antibodies of the disease-causing agent, for chickenpox/shingles yet none 
of them. Overall, most individuals reporting never having had the disease were antibody 
positive. This is explainable by the fact that, with the exception of VZV, the addressed 
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herpesviruses rarely cause clinical disease after infection of the host (reviewed by Pass, 2001; 
Arvin, 2001; Rickinson and Kieff, 2001; Whitley, 1990).  
Interestingly, each two patients with glioma and meningioma reported a previous occurrence 
of chickenpox although they were seronegative for IgG antibodies to VZV. There are three 
possible explanations for this phenomenon: 
a) The patients did not exactly remember whether they had chickenpox during childhood 
and just suggested they had, because they knew it is a common childhood disease 
(potential recall bias); 
b) The patients mistook the disease with another condition occurring during childhood, 
such as rubella and measles, or with other diseases like smallpox and scabies; 
c) Antibody titers decline with increasing age and decrease in immunocompromised 
individuals [Arvin, 2001]. Taking into account the median age of the patients and 
cancer as an immunocompromising condition, this could explain the discrepancy 
between a positive self-reported history of chickenpox and seronegativity. 
The presence of IgG antibodies to VZV by reported history of chickenpox has been addressed 
by Wrensch et al. [Wrensch et al., 1997b] in a subgroup of another population-based case-
control study [Wrensch et al., 1997a] for whom serum samples were available. Among those 
reporting a positive history of chickenpox, glioma cases were more likely to have IgG 
antibodies to VZV than controls, though not statistically significant. Recently, this finding 
could be corroborated focusing on the levels of anti-VZV antibodies. Glioma cases had lower 
levels than population-based controls. In addition, glioblastoma cases were less likely to 
report a previous chickenpox history [Wrensch et al., 2005]. 
In the present study, all different tumor types investigated were more likely to have VZV IgG 
antibodies when they reported a positive history of chickenpox whereas most of the patients 
were not aware to be affected by any other diseases although they were seropositive for the 
respective virus (HCMV, HSV, and EBV). This is in the line with the fact that most 
herpesvirus infections (except VZV) rarely cause manifest disease (cf. above). For VZV, 
present results are in conformity with several other studies reporting that only about 50% of 
seropositive individuals give a clinical history of varicella, indicating either asymptomatic or 
mild disease or misdiagnosis [Ronan and Wallace, 2001; Arvin, 2001].  
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Only one third of the meningioma patients were IgG-positive despite a negative self-reported 
history of herpes labialis or genitalis in contrast to more than half of the glioma patients. 
Clinically apparent diseases have been suggested to have a negative influence towards the 
development of brain tumors, mainly gliomas [Schlehofer et al., 1999]. However, the 
seroprevalence of HSV IgGs and the prevalence of apparent orolabial disease in glioma 
patients in the present study were similar to that reported in the population (cf. above and 
below).  
For other herpesvirus diseases, no differences could be observed in the different tumor types 
concerning seroprevalence and the respective condition.  
Therefore, the conclusion of comparing self-reported history of a disease and the respective 
serology is that self-reported history of disease can not at all be a surrogate for the occurrence 
of IgG antibodies to the disease-causing agent.  
 
4.3.2 Vaccinations 
Vaccinations support the immune system by improving defense against certain antigens, 
thereby reducing the possibility of being affected by the respective disease. On the other hand, 
population prevalences of these diseases are generally low, and vaccinations generally 
stimulate the immune system by confronting it with an antigen. As discussed in Chapt. 4.3, 
there is evidence that people frequently affected by common colds are at lower risk for brain 
tumor development, possibly by stimulation of the immune system. Therefore, it might be 
possible that frequently vaccinated individuals are at lower risk for tumor development due to 
a triggered immune system, similar to the suggested inverse association of brain tumor 
development and allergies or common colds [Brenner et al., 2002; Schlehofer et al., 1999; 
Schlehofer et al., 1992; Abel et al., 1991].  
In Germany, there is no compulsory vaccination, and most people are not aware of how often 
they were vaccinated against which disease (especially those that are vaccinated in childhood) 
and if the protection provided by immunization is still sufficient. Therefore, “ever being 
vaccinated” against a certain disease was addressed in the questionnaire. As participants were 
adults, some of the vaccinations nowadays applied to children were not inquired. For instance, 
vaccination against varicella has only been recommended by the Permanent Immunization 
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Committee (Ständige Impfkommission, STIKO) of the Robert Koch-Institute, Germany, since 
July 2004, which was after the present study period, and therefore, this vaccination was not 
assessed in the questionnaire.  
Several studies had analyzed vaccination rates in the German population. According to the 
Robert Koch-Institute, Germany, rates in adults are 33% for diphtheria, and 63% for tetanus 
[Reiter and Rasch, 2004; RKI, 2002]. Immunity levels against diphtheria, tetanus and 
poliomyelitis were reported to be 60%, 72% and 79%, respectively, in a study among blood 
donors in Berlin [Stark et al., 1999].  
Tetanus was the commonest vaccination in the study subjects with over 79% being 
vaccinated, followed by vaccination against diphtheria and poliomyelitis with an overall 
proportion of 45% and 60%, respectively. It could be suggested that high prevalences of 
tetanus vaccination are a result of the patients being aware of tetanus vaccination prior to 
brain tumor surgery, which is common in Germany. Poliomyelitis vaccination seems to be 
less prevalent in the patients of the present study than in the survey of Stark et al. [1999], 
which might be due to a potential recall bias as this vaccination is usually administered in 
early childhood. However, the proportion of brain tumor patients vaccinated against 
diphtheria was in-between the two studies mentioned above.  
Vaccinations against childhood diseases such as rubella, mumps and measles were rarely 
reported by all brain tumor patients compared to published evaluations in first-year school 
attendees [Reiter and Rasch, 2004; RKI, 2002; Buxbaum et al., 2001]. This might be 
explainable by the median age of the study participants and the fact that vaccinating against 
these diseases first became common when they were already grown up.  
In fact, age seems to be the most likely reason for differing vaccination rates. For instance, 
hepatitis A and B vaccinations are most prevalent in younger individuals who are frequently 
traveling, as well as in children born during the last decade, where hepatitis B vaccination 
became usual during nursery. Tuberculosis vaccination rates are supposed to be higher in the 
elderly than in younger individuals because this vaccination was no longer recommended by 
STIKO after 1982.  
Pertussis vaccination has not been recommended by STIKO between 1974 and 1991; 
therefore, due to the median age of all patients, vaccination rates should be higher than those 
reported [RKI, 2000b]. However, pertussis is a disease most prevalent in small children and 
adolescents; study participants could have been affected by this condition during childhood 
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and therefore were not vaccinated. On the other hand, patients may presumably not remember 
being vaccinated during childhood (potential recall bias). 
Vaccination against influenza is recommended for persons older than 60 years, individuals 
with chronic diseases and persons with high-level contact to humans. However, influenza 
vaccination is still very unpopular in Germany, although medical education is rising. Rates 
are 20-25% in the German population, and the prevalence is significantly increasing in older 
persons in which rates can be as high as 37% [Muller et al., 2005; Rehmet et al., 2002]. The 
overall proportion in the present study was 25% with differences between the different 
histologic tumor types (range 13% to 39%), being in the line with the data aforementioned.  
In the study participants, the mean number of lifetime vaccinations was three to four 
vaccinations (glioma 3.2, meningioma 3.7, and acoustic neurinoma 3.9). Considering advices 
from STIKO, which recommends vaccination against multiple diseases (at least 12 during the 
whole life; RKI, 2004), this seems to be a very low prevalence. This, however, could be 
carefully interpreted as pointing in the same direction as the suggestion that people with a 
boosted immune system are at lower risk for tumor development.  
In summary, lifetime vaccinations were difficult to obtain from the study participants. Age 
seemed to be the most important factor for the presumably high recall bias for this question. 
Therefore, the hypothesis of an influence of immunomodulation in brain tumor development 
remains elusive due to the small sample size of the present study, and further research may be 
required to evaluate this hypothesis.  
 
4.3.3 Participants’ Children as Indicator for Parental HCMV Infection 
The questionnaire addressed malformations and diseases of participants’ children during their 
first year of life to control for a possible prenatal transmission of HCMV from mother to child 
or a postnatal transmission from father to child. Jaundice, anemia, pneumonia and 
gastrointestinal diseases are frequently seen after perinatal HCMV infection. In addition, 
HCMV is the leading infectious cause of congenital malformations [Landolfo et al., 2003; 
Pass, 2001], and can also lead to hearing loss and mental retardation [Nagy et al., 2004]. 
None of the children of acoustic neurinoma patients had any malformations or any of the 
addressed diseases.  
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Jaundice was the most frequently reported disease occurring in the first year of life in affected 
offspring of the patients. In general, jaundice is reported to be present in more than 50% of all 
newborns; however, most cases of neonatal icterus do not need any treatment [Brown et al., 
1999]. One can argue that patients reporting jaundice occurring in their children meant the 
more severe form that needed treatment. On the other hand, “disease” is a highly subjective 
variable. What is a notably disease for one person might not be recognized as disease by 
another person. Thus, participants might also have reported the common mild form, thereby 
introducing a potential recall bias.  
In the present study, one single child of a glioma patient was affected by jaundice; however, 
the parent was seronegative for HCMV. In meningioma patients, six children from five 
patients were affected by jaundice. However, only two of the parents were HCMV 
seropositive and the single patient with two jaundice-affected children was seronegative. 
Therefore, it seems unlikely that HCMV transmission had been the causing factor for jaundice 
in study participants’ children.  
One glioma and one meningioma patient reported the occurrence of hereditary amblyopia in 
their offspring. This might be indicative for a congenital HCMV infection, which frequently 
results in neurologic malformations, e.g. of the perceptual organs [Mets, 2001; de Jong et al., 
1998]. However, none of the other conditions known to be frequently present after congenital 
infection (pneumonia, jaundice, anemia, gastrointestinal disease) had occurred in these 
children. In addition, only the meningioma patient was HCMV seropositive and this sample 
size is unequivocally too small to draw a definite conclusion.  
One child of another meningioma patient was affected by neurodermatitis, asthma and 
chronic gastrointestinal disease during the first year of life. To the author’s knowledge, there 
is no report on an association between neurodermatitis and congenital HCMV infection. 
Asthma has been reported to be present in congenitally HCMV-infected neonates [Nagy et al., 
2004] and gastrointestinal disease is a well known condition after prenatal HCMV infection 
[Pass, 2001]. However, no IgG antibodies to HCMV were found in this patient, thereby ruling 
out the possibility of a perinatal infection.  
One meningioma patient reported the occurrence of intestinal obstruction and pneumonia in 
the offspring. Both conditions are typical for congenital HCMV infection, indicating 
maternal, i.e., brain tumor patients’ HCMV seropositivity. Another meningioma patient 
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reported one child affected by jaundice and pneumonia and another child with jaundice. 
However, both patients were HCMV seronegative.  
In summary, the offspring of glioma and meningioma patients was most commonly affected 
by jaundice, which, however, is a frequent condition in neonates and therefore may not be a 
compulsory indicator for congenital HCMV infection.  
More interesting is the serological status concerning HCMV IgGs in patients with affected 
children. None of the glioma patients was seropositive for HCMV IgGs. Therefore, neither 
jaundice nor amblyopia occurring in glioma patients’ children could be traced back to a 
parental transmission. In total, only 40% (n=4) of the meningioma patients with affected 
children were HCMV seropositive, of which two had kids suffering from jaundice only.  
The serological status of the participants is discussed in Chapt. 4.7. However, the serological 
status evaluated in the study subjects is likely to differ from that obtained years ago at the 
time when their offspring was born and may have been even lower at that time. Therefore, no 
definite conclusion can be drawn. There are some conjecturable conditions present in 
individuals’ children suggesting a parental HCMV infection and subsequent transmission to 
the offspring. However, it seems unlikely in most of the cases comprising the serological 
status of the children’s parents that the addressed medical conditions were an implication of 
parental HCMV infection and subsequent transmission to the offspring.  
 
4.3.4 Immunosuppression 
HCMV could facilitate tumor pathogenesis and enhance tumor growth, as reported for in vitro 
analyses. It is also well documented that HCMV has the ability to modulate functional 
properties of neuroblastoma cells [Scholz et al., 1999], and that HCMV IE proteins can block 
apoptosis and activate replication enzymes [Cinatl, Jr. et al., 1996].  
In addition, higher prevalences of brain tumors in graft recipients, in individuals that use 
immunosuppressive drugs and individuals immunocompromised by viral infections (e.g. HIV 
infection) are well documented [Kinlen, 2004; Buell et al., 2004; Salvati et al., 2003; Vial and 
Descotes, 2003; Schiff et al., 2001; Detry et al., 2000]. Therefore, the occurrence of any 
immunosuppression caused by infections, chemotherapy and drugs, or organ transplantation 
medication that may have led to HCMV infection or reactivation was evaluated.  
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Furthermore, the history of previous blood transfusions of the study participants was assessed, 
as they are a major source of an infection with herpesviruses by transmission from donor to 
recipient [Kuhn, 2000]. HCMV infection or reactivation is frequently reported in individuals 
receiving blood transfusion where it can lead to severe disease.  
This study included brain tumors with different latency periods. Gliomas are known to have a 
short latency period, but meningiomas are reported to be diagnosed even years after onset of 
development [Inskip et al., 1995]. Furthermore, HCMV is a virus with a long replication cycle 
and it could be presumed that if it were a causing agent in brain tumor pathogenesis, it would 
take several months to transform normal brain tissues [Roizman and Pellet, 2001]. Therefore, 
only immunosuppressive conditions indicative for HCMV infection or reactivation occurring 
at least 2 years prior to the present tumor were taken into account. 
 
Drugs 
One glioma and one meningioma patient had to be excluded from this analysis because the 
intake of an immunosuppressive drug took place less than 2 years prior to brain tumor 
surgery.  
The single meningioma patient supposed to be immunosuppressed had received 
chemotherapy after each of two breast cancer surgeries. Meningioma had occurred four years 
after the first chemotherapy. As meningiomas are very slow growing tumors with a latency 
period of several decades [Gosztonyi et al., 2004; Strojan et al., 2000], it is questionable 
whether HCMV reactivation influencing subsequent meningioma development could have 
happened in this short time period. The crucial point is, though, that this patient was HCMV 
seronegative, clearly indicating that this tumor development was not influenced by HCMV. 
 
Blood Transfusion 
Another question addressed the prevalence of blood transfusions in the study participants. 
Blood transfusions are a major source of an infection with HCMV and other herpesviruses by 
transmission from donor to recipient [Kuhn, 2000]. Latent HCMV in blood cells of the donor 
can be reactivated following transfusion when encountering an allogeneic stimulus [Landolfo 
et al., 2003]. To prevent this transmission, blood donors are commonly screened for HCMV 
seropositivity.  
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One acoustic neurinoma patient reported a blood transfusion 30 years ago. Four glioma 
patients and one meningioma patient had received blood bottles 10 to 40 years prior to the 
present brain tumor surgery.  
Generally, about 10% to 15% of persons receiving HCMV seropositive blood get infected 
[Albert et al., 1990]. Therefore, HCMV IgG testing is useful at every blood donation to 
provide a large pool of HCMV negative blood donors [Sibrowski et al., 1990]. At the time of 
the present tumor surgery, four of the six patients (66.7%) who reported a previous blood 
transfusion were HCMV seropositive. However, nothing is known about where the subjects 
received the transfusion and whether the hospital used filtered blood or used blood from 
seronegative donors. In principle, it is possible that study participants who obtained foreign 
blood acquired an HCMV infection, reinfection or reactivation during blood transfusion, and 
that this could have been a risk factor for brain tumor development. However, nothing is 
known about the serological status of the study subjects prior and shortly after transfusion 
concerning HCMV. The percentage of patients with a history of blood transfusion positive for 
anti-HCMV IgGs did not differ from the prevalence given by RKI [2000a], and there are so 
far no studies addressing time periods of HCMV infection prior to tumor pathogenesis. 
Therefore, no definite conclusion can be drawn. 
 
4.3.5 Previous Cancers 
Hereditary predisposing conditions (e.g. neurofibromatosis, tuberous sclerosis, Li-Fraumeni 
syndrome) are well-established risk factors for the development of primary brain tumors. 
However, only 4% of all brain tumor patients are affected by them [Preston-Martin, 1996]. 
In the present study, patients were asked about the occurrence of neurofibromatosis or 
tuberous sclerosis, two hereditary diseases associated with primary brain tumors. None of the 
subjects reported to be affected by either of the hereditary conditions. However, patients 
might not be aware of being affected by any of the hereditary diseases addressed. Wrensch et 
al. [2002], for example, suggested that some hereditary syndromes are not readily diagnosed 
because patients with brain tumors are not routinely referred to a clinical geneticist. 
Therefore, the proportion of cancer syndromes in brain tumor pathogenesis may be 
underestimated. To control for possible unrecognized cancer syndromes, cancer histories were 
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obtained from all study participants. Tab. 35 gives a condensed survey of hereditary cancer 
syndromes predisposing to CNS tumors and the corresponding cancers at other sites. 
No previous cancers were seen in participants with acoustic neurinoma. Breast cancer had 
occurred in three glioblastoma patients, which could give hints to the presence of Li-Fraumeni 
syndrome in these subjects. For this syndrome, the frequent occurrence of both glioblastoma 
multiforme and breast cancer is common [Hisada et al., 1998].  
An association between breast cancer and meningioma as seen in one of the patients was 
reported, and there is a trend towards breast cancer presentation first [Lieu et al., 2003]. An 
increase in incidence of meningioma of 80% following the diagnosis of breast cancer has 
been reported in 1975 and subsequently, similar results were seen in several studies [Wahab 
and Al Azzawi, 2003; Schoenberg et al., 1975], though this trend may simply reflect the slow 
growth of meningiomas.  
The occurrence of thyroid gland cancer, which was the case in two of the meningioma 
patients, has been reported to have an elevated standardized incidence ratio prior to brain 
neoplasms by Inskip [2003]. However, their analysis suggested that brain neoplasms were 
most probably a consequence of cancer treatment of previous malignancies rather than of any 
genetic factors.  
Myomas were more common in meningioma patients, which is not astonishing as more 
women develop meningiomas.  
In summary, it was difficult to determine the possible occurrence of hereditary cancer 
syndromes in the present study population. Two syndromes were addressed in the 
questionnaire (neurofibromatosis or tuberous sclerosis) and none of the subjects reported to 
have either of them. Prevalences of previous cancers are dubious concerning the suggestive 
occurrence of hereditary syndromes, which patients are not aware, because these cancers of 
course also occur in individuals not affected by hereditary cancer syndromes. Other cancers 
(such as breast and thyroid gland cancer) have been reported to be associated with brain 
tumors. However, the total number of patients in the present study was too small for a definite 
conclusion concerning this issue.  
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Table 35: Review of hereditary cancer syndromes (according to Melean et al., 2004) 
Syndrome CNS tumors Cancer at other sites 
   
Neurofibromatosis 
type 1 
Astrocytoma, meningioma, 
neurofibroma, neurofibrosarcoma 
Hypothalamic tumor, parathyroid 
adenoma, pheochromocytoma 
   
Neurofibromatosis 
type 2 
Schwannoma, meningioma, 
ependymoma, astrocytoma, neurofibroma  
   
Tuberous sclerosis Ependymoma, giant cell and retinal astrocytoma 
Renal carcinoma, renal cysts, 
gingival fibroma 
   
Li-Fraumeni Astrocytoma, glioblastoma multiforme Breast cancer, lymphoma, leukemia, sarcomas 
   
Gorlin Cerebellar medulloblastoma 
Ovarian carcinoma and fibroma, 
cardiac fibroma, basal cell nevi 
and carcinoma 
   
Turcot Medulloblastoma, glioblastoma multiforme, astrocytoma, ependymoma 
Colon cancer, basal cell 
carcinoma, gastric cancer 
   
CNS, central nervous system 
 
Despite giving hints for undiagnosed cancer syndromes, previous malignancies and their 
treatment are immunosuppressive conditions that might contribute to HCMV infection or 
reactivation possibly leading to brain tumor development or progression. However, the single 
meningioma patient who reported the intake of chemotherapeutics was seronegative for anti-
HCMV IgG (see Chapt. 4.3.4).  
In total, 72.7% of the patients with cancer history were seropositive for anti-HCMV IgGs, 
with slight differences in analyses stratified by tumor type. This, although the proportion 
being in the line with RKI prevalences [RKI, 2000a], could be a hint for an 
immunomodulation leading to HCMV infection or reactivation at the time of the previous 
neoplasm.  
However, the sample size in the study was too small and nothing was known about the 
serological status of the participants prior and shortly after the previous cancer, to establish a 
hypothesis. Furthermore, it is conjecturable whether brain tumors are rather a consequence of 
treatment of previous malignancies than of any genetic factors [Inskip, 2003]. Therefore, 
further research may be needed to clarify this issue. 
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4.3.6 Allergic Conditions 
An inverse association between the occurrence of allergies and brain neoplasms, mainly 
gliomas, has been reported in several studies. In fact, this is one of the few consistent factors 
suggested to be involved in brain tumor development.  
In a population-based case-control study, a decreased risk of glioma in those with a history of 
allergies has been detected [Ryan et al., 1992]. Schlehofer et al. [1992] could confirm this 
result in a population-based case-control study in the Rhein-Neckar-Odenwald area, 
suggesting that a general activation of the immune system might be protective for gliomas. 
Furthermore, in pooled analyses of an international case-control study on brain tumors, in 
which the data of Ryan et al. [1992] and Schlehofer et al. [1992] were included, a significant 
risk reduction for subjects reporting a history of allergies was found [Schlehofer et al., 1999].  
A study by Cicuttini et al. [1997] could not significantly confirm these results; however, the 
results in their population-based case-control study also suggested a protective role of allergic 
conditions in brain tumor pathogenesis. Similarly, more recent case-control studies by 
Brenner et al. [2002] and Wiemels et al. [2004; 2002], and a cohort study by Schwartzbaum et 
al. [2003] also reported that adults with glioma were significantly less likely to have a variety 
of allergic conditions.  
A possible explanation for these findings is that frequent activation of the immune system, 
which occurs in people with allergies, leads to a lifelong hyperresponsiveness to multiple 
antigens (including tumor cells) and therefore to a more efficient tumor immunosurveillance. 
However, this hypothesis has not yet been confirmed. In summary, there seems to be an 
inverse correlation between glioma development and history of allergy, though no causative 
agent or immunologic pathways could be determined to date.  
Therefore, the occurrence of hay fever, asthma, eczema and allergies were addressed in the 
present study to evaluate this association.  
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Allergies 
The evaluation of the questionnaire in the present study is limited by a relatively small sample 
size. Therefore, no differences were made in data collection between food and other allergies 
(like dust, pollen etc.). Hermann-Kunz [1999a] investigated the prevalence of allergic 
diseases in Germany using data from the German National Health Interview and Examination 
Survey, 1998. Food allergy and “other allergies” were reported to be prevalent in 6.3% and 
16.6%, respectively, in the German population. This would suggest a significant increase in 
the occurrence of allergies in meningioma patients in the present study (35%), being at 
variance with the hypothesis of an inverse association between brain tumors and allergies. 
 
Hay Fever and Asthma 
With regional differences, hay fever affects 9.5–40.9% of the European population [Heinrich 
et al., 2002; ECRHS, 1996]. For Western Germany, the German National Health Interview 
and Examination Survey, 1998 reported a prevalence of 11% [Hermann-Kunz, 1999b]. In the 
present study, prevalences were 13% for glioma patients and 8% for meningioma patients, 
being similar to published prevalences. Similar results were found for asthma prevalences; 
4% of the glioma and 5% of the meningioma patients reported being affected by asthma, 
being commensurate to the proportion in the German population (6.1%; Hermann-Kunz, 
1999a). Hence, the findings of the present study do not suggest an association of asthma and 
hay fever and brain tumors as previously reported.  
 
Eczema 
Due to the small sample size in the present study, neurodermatitis and urticaria were not 
distinguished from eczema and contact eczema in contrast to previous studies, resulting in 
limitations for adequate comparison of the present data with published prevalences. A 
proportion of 16% for contact eczema and 9% for urticaria were reported in the German 
population [Hermann-Kunz, 1999a], resembling the prevalences found in the brain tumor 
patients (17% for glioma and 15% for meningioma patients). From previous publications (cf. 
above), however, a decreased prevalence would have been expected.  
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All Allergic Conditions Combined 
The occurrence of at least one allergic condition (asthma, hay fever, eczema, or other 
allergies) was reported by 39% of glioma patients and 39% of meningioma patients. In a 
survey of Hermann-Kunz et al. [1999a], the prevalence of at least one physician-diagnosed 
allergic disease in West Germans was assessed to be 42.8%.  
It is well known that the frequency of allergies decreases with increasing age. Age-stratified 
analyses in that survey yielded a prevalence of 50.9% in persons aged 30-39 years, 43.2% in 
persons from 40-49 years and 40.9% in people at the age from 50-59 years [Hermann-Kunz, 
1999a]. A dose-response has been reported for allergy on brain tumor risk in the study of 
Wiemels et al. [2002]. This was not observed in the present study.  
Prevalences in the present study were similar to the study of Hermann-Kunz et al. [1999a], 
indicating that no differences (especially no decreased occurrence of allergic conditions) 
occurred, which would have been expected from the above-mentioned studies.  
 
Distribution of Allergic Conditions – Summary 
In summary, a suggestive positive correlation was seen in the occurrence of allergies in 
meningioma patients. This does not support the hypothesis of better tumor immuno-
surveillance of people suffering from allergic conditions. However, as an inverse association 
has frequently been reported by several studies and considering the small sample size in the 
present study, further research is needed to clarify this possible correlation.  
Overall, the results for allergic conditions have to be interpreted carefully due to the lack of 
adequate comparative data. 
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4.3.7 Hearing Impairment and Tinnitus 
Tinnitus 
The prevalences of hearing impairment and tinnitus at least 2 years prior to brain tumor 
surgery were addressed in the questionnaire. Because this question was added to glioma and 
meningioma patients’ interviews later on in the study, 46% of the glioma and 35% of the 
meningioma patients did not answer the question concerning tinnitus, resulting in a high 
number of missing data for this question.  
None of the surveyed patients reported the occurrence of tinnitus. In previous reports, 
prevalences for tinnitus in acoustic neurinoma patients ranged from 8% to 34% [Tos et al., 
1998; Deen et al., 1996; Symon et al., 1989], being conflictive to present results. However, 
due to the small sample size and the fact that this question was included later on in the study, 
the present result could also be compatible with chance.  
 
Hearing Impairments 
The question on hearing impairments at least 2 years prior to brain tumor surgery was 
intended to evaluate a possible congenital HCMV infection of the patient, after which hearing 
impairments are frequently reported [Pass, 2001].  
Two patients with acoustic neurinomas, one glioma patient and all meningioma patients 
reporting hearing impairments reported to be affected for more than 10 years (range 13 to 16 
years). No previous brain tumors were reported that could have caused this condition. Some 
patients were rather young at the onset of hearing defects. One participant with acoustic 
neurinoma was 18 years old (16 years prior to surgery), and one of the glioma patients was 30 
years old (16 years prior to surgery), which is relatively young for the occurrence of hearing 
impairments. On the other hand, acoustic neurinomas as well as meningiomas are very slow-
growing tumors and it could be suggested that the occurrence of hearing impairments could 
be an early symptom for these malignancies [Inskip et al., 1995]. The questionnaire did not 
address any other conditions that might have caused this disease, such as noise trauma; 
therefore, it remains unclear how and why these subjects acquired hearing impairments.  
Another possible explanation for hearing impairments could be a reactivation of congenitally 
acquired HCMV infection. In manifest disease of congenital HCMV infection, hearing 
impairments are one of the most frequent symptoms. In fact, symptomatic congenital HCMV 
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infection is the most common infectious cause of deafness. Up to 60% of infected infants 
develop hearing loss [de Jong et al., 1998]. In addition, long-term follow-up studies showed 
that 7% to 25% of asymptomatically infected infants at birth may develop hearing defects 
[Landolfo et al., 2003; Pass, 2001]. Three of the six patients affected by hearing impairments 
were HCMV seropositive. However, even if stratified by tumor type, no increase in the 
prevalence of IgG antibodies to HCMV could be observed in affected patients, suggesting that 
HCMV was not the agent causing hearing impairments. However, due to the small sample 
size, this result could also be due to chance. 
 
4.3.8 Epilepsy 
The scientific literature on a possible association between a history of seizures and brain 
tumors is inconsistent. While some epidemiological studies showed significant associations 
[Schlehofer et al., 1999; Wrensch et al., 1997a], others failed to detect a correlation [Cicuttini 
et al., 1997]. Despite being a putative risk factor, seizures are a common first manifestation of 
brain tumors. Even if convulsions occurred several years prior to brain tumor diagnosis, the 
chance of a slow-growing tumor causing these symptoms cannot be excluded [Grisold et al., 
2000]. In the present study, ever-occurring epilepsy or seizures were addressed. None of the 
study participants reported epilepsy occurring more than one year prior to brain tumor 
surgery. From the results of the present study, it seems more likely that epilepsy is rather a 
symptom than a cause of primary brain tumors.  
 
4.4 Assessment of Occupational History 
Occupational risk factors for the development of primary brain tumors had been investigated 
in several studies, with controversial results (reviewed by Preston-Martin and Mack, 1996). 
Elevated risks were reported for occupations such as farmers [Inskip et al., 1995] and 
agricultural exposures [Khuder et al., 1998], whereas other studies found decreased risks for 
general farm workers [Menegoz et al., 2002]. Increases in brain tumor incidence were also 
seen for people working in specific industries (e.g. rubber, oil) or white-collar occupations, 
and health care workers [Inskip et al., 1995].  
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Most studies used occupation titles as a measure of exposure and did not focus on specific 
substances. This, however, can act only as a surrogate for potential causal agents in the 
workplace. Therefore, studies are conflictive about the particular occupational exposures 
suggested to lead to brain tumors. For example, elevated risks in farmers are suggested to be 
either due to increased exposure to pesticides [Musicco et al., 1988], or due to an influence of 
immunological factors (e.g. infections) or animal contact [Menegoz et al., 2002]. In health 
care workers, an increased risk was suggested to be due to high-level contact to humans 
(‘infectious agents’-hypothesis) as well as to be due to the intake of drugs and drug handling 
or the use of formaldehyde [De Roos et al., 2003; Krishnan et al., 2003; Menegoz et al., 2002; 
Inskip et al., 1995].  
Schlehofer et al. [2005] investigated 16 occupational categories a priori defined according to 
the International Standard Classification of Occupations (ISCO). In contrast to other studies 
reporting an influence of occupations on brain tumor development, this international case-
control study did not provide evidence of a strong association between occupational 
exposures and glioma development. 
In the present study, a detailed occupational history was obtained from 54 brain tumor 
patients. Occupations were classified into 16 categories in accordance to Schlehofer et al. 
[1990] following ISCO [2003]. The most frequent categories in all participants were ‘office’ 
and ‘service’.  
As the main study intention was to evaluate the risk of neuro-oncogenic infections in brain 
tumor pathogenesis, ‘agriculture’ and ‘health system’ were the most intriguing categories. 
However, only one meningioma and one acoustic neurinoma patient reported having worked 
in the ‘agriculture’ sector. 13% of glioma patients and 20% of acoustic neurinoma patients 
had worked in the health system. There were obviously more meningioma patients working in 
that category (65%). It is suggestible whether working in the health system and being exposed 
to certain substances or infectious agents increases the risk for meningioma development, but 
further research is needed to clearly establish this hypothesis.  
Similarly, obviously more meningioma patients were working in occupations belonging to the 
‘service’ category. Over 90% reported to have worked in jobs such as hairdresser, cleaner, 
cook, or manager in hotels or public houses, thereby being at risk for acquiring potential 
neuro-oncogenic infections. However, these findings are difficult to interpret because of the 
small sample size in the present study.  
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Few epidemiological studies have evaluated occupations being putative risk factors for 
meningioma or acoustic neurinoma. Elevated risks were reported for cooks, insurance agents, 
university lecturers, social workers, computer specialists, glassmakers, chemists, technicians, 
toolmaker setters and operators, inspectors, carpenters, gas station attendants, motor vehicle 
drivers, auto body painters, designers, decorators, in military occupations, industrial 
production, teachers, managers and machine operators [Rajaraman et al., 2004; Menegoz et 
al., 2002; Navas-Acien et al., 2002; Preston-Martin, 1989; McLaughlin et al., 1987]. 
However, most studies investigated vocational contact to certain exposures (electromagnetic 
fields, chemicals, metals, etc.; reviewed in Inskip et al., 1995), which were not addressed in 
the present study. Furthermore, a major problem for comparing obtained results to previous 
studies is that studies on brain tumor risk factors frequently combine gliomas and 
meningiomas in one group. Nowadays, authors try to report results separately for the different 
histological types because it is likely that gliomas and meningiomas have different 
pathogeneses. 
In summary, no considerable increase was seen in either subgroup except for the elevated 
number of meningioma patients working in the ‘health’ and ‘service’ category. Nevertheless, 
the high percentage of people working in the ‘office’ and ‘service’ category, both likely to 
have potential high-level contact to humans, might be a hint for immunological factors 
contributing to brain tumors, especially meningiomas. However, due to the small sample size 
in the present study, this finding has to be further investigated.  
The issue of potential high-level contact to animals and/or humans is discussed in the next 
chapter. 
 
4.5 Contact to Animals and/or Humans and Primary Brain Tumors 
For several zoonotic diseases, it is well known that they affect the central nervous system. For 
example, there is evidence that Borna virus, which most often affects horses, might contribute 
to psychological changes in humans [Bajramovic et al., 2002; Richt and Rott, 2001]. 
Furthermore, prions are suggested to lead to neurological damage in humans (e.g. new variant 
of Creutzfeld-Jacob disease, CJD) after transmission from cattle suffering from Bovine 
Spongiform Encephalopathy (BSE; Beghi et al., 2004). Rabies and tick-borne encephalitis 
(Frühsommermeningoenzephalitis, FSME) also affect the CNS after transmission from animal 
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to human [Lafon, 2005; Sambri et al., 2004]. Furthermore, despite zoonotic diseases, there are 
several human infectious agents affecting the CNS [Debiasi and Tyler, 2004]. In addition, it is 
well known since several years that some infectious agents can induce neoplasms (e.g. EBV, 
or helicobacter pylori), and that inflammation in general contributes to malignancies.  
As mentioned above, living on a farm and thus being exposed to several animals as well as 
exposure to pets has been suggested to be involved in brain tumor pathogenesis for a long 
time. In people with high-level contact to animals, exposure to potentially hazardous agents 
may occur, such as animals’ feces, body fluids, and contact, inhalation or absorption of 
zoonotic viruses, bacteria, and other antigens [Inskip et al., 1995].  
However, studies on animal contact and brain tumor development are at variance in their 
findings on the species responsible for tumorigenesis. Preston-Martin et al. [1993] found 
increased risks for brain tumor development in dairy workers as well as in sheep workers. 
These findings could not be confirmed in another case-control study, but up to 4-fold elevated 
risks to develop PNETs (primitive neuroectodermal tumors) were found for children with 
contact to pigs or poultry [Holly et al., 1998]. Efird et al. [2003] could confirm the findings on 
contact to pigs. In addition, these investigators found elevated odds ratios for contact with 
horses, dogs, and cats and the development of childhood brain tumors.  
Menegoz et al. [2002] addressed the role of animal contact in brain tumor development in a 
multi-center case-control study. No association between brain tumors (gliomas and 
meningiomas) and contact to nine species of animals or working in occupations with high-
level contact to animals was observed, except an inverse association of women having contact 
to horses and meningioma (OR 0.66, 95%CI 0.46-0.94). Analyses on suggested high-level 
contact to humans or human tissues also did not show any effects. In addition, no increase of 
the risk with increasing number of animal types was found. However, study centers in this 
multicenter study were not always homogenous in their results [Menegoz et al., 2002]. 
In the present study, all occupations reported by the study participants were additionally 
classified into occupations with high-level contact to animals, humans, both animals and 
humans, or neither of them (according to Menegoz et al., 2002), to evaluate the possible role 
of a transmission of infections leading to brain tumor development. People working as 
physicians, teachers, nurses, hairdresser and trained retail sales clerk were considered to have 
high levels of contact with humans or human tissues. Farmers and cooks were considered to 
have potential high-level contact to animals or animal tissue. Subjects working for a catering 
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service, in gastronomy (serving and cooking) or as trained retail sales clerk at a butchery were 
considered to have high-level exposure to both, humans and animals.  
An obviously higher number of meningioma patients having potential high-level contact to 
animals or animal tissue and contact to animals and humans were found in the present study. 
Furthermore, more meningioma patients had potential high-level occupational contact to 
humans compared to glioma or acoustic neurinoma patients. This result could be interpreted 
as in the line with the finding that most meningioma patients were working in the vocational 
categories ‘service’ and ‘health’ (see Chapt. 4.4), thus eventually supporting the theory of 
immunologic factors being related to meningioma etiology.  
Furthermore, the present study evaluated self-reported occupational and private contact to 
animals, extending the analyses according to Menegoz et al. [2002] that were focusing only 
on occupational contact. 
Contact to animals was frequently reported. Over 70% in each group reported private 
exposure to animals. According to the Industrieverband Heimtierbedarf e. V. (IHV‡‡), around 
22.7 million domestic animals were living in German households in 2002. Taking 38.7 
million households in Germany in 2002 (Statistisches Bundesamt, Germany), this would 
mean that nearly 60% of all households are exposed to animals. Therefore, and because the 
questionnaire addressed lifetime contact, the proportion of 70% and more of the study 
subjects having had contact to animals is quite realistic.  
Dogs and cats were the most frequently reported pets, followed by rabbits, rodents and birds. 
According to the IHV, the population of dogs and cats in Germany is 5 million and 7.2 
million, respectively. The number of small animals is given as 5.8 million, and 4.7 million 
birds are living in German households. The distribution of animal species reported by the 
participants is in the line with these data, although the proportion of patients having small 
animals was less than expected. Interestingly, contact to farm animals was most prevalent in 
meningioma patients. As mentioned above, previous studies were inconsistent about contact 
to farm animals or living or working on a farm and the association to brain tumors. Infectious 
microorganisms as well as hazardous agents such as pesticides or insecticides were suggested 
to be involved in the development of brain malignancies. On the other hand, these 
immunological factors might be protective as well. 
                                                          
‡‡ see website: http://www.ihv-online.de 
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Summarizing the analyses on private and occupational self-reported or suggested high-level 
contact to animals and/or humans or the respective tissues, there seems to be an association 
between meningioma and contact to mammalians. Obviously elevated numbers of 
meningioma patients having high-level contact to animals and humans were found in either 
analysis. Therefore, it could be suggested that immunological factors (infectious organisms or 
other antigens) might be a factor correlated with meningioma pathogenesis. However, 
regarding the small sample size and the inconsistent results in larger studies, this finding 
could also be due to chance and further research might be needed on this issue. 
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(B) Laboratory Analyses 
4.6 HCMV and Primary Brain Tumors 
Since several years, HCMV is controversially discussed to be involved in the pathogenesis of 
miscellaneous malignancies, including human brain tumors. HCMV is an ubiquitous β-
herpesvirus, which is known to be trophic for glial cells, aside from other tissues [Fritschy et 
al., 1996]. This herpesvirus persistently infects 50-90% of the population [Pass, 2001]. 
Furthermore, HCMV is well known as the most frequent cause of congenital malformations 
[Landolfo et al., 2003; Trincado and Rawlinson, 2001]. Infants with congenital HCMV 
infection are more prone to disorders involving the perceptual organs and the nervous system 
[Ho, 1990]. In immunocompromised persons, it can cause severe and fatal diseases such as 
HCMV-encephalitis and graft rejection, and lymphomas and brain tumors occur rather 
frequently in these individuals.  
In vitro, it has been shown that HCMV can be activated in astrocytic cells by inflammatory 
stimuli [Wolff et al., 1994] and that it can induce malignant transformation [Doniger et al., 
1999], possibly by its ability to repress cell growth arrest and p53 mediated apoptosis 
response [Castillo and Kowalik, 2002; Castillo et al., 2000; Cinatl, Jr. et al., 1999; 
Lokensgard et al., 1999]. Furthermore, there is evidence that HCMV dysregulates other key 
cellular pathways such as angiogenesis, cell invasion, and host immune response [Loenen et 
al., 2001; Scholz et al., 2000; Salvant et al., 1998; Shen et al., 1997]. Additionally, HCMV 
gene products can transactivate other oncogenic viruses that are suspected to be associated 
with malignant gliomas (e.g. JC virus), and may synergize with these viruses to promote 
oncogenesis [Del Valle et al., 2000; Winklhofer et al., 2000; Becker and Wahrendorf, 1998].  
Glioma cell lines have been shown to be permissive to in vitro HCMV infection [Cheeran et 
al., 2001; Lokensgard et al., 1999; Fritschy et al., 1996; Kuhn et al., 1995; Poland et al., 
1990]. Cinatl et al. [1996] suggested from in vitro analyses that HCMV may play the role of 
an either direct or indirect non-obligate cofactor for neuroblastoma genesis, e.g. by blocking 
apoptosis, which may be an essential requirement for tumor progression. Furthermore, 
HCMV may modulate the malignant potential for tumor cells by stimulation of growth factors 
and/or inhibition of anti-oncogenes by its gene products.  
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In 2002, Cobbs et al. [2002] examined tissues from primary brain tumors, normal brain tissue 
and tissues from several other brain diseases to detect HCMV-specific nucleic acids or gene 
products. In immunohistochemical analyses, all of 27 gliomas examined were positive for 
various HCMV-specific proteins. In addition, the presence of nucleic acids was demonstrated 
in a subset of these gliomas. In contrast, tissues from meningiomas and non-tumorous brain 
diseases (such as Alzheimer’s disease, stroke, encephalitis) were not infected by this 
herpesvirus, leading the authors to the suggestion that HCMV may be involved in glioma 
pathogenesis. One of the main intentions of the present study was to evaluate this hypothesis.  
Prior to PCR analyses of brain tumor tissues, nested PCR for the detection of HCMV DNA 
was performed in blood samples from the patients to control for the possibility that positive 
results in brain tumor tissues were due to a contamination of the tissue with HCMV-positive 
blood cells. It is generally accepted that in seropositive persons, peripheral blood cells such as 
monocytes and macrophages are a major site of carriage of HCMV DNA [Sinclair and 
Sissons, 1996]. However, HCMV DNA is not consistently detectable in peripheral blood cells 
of healthy seropositive individuals. Some studies reported rather high detection rates using 
PCR, others failed to detect any HCMV DNA in seropositive subjects [Roback et al., 2003; 
Larsson et al., 1998; Urushibara et al., 1995; Taylor-Wiedeman et al., 1991]. In the present 
study, only blood clot DNA was extracted for PCR analyses, thereby increasing the density of 
peripheral blood cells in which HCMV persists during its latent state. However, no HCMV 
DNA could be detected in the participants’ blood samples, though different PCR protocols 
addressing several gene sequences coding for different HCMV proteins were used. Therefore, 
possibly obtained positive results in PCR on HCMV DNA in brain tumor samples would have 
been unlikely to be a result of contamination.  
In none of the brain tumor tissues examined in the present study, HCMV DNA was found 
using nested PCR amplifying sequences of two different regions of the viral genome (IE-1, 
gB), including protocols as described by Cobbs et al. [2002] and Mangano et al. [1992]. 
Furthermore, every single tumor DNA sample had been successfully checked for the presence 
of GAPDH, demonstrating that DNA isolation was sufficient and that no inhibitors of the 
PCR were present in the sample.  
It is well known for HCMV detection that false negative results may occur. In a study by Gass 
et al. [1993], HCMV DNA sequences could only sporadically be amplified by PCR in 
immunohistochemically proven HCMV encephalitis. In addition, in the study of Cobbs et al. 
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[2002], HCMV nucleic acids were found only in 5 out of 7 brain tumor DNA samples, which 
where positive for several HCMV-specific proteins in immunohistochemistry. The same 
phenomenon had been observed by other studies [Knosel et al., 2004]. Therefore, 
immunohistochemistry was also performed in the present study using three different 
monoclonal antibodies recognizing the HCMV-specific proteins pp65, EA, and IE-1. 
Paralleling the PCR results, immunohistochemistry failed to demonstrate the presence of 
HCMV molecules in primary brain tumor tissues. As mentioned above, conflicting results in 
the same samples using different methods for detecting HCMV molecules are common. In the 
present study, however, results of PCR and immunohistochemistry were consistent, 
demonstrating the authenticity of all analyses performed.  
It is suggestive whether geographical differences in HCMV prevalence in brain tumor tissues 
may have led to the conflicting results between the data of Cobbs et al. [2002] and those of 
the present study. However, a more recent US study by Lau et al. [2005] supports the present 
results. In their study, 22 gliomas had been investigated for the presence of HCMV, partly 
using the same protocols as Cobbs et al. [2002]. Additionally, tissues from normal brain and 
various other malignancies had been examined. Paralleling the results of the present study, all 
tumors tested demonstrated no evidence of HCMV proteins or nucleic acids. Similarly, a very 
recent French study could not confirm an association between HCMV and primary brain 
tumors [Sabatier et al., 2005b]. Therefore, considering the results of these two studies [Lau et 
al., 2005; Sabatier et al., 2005b] and the results obtained in the present study, the hypothesis 
of an association between HCMV and the development or progression of primary brain 
tumors cannot be supported.  
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4.7 Herpesvirus Infections in Brain Tumor Patients 
There are five major classes of antibodies: IgG, IgM, IgA, IgD, and IgE.  
IgM is the first antibody present in an immune response after the first contact with an 
infectious agent. IgM antibodies do not persist for a long time; therefore, IgM antibodies in 
the serum indicate a primary infection.  
The production of IgM antibodies is followed by the raise of IgG antibodies. IgG antibodies 
are the backup antibodies and respond to repeated exposures and/or infections. In early phases 
of an infection, it is not unusual to have IgM and IgG antibodies at the same time. IgG 
antibodies can last up to a very long time greater than one year.  
For herpesviruses, there is agreement that estimates of antibody prevalences presented as 
single summary measures (e.g. mean or median) can be misleading when the age of the 
population sample is not considered [Smith and Robinson, 2002]. Therefore, despite the small 
study size, prevalences in the present study were stratified by age (20-years age groups). In 
addition, overall prevalences were presented despite of the aforementioned publication, 
because most of the reference values in the scientific literature are given as overall 
prevalence. Where published data presented differing age groups, additional analyses were 
performed in the present study for adequate comparison of herpesvirus seroprevalences.  
 
4.7.1 Infection with HCMV, HSV, EBV, or VZV Present at Surgery 
The seroprevalences of IgM antibodies to HCMV, HSV, EBV and VZV were evaluated in all 
study participants providing a blood sample. None of the patients was seropositive for IgM 
antibodies to any of the viruses investigated, indicating that none of them had a primary 
infection with these herpesviruses at the time of surgery.  
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4.7.2 Previous Infection with HCMV, HSV, EBV, or VZV 
Seroprevalences of IgG antibodies to HCMV, HSV, EBV, and VZV were assessed to control 
for previous infections with these herpesviruses in brain tumor patients. The prevalences of 
IgG antibodies to HCMV, HSV, EBV, and VZV had been investigated in several previous 
studies on brain tumors.  
After the study group of Wrensch et al. found that glioma cases were significantly less likely 
to report a history of chickenpox and shingles [Wrensch et al., 1997a], they conducted a 
population-based case-control study to further analyze this issue. Serological analyses were 
performed with serum samples obtained from a subset of the participants of the first study. 
These analyses showed that among people reporting a positive history of chickenpox or 
shingles, glioma cases were less likely to have IgG antibodies to VZV than controls [Wrensch 
et al., 1997b]. To additionally confirm these results, the same study group investigated the 
presence of IgG antibodies to HCMV, HSV, EBV and VZV in serum samples of another 
subgroup of participants from their first study [Wrensch et al., 2001]. With this case-control 
study, they could show that glioblastoma cases were significantly less likely to have IgG 
antibodies to VZV than controls. Similarly, though not statistically significant, glioblastoma 
cases were less likely to have IgG antibodies to EBV. Furthermore, the seroprevalences of 
IgG antibodies to HSV and HCMV were slightly increased, though not statistically 
significant. Prevalences for glioblastomas (WHO IV) and gliomas other than glioblastoma 
(WHO grade I-III) frequently showed converse trends compared to the controls, but none 
statistically significant (prevalences of Wrensch et al., 2001, are given in Tab. 36).  
Recently, the same study group (but this time in a different study population) found no 
differences in the prevalence of anti-VZV antibodies; however, the levels of anti-VZV 
antibodies were significantly lower for glioblastoma cases than for population-based controls 
[Wrensch et al., 2005]. 
Seroprevalences in the present study were compared to published results (German data if 
procurable) and additionally compared to the seroprevalences assessed in the study of 
Wrensch et al. [2001], all of which are shown in Tab. 36.  
In addition, the seroprevalences of all glioma patients as well as prevalences stratified by 
WHO grading are given to be further discussed.  
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Table 36: Prevalences and 95% confidence intervals (95%CI) of glioma patients (all gliomas, glioblastoma 
multiforme, and WHO grade I-III) and population-based literature/controls positive for IgG antibodies to 
HCMV, HSV, EBV and VZV in the present study and in the study of Wrensch et al. [2001] 
SP of 
IgGs to 
Glioma patients  
in the present study 
Glioma patients  
in the study of Wrensch et al., 2001 
 All * (n=34) 
GBM 
IV * 
(n=23) 
WHO  
I-III  
(n=11) 
SP in the 
Literature All  
(n=134) 
GBM 
IV  
(n=57) 
WHO  
I-III  
(n=77) 
Controls 
(n=165) 
         
HCMV 59% 57% 64% 40-80% 57% 66% 51% 57% 
 (41-75%) (35-77%) (31-89%) (Germany)     
         
HSV 91% 91% 91% 64-85% 67% 82% 57% 73% 
 (76-98%) (72-99%) (59-100%) (Germany)     
         
EBV 85% 83% 91% >90% 88% 86% 90% 92% 
 (69-95%) (61-95%) (59-100%) (World)     
         
VZV 91% 91% 91% >86% 88% 82% 92% 92% 
 (76-98%) (72-99%) (59-100%) (Germany)     
         
* no blood samples available for 5 glioma patients (one patient with glioblastoma multiforme);  
**References: [Rabenau et al., 2002; Wutzler et al., 2001; Hellenbrand et al., 2001; Wutzler et al., 2000; Cohen, 
2000; RKI, 2000a; RKI, 2000c; Krech, 1973]  
HCMV, human cytomegalovirus; HSV, herpes simplex virus; EBV, Epstein-Barr virus; VZV, varicella-zoster virus; 
SP, seroprevalence; IgG, immunoglobulin G; GBM, glioblastoma multiforme; WHO, World Health Organization 
 
4.7.2.1 Previous HCMV Infection 
In two studies of Wrensch et al. [2005; 2001], the occurrence of anti-HCMV IgGs was 
reported to be higher in glioblastoma patients than in population controls, but decreased titers 
compared to population controls were found in glioma other than glioblastoma (Tab. 36). 
However, none of the results was statistically significant.  
The overall seroprevalence for IgG antibodies to HCMV in the present study was 63% 
(95%CI 51-75%). Stratified by age and by tumor type, seroprevalences increased with 
increasing age, with a conspicious trend as expected from the literature. The Robert-Koch 
Institute (RKI), Germany, reported a prevalence of HCMV IgGs between 40% and 80% in the 
German population [RKI, 2000a]. Infection with HCMV can already be acquired during birth 
or following breast-feeding. During the first 6 months of life, 8% to 60% of infants become 
infected by HCMV. Afterwards, infection rates increase steadily in most developed countries. 
40% to 80% of children are infected before puberty [Pass, 2001].  
In the Freiburg area (Southern Germany), a prevalence rate of 42% has been estimated. In this 
study, male and female healthy blood donors between 20-39 years of age were included 
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[Krech, 1973]. Analyses stratified by age in the present study similar to the study of Krech 
[1973] evaluated a similar proportion. The distribution of HCMV in children and adults in the 
Munich area was investigated by Peller and Goetz [1978]. In this survey, 48% of subjects 
aged 17-40 years and 57% of persons aged 40-65 years were positive for HCMV antibodies.  
Hence, in contrast to the survey of Wrensch et al. [2001], the overall seroprevalence of 
HCMV in the present study was in the line with published data. Furthermore, no trend similar 
to the studies of Wrensch et al. [2005; 2001] could be observed. Therefore, it seems unlikely 
from the results of the present study that previous HCMV infection contributes to brain tumor 
development. 
 
4.7.2.2 Previous HSV Infection 
The study group of Wrensch et al., who investigated the prevalence of anti-herpesvirus 
antibodies in glioma patients [2005; 2001], found that gliomas other than glioblastoma cases 
were less likely to have antibodies to HSV than population-based controls. On the other hand, 
glioblastoma cases were more likely to have IgG antibodies to HSV. 
In the present study, an overall seroprevalence of 86% (95%CI 76-93%) of IgG antibodies to 
HSV was found. A slight age-dependent increase in prevalence was seen, though not as 
clearly as expected from the literature [Whitley, 1990]. According to Wutzler et al. [2000], 
the proportions of HSV IgG-seropositive individuals were 72-83% among blood donors and 
hospital patients between 20 and 39 years of age. Prevalence increased afterwards up to 92% 
in persons above the age of 70 years. Overall, in their survey, 73% (95%CI 71-74%) of the 
subjects were seropositive for HSV IgGs. Furthermore, a cross-sectional survey assessed a 
proportion of HSV susceptible persons of 30-35% in 20-29 year old persons and a proportion 
of 9-14% for subjects above the age of 30 years [Pebody et al., 2004]. The seroprevalences of 
IgG antibodies to HSV in the Frankfurt am Main area, Germany, reported a lower prevalence 
in hospital attendees aged 15-39 years (62% in male, 70% in female) compared to organ 
transplant recipients (85% for both sexes). 82-85% of persons above 40 years of age were 
HSV-seropositive [Rabenau et al., 2002]. In another population-based survey, the prevalence 
of antibodies to HSV in Western Germany was 85% (95%CI 83-87%; [Hellenbrand et al., 
2001]). Age stratification in the present study resulted in a prevalence of 78.6% (95%CI 49%-
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95%) for participants under the age of 40 years and a proportion of 87.9% (95%CI 77%-95%) 
in older subjects, being similar to published data.  
In analyses stratified by tumor type, though, an increase in the HSV seroprevalence in glioma 
patients could be observed, which was still prominent after stratification by age. Analyses 
separately for gliomas WHO grade I-III and glioblastoma multiforme (WHO grade IV) 
resulted in equally higher prevalences in either subgroup compared to population-based data. 
This is conflictive to the results of Wrensch et al. [2001], who found that gliomas other than 
glioblastoma cases were less likely to have antibodies to HSV than population-based controls. 
On the other hand, glioblastoma cases were more likely to have IgG antibodies to HSV in this 
[2001] as well as in the more recent study of Wrensch et al. [2005], supporting the finding of 
the present study.  
Similarly, Hadfield et al. [1984] found that glioblastoma cases had higher serum titers to HSV 
than controls. Furthermore, HSV is known as causative agent for severe encephalitis 
[Whitley, 1990], and this virus has been controversially discussed throughout decades to be 
involved in tumorigenesis [Wu et al., 2005; zur Hausen, 1975]. On the other hand, there is 
increasing evidence that an involvement of HSV in cancer development is unlikely [Lopez et 
al., 2003; Chang et al., 2000]. 
However, considering the studies of Wrensch et al. [2005; 2001] and the results of the present 
study, further research may be needed to clarify the possible role of HSV in glioma 
(especially in glioblastoma) development.  
 
4.7.2.3 Previous EBV Infection 
EBV is involved in the pathogenesis of several malignancies, e.g. Burkitt’s lymphoma, 
Hodgkin’s disease, Kaposi’s lymphoma and nasopharyngeal cancer [zur Hausen, 1999; 
Gaffey and Weiss, 1992]. Furthermore, it is known that EBV can infect astrocytes in vitro 
[Menet et al., 1999], and glioma cases were reported to be less likely to have IgG antibodies 
to EBV (Wrensch et al., 2001; Tab. 36). 
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In the present study, a seroprevalence of anti-EBV IgGs of 89% (95%CI 79%-95%) was 
found in the study subjects. According to Cohen [2000] and Berger [2003], IgG antibodies to 
EBV have an overall seroprevalence of more than 90% in the adult population.  
In age-stratified analyses, antibody titers were slightly decreasing with increasing age (100% 
in the youngest to 81% in the oldest age group), which was not expected from published 
studies, in which the seroprevalences in the population rose with increasing age. The observed 
decrease was consistent after stratification by tumor type and age.  
In both studies of Wrensch et al. [2005; 2001], all gliomas combined and glioblastoma cases 
alone were reported to be less likely to have IgG antibodies to EBV. This was also observed 
in the present study. Glioblastoma patients were less likely to have anti-EBV antibodies, 
whereas low-grade gliomas were similar to those reported in the literature. Therefore, further 
research may be needed to evaluate this suggestive inverse association between previous EBV 
infection and glioma.  
 
4.7.2.4 Previous VZV Infection 
Prior infection with VZV has been suggested to have an influence on the risk of adult glioma 
since it was reported that glioma patients were significantly less likely to have had 
chickenpox and shingles prior to tumor diagnosis than population controls [Wrensch et al., 
1997a]. In addition, among a subsample selected for serological analyses, those reporting a 
positive history, glioma cases were less likely to test positive for IgG antibodies to VZV. 
However, no association was found for those reporting a negative history and for all glioma 
cases combined [Wrensch et al., 1997b]. In 2001, these findings had been evaluated again in 
another subset of blood specimens of the 1997 study [Wrensch et al., 1997a]. In this case-
control study, addressing seroprevalences of four herpesviruses (HCMV, HSV, EBV, and 
VZV), glioblastoma cases were significantly less likely to have IgG antibodies to VZV than 
population-based controls [Wrensch et al., 2001], suggesting an association of anti-VZV IgGs 
and glioblastoma. Recently, the previous finding concerning self-reported history of 
chickenpox was corroborated by the same study group in another study population [Wrensch 
et al., 2005]. In addition, although prevalences of anti-VZV IgGs did not differ between 
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glioma cases and population-based controls, the levels of antibodies to VZV were lower in 
glioma (especially glioblastoma) cases. 
In the present study, the brain tumor patients showed an overall seroprevalence of IgG 
antibodies to VZV of 92% (95%CI 83-97%). In tumor type stratified analyses, a decrease of 
seroprevalences in the present study compared to published data was observed in the youngest 
meningioma patients. Wutzler et al. [2001] investigated the seroprevalence of IgG antibodies 
to VZV in the German population. They found that already at the age of 11 years, over 90% 
of the study subjects were positive for VZV IgGs. Other German data confirmed these 
findings [RKI, 2000c].  
 
4.7.2.5 Summary of Previous Infections with HCMV, HSV, EBV, and VZV 
In summary, the results of the present study showed no considerable differences in the 
seroprevalence of brain tumor patients compared to the general population. In contrast to the 
studies mentioned above, an inverse association between VZV seropositivity and brain 
tumors, especially gliomas, could not be observed. Therefore, the hypothesis of an influence 
of VZV infection on brain tumor development cannot be confirmed in the present study. 
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(C) Strengths and Limitations of the Study 
4.8 Limitations 
Participants in any survey are likely to differ in some of their characteristics from those who 
do not participate. In prevalence studies, selection bias may occur if the subjects who 
participate in the study are not representative of the underlying population (i.e., brain tumor 
cases). However, a selection with regard to the laboratory analyses performed is unlikely in 
the present study, because the study subjects are not suspected to know their latency status 
concerning herpesviruses, as these do not cause apparent disease during latency. For the 
questionnaire evaluation, however, it is essential to try to obtain information about those who 
could not be interviewed for different reasons. This has been done in the present study, as 
well as Fisher’s exact testing for heterogeneity focusing on the histological distribution of 
brain tumors in both groups. No significant difference between the two groups was found. 
Furthermore, in comparison with published data for brain tumor patients, age and gender were 
equally distributed. Hence, it seems very unlikely that obtained results are distorted by 
selection bias.  
A commonly raised criticism in studies using retrospective questionnaires is the potential 
recall bias. Whereas laboratory methods are obviously not affected by that kind of bias, 
subjects with a serious disease are likely to have been thinking hard about possible causes of 
their condition, and so participants may be inclined to give answers that fit with what they 
believe is the cause of the disease. However, to the author’s knowledge, herpesviruses as 
potential risk factors for brain tumor development have not yet been published in daily 
newspapers, so that it seems unlikely that patients thought about herpesviruses as potential 
brain cancer-causing agents. Therefore, it is unlikely that the occurrence of certain medical 
conditions was overreported. Furthermore, if the study participants may have been convinced 
that former medical conditions led to the present brain tumor, this may have led to an 
increased prevalence. However, the distribution of most variables addressed was similar to 
that of the general population. Furthermore, the study participants were kept unaware of the 
hypothesis under the study. Hence, the potential recall bias is likely to be marginal.  
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The question on tinnitus history was included to control for a possible prenatal HCMV 
infection in the study subjects. Unfortunately, this question has been included in the study 
later on during the study period, resulting in an increased amount of missing data for that 
variable. Therefore, the prevalence of tinnitus in brain tumor patients is most likely to be 
underestimated. However, various questions as well as the serological analyses were included 
in the present study to assess the prevalence of HCMV infection in the study participants. 
Hence, the lack of these data is of less importance for the overall study intention, though of 
course, the distribution of tinnitus in the study subjects has to be interpreted with great care. 
The major limitation of the present study with regard to the evaluation of questionnaire data is 
the small number of patients that could be interviewed. It was, however, not possible to get 
more brain tumor patients interviewed due to organizational issues and the part-time 
anonymous collection of the brain tumor tissue samples. Therefore, the prevalences obtained 
from interviews can only act as an estimate of the true value in the brain tumor population. 
Due to the resulting small sample size, the estimated proportions were characterized by large 
95%CI. Therefore, it cannot be excluded that the findings of the questionnaire were due to 
chance. 
 
4.9 Strengths 
The present study was a well-designed and thoroughly conducted epidemiological study, 
combining laboratory as well as questionnaire data analyses. Only incident brain tumors were 
included and data collection was performed blinded for tumor type in each analysis.  
The reliability of the laboratory methods was assured by using PCR and 
immunohistochemical analyses, and various protocols in both. An advantage of the present 
study in the PCR analyses was the use of fresh-frozen tissues (stored at -80°C, because 
HCMV is known to be relatively unstable at temperatures exceeding -70°C; Mocarski, Jr., 
1996), which were not formalin-fixed. Formalin fixation has been suggested to decrease PCR 
specificity in some studies [Wilkens et al., 1994; Rogers et al., 1990], whereas others did not 
support this thesis [Boeckh et al., 1994]. However, even Boeckh et al. [1994], who found that 
storage at room temperature for a certain time and formalin fixation did not influence 
detection results, preferred a direct procession of materials. 
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Furthermore, the possibility of false positive results due to a contamination of the tissues by 
HCMV-positive blood cells was excluded by PCR on patients’ blood samples. For PCR 
detection of HCMV in peripheral blood, the European Group for Blood and Marrow 
Transplantation (EBMT) Infectious Disease Working Party recommends that 
1. peripheral blood is collected into EDTA or citrate, 
2. a standard number of leucocytes is processed, 
3. DNA from a standard amount of DNA is added per PCR, 
4. cellular gene control of amplificability of the sample is included, 
5. a specificity control (nesting or hybridization) is included, and 
6. primers in a conserved part of the HCMV genome are chosen [Grundy et al., 1996]. 
In the present study, analyses followed most of these recommendations, except that the 
amount of leucocytes processed and the amount of DNA used was not evaluated. However, to 
eliminate the possibility of false negative results, all brain tumor DNA samples were 
additionally checked for the presence of the cellular GAPDH gene, with positive result. 
Furthermore, blood clot was taken for DNA extraction and subsequent PCR analyses, 
providing a high density of peripheral blood cells.  
This study was performed notably to evaluate the findings of Cobbs et al. [2002], suggesting a 
role of HCMV in glioma pathogenesis, which included only 27 gliomas. More recent studies 
by Lau et al. [2005] and Sabatier et al. [2005b], which focused on the same hypothesis, were 
limited either by a small sample size (22 gliomas in Lau et al., 2005) or by the fact that only 
few analyses were performed without any quality controls (only one protocol for 
immunohistochemistry and in situ hybridization in Sabatier et al., 2005b).  
Therefore, the major advantages of the present study in contrast to the studies of Cobbs et al. 
[2002], Lau et al. [2005], and Sabatier et al. [2005b] are  
a) the amount of brain tumors included, and  
b) the number of analyses performed using different protocols, 
and therefore, the hypothesis of an association of HCMV and gliomas can definitely not be 
supported in the present study. 
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5 Conclusion 
Analyses performed to confirm the hypothesis of Cobbs et al. [2002] clearly demonstrated the 
absence of HCMV molecules in all primary brain tumors analyzed. This finding is confirmed 
by two very recent studies, which also did not find HCMV gene sequences and proteins in 
brain tumor tissues [Lau et al., 2005; Sabatier et al., 2005b]. Therefore, the hypothesis of an 
association between HCMV and glioma pathogenesis cannot be supported.  
Furthermore, the present study could not find an association between previous infections with 
VZV or HCMV and either different histological type of glioma. Prevalences of IgG 
antibodies to HCMV and VZV, respectively, were similar to published German data. For 
glioblastoma patients, a decreased prevalence of anti-EBV antibodies and an increased 
prevalence of anti-HSV IgGs compared to published data was found, paralleling the trends 
observed in two previous studies of Wrensch et al. [2005; 2001]. However, because of the 
small sample size regarding this issue, and the consistency of previous results, the association 
of previous herpesvirus infections and brain tumors deserves further research. 
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6 Summary 
Herpesviruses are suggested to be involved in cancer pathogenesis since several years. A 
recent study suggested HCMV to be involved in glioma development or progression, and 
other studies found an inverse correlation between previous VZV infection and glioblastoma 
pathogenesis. The present study was conducted to evaluate these assumptions.  
Brain tumor tissues from 76 gliomas, meningiomas, and acoustic neurinomas were obtained, 
together with 71 corresponding blood samples. Nested PCR and immunohistochemistry were 
performed using several protocols to assess the prevalence of HCMV DNA and proteins in 
brain tumor tissues, blood samples, and short-term cultures of brain tumor tissues. 
Additionally, the serological status of 71 brain tumor patients concerning the prevalence of 
IgM and IgG antibodies to HCMV, HSV, EBV, and VZV was analyzed. Furthermore, a 
questionnaire was developed to control for putative medical risk factors indicating 
herpesvirus infection or reactivation, and to control for other putative (mainly medical) risk 
factors in brain tumor development.  
None of the 76 brain tumor tissues was positive for HCMV molecules in any analysis 
performed. The conflicting results may be due to geographical differences in the prevalence 
of HCMV; however, very recent studies conducted in the US and in France confirmed the 
absence of any HCMV molecules in primary brain tumors.  
In general, the overall seroprevalences of IgG antibodies to HCMV, HSV, EBV and VZV in 
brain tumor patients were similar to those of the German population. However, the 
prevalences of anti-HSV and anti-EBV IgGs in glioma patients showed trends that resemble 
previous findings. 
Overall, the questionnaire did not provide evidence for viral infections being involved in brain 
tumor development. For some factors such as the occurrence of allergies, hearing 
impairments, and especially the frequent high-level contact to animals in meningioma patients 
(private and occupational), the results were indicative but not conclusive for an association 
with brain tumor pathogenesis, and further research may be needed to clarify these issues. 
In summary, considering the results from laboratory analyses and the results of the 
questionnaire, the hypothesis of an association between herpesviruses and the development or 
progression of brain tumors cannot be supported.  
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Schedular Annexes 
Patients’ Education 
 
Studie „Umwelt und Gesundheit 2003“ 
 
Liebe Patientin, lieber Patient 
Die Arbeitsgruppe Umwelt- Epidemiologie des Deutschen Krebsforschungszentrums (DKFZ) in Heidelberg 
(Leiter: Prof. Dr. Jürgen Wahrendorf) führt mit der Neurochirurgischen Klinik der Universität Heidelberg 
zurzeit eine Studie zu „Umwelt und Gesundheit 2003“ durch. An dieser Studie beteiligen sich insgesamt 14 
Länder unter Leitung der Weltgesundheitsorganisation (WHO). Sie ist von der Ethikkommission genehmigt. 
 
Was ist das Ziel der Studie? 
Bisher ist wenig über Ursachen von Tumoren des Kopfbereiches bekannt. Mit dieser Studie sollen Faktoren 
gefunden werden, die zur Entstehung von Hirntumoren beitragen. Dazu untersuchen wir den Einfluss 
verschiedener Aspekte der Umwelt, von Lebensgewohnheiten, der Arbeitswelt und einiger Vorerkrankungen 
(z.B. Virusinfektionen). Damit wollen wir einen Beitrag dazu leisten, dass in Zukunft bessere 
Schutzmaßnahmen zur Verhinderung dieser Erkrankung getroffen werden können. 
 
Warum ich? 
Wir nehmen in diese Studie alle Patienten der Neurochirurgischen Universitätsklinik Heidelberg auf, die an 
einem Hirntumor erkrankt sind. Die Aussagekraft der Studie hängt von der Teilnahme möglichst aller 
angesprochenen Patienten ab. 
 
Wie soll die Mitarbeit aussehen? 
Wir möchten mit Ihnen eine kurze telefonische Befragung durchführen. Dafür können Sie auf der 
beiliegenden Einverständniserklärung einen Wunschtermin angeben, an dem unsere Mitarbeiterin mit Ihnen 
Kontakt aufnehmen kann, um einen genauen Termin für ein kurzes telefonisches Interview zu vereinbaren. 
Im Fall einer operativen Entfernung des Tumorgewebes wird dieses routinemäßig feingeweblich untersucht. 
Ein Teil dieses Gewebes soll auch auf frühere Infektionen mit Herpesviren getestet werden, ebenso Serum 
von den Blutproben, die bereits zur Diagnostik entnommen wurden. Es werden daher keine zusätzliche 
Blut- oder Gewebeentnahme vorgenommen; das Ausmaß der Operation ändert sich nicht. Es wird keine 
AIDS-Diagnostik durchgeführt. 
 
Ihre Sicherheit! 
Wir versichern Ihnen, dass die Einhaltung der Vorschriften über die ärztliche Schweigepflicht und des 
Datenschutzes im Rahmen dieser Studie gewährleistet ist. Ihre Angaben werden nur anonymisiert, das heißt 
nur mit Studiennummer und ohne Namensnennung, weiter verwendet und zu Statistiken zusammengefasst.  
Die Teilnahme an dieser Studie ist freiwillig. Sie können Ihr Einverständnis jederzeit ohne Angabe von 
Gründen und ohne Nachteile für Ihre weitere medizinische Versorgung zurückziehen. In diesem Fall werden 
Ihre persönlichen Daten gelöscht. 
 
Wir bitten Sie herzlich um Ihre Teilnahme!  
Für Fragen stehen Ihnen zur Verfügung: die Studienleitung: 
Dr. med. B. Schlehofer und S. Poltermann, DKFZ Heidelberg (Tel.: 06221/42 2346), bzw.
Dr. med. K. Geletneky (Tel.: 06221/56 39672), Neurochirurgische Klinik Uni Heidelberg.  
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Informed Consent 
 
Studiennummer      B |__|__|__| 
 
Studie „Umwelt und Gesundheit 2003“ 
 
Einverständniserklärung  
Vorname Name:  «Vorname» «Nachname» 
Anschrift:   «Strasse» 
    «PLZ» «Ort» 
Tel. Nr.: _________ / __________________ Handy 
Nr._____________________________ 
 
Die schriftliche Patienteninformation habe ich erhalten und gelesen. Darüber hinaus bin ich 
auf meinen Wunsch hin mündlich aufgeklärt worden. Dabei wurden meine Fragen 
beantwortet. 
 
Ich möchte mich an der Studie „Umwelt und Gesundheit 2003“ beteiligen. Dies 
schließt auch Untersuchungen zur Rolle von Herpesvirus- Infektionen bei der 
Entstehung von Hirntumoren ein. 
ٱ ja     Wunsch- Termin _______________________ 
Wegen der Terminabsprache für ein Interview bin ich telefonisch zu erreichen am: 
Datum ___________________ Uhrzeit  _______________________ 
Datum ___________________ Uhrzeit  _______________________ 
 
 
Datum __________________ Unterschrift   
__________________________________ 
 
Ich stimme der Teilnahme freiwillig zu. Ich weiß, dass ich diese Zustimmung ohne Angabe 
von Gründen jederzeit und ohne Nachteile für meine weitere medizinische Versorgung 
widerrufen kann. 
Ich wurde darüber aufgeklärt, dass die im Rahmen dieser Studie erhobenen Daten nur in 
anonymisierter Form dokumentiert und in Form von Statistiken zusammengefasst werden, 
die keine Rückschlüsse auf Einzelpersonen zulassen. 
------------------------------------------------------------------------------------------------------------- 
ٱ nein 
Falls Sie nicht teilnehmen möchten, bitten wir Sie um eine  
Begründung: 
_________________________________________________________________________
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DEUTSCHES KREBSFORSCHUNGSZENTRUM
Stiftung des öffentlichen Rechts
in der Helmholtz-Gemeinschaft
Umwelt und Gesundheit 2003
„Die Rolle von Herpesviren bei der Entstehung von 
Hirntumoren“
Fragebogen
In Zusammenarbeit mit der
Neurochirurgischen Universitätsklinik Heidelberg
Wie lautet die Adresse Ihres jetzigen Wohnortes?
Strasse _______________________ Haus-Nummer |__|__|__|
Postleitzahl |__|__|__|__|__| 
Ort _________________ Bundesland: ________________
Wie lautet die Adresse Ihres Hauptwohnsitzes? 
Ist dieser mit obiger Adresse identisch? Keine Eintragung
vornehmen, wenn identisch mit obiger Adresse
Strasse ________________________ Haus-Nummer |__|__|__|
Postleitzahl |__|__|__|__|__|    
Ort _________________Bundesland: _________________
Wie lauten Ihre Telefonnummern?
Privat: |__|__|__|__|__| / |__|__|__|__|__|__|__|__|
Vorwahl Rufnummer
Arbeitsplatz: |__|__|__|__|__| / |__|__|__|__|__|__|__|__|
Vorwahl Rufnummer
Handy: |__|__|__|__|__| / |__|__|__|__|__|__|__|__|
Vorwahl Rufnummer
Handy: |__|__|__|__|__| / |__|__|__|__|__|__|__|__|
Vorwahl Rufnummer
Interviewpartner (Nicht fragen, ist vom Interviewer auszufüllen):
 Studienteilnehmer/in selbst
oder Proxy (stellvertretend für Teilnehmer)
 Ehepartner/In / Lebensgefährte/In
 Andere, 
bitte geben Sie das Verwandtschaftsverhältnis an: ___________
A. Allgemeine Informationen I
Die folgenden Fragen müssen vor dem Interview ausgefüllt
werden.
Die Angaben müssen mit dem Studienteilnehmer
nochmals überprüft werden.
Studiennummer : B  |__|__|__|
Tag des Interviews: |__|__| |__|__| |__|__|__|__|        
Tag   Monat Jahr
Uhrzeit: |__|__| : |__|__|
Name des Interviewers:   __________________
Code des Interviewers:    |__|__|__|
OP- Datum   |__|__| |__|__| |__|__|__|__|
Tag             Monat Jahr
Beginn des Interviews
Ich möchte mit Ihnen Ihre persönlichen Angaben
durchgehen, um diese zu ergänzen und mit Ihnen
gemeinsam zu überprüfen.
Bitte nennen Sie mir Ihren Familiennamen und 
Ihren Vornamen:
Familienname:   ____________________________________
Vorname:           ____________________________________
Bitte nennen Sie mir Ihr
Geburtsdatum: |__|__| |__|__| |__|__|__|__|
Tag     Monat Jahr
Nicht fragen, ist vom Interviewer anzukreuzen.
Geschlecht: männlich  weiblich 
Grund, warum nicht der Teilnehmer selbst befragt wird:
 verstorben
 zu krank, um zu antworten
 andere Gründe: ___________________________
Folgende Fragen bitte an den Proxy- Teilnehmer richten:
Bitte nennen Sie mir Ihren vollständigen
Namen und Ihre Adresse.
Familienname:   __________________________________
Vorname:           __________________________
Adresse nicht ausfüllen, falls identisch mit Adresse des Teilnehmers.
Strasse ______________________ Haus-Nummer |__|__|__|
Postleitzahl |__|__|__|__|__| 
Ort __________________ Bundesland: ________________
Können Sie mir bitte Telefonnummern nennen, 
unter denen Sie erreichbar sind:
Privat:       |__|__|__|__|__| / |__|__|__|__|__|__|__|__|__|
Vorwahl Rufnummer
Arbeitsplatz: |__|__|__|__|__| / |__|__|__|__|__|__|__|__|__|
Vorwahl Rufnummer
Handy :        |__|__|__|__|__| / |__|__|__|__|__|__|__|__|__|
Vorwahl Rufnummer
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B. Medizinische Vorgeschichte des Studienteilnehmers
Ich möchte Ihnen nun einige Fragen zu Ihrer medizinischen
Vorgeschichte stellen! Zu einigen Punkten frage ich Sie auch,
wie alt Sie beim Auftreten verschiedener Erkrankungen waren. 
Hier können Sie mir alternativ auch das Jahrnennen, in welchem
die Erkrankung auftrat, wenn Ihnen dies leichter fällt.
1. Ich werde Ihnen nun eine Reihe von Infektionskrankheiten
vorlesen. 
Wurde eine davon jemals von einem Arzt festgestellt?:
Windpocken?
 Nein 
 Ja      Wie alt waren Sie, als dies zum ersten Mal 
auftrat? |__|__| Jahre
Sie können mir auch das Jahr nennen.
|__|__|__|__| Jahreszahl
 Weiß nicht
Gürtelrose?
 Nein 
 Ja       Wie alt waren Sie, als dies zum ersten Mal 
auftrat? |__|__| Jahre
Sie können mir auch das Jahr nennen.
|__|__|__|__| Jahreszahl
 Weiß nicht
Pfeiffersches Drüsenfieber?
 Nein 
 Ja       Wie alt waren Sie, als dies zum ersten Mal 
auftrat? |__|__| Jahre
Sie können mir auch das Jahr nennen
|__|__|__|__| Jahreszahl
 Weiß nicht
Dreitage-Fieber (Exanthema subitum)?
 Nein 
 Ja     Wie alt waren Sie, als dies zum ersten Mal 
auftrat? |__|__| Jahre
Sie können mir auch das Jahr nennen.
|__|__|__|__| Jahreszahl
 Weiß nicht
Herpes simplex (Bläschen an den Lippen oder
an anderen Körperstellen)?
 Nein 
 Ja    Wie alt waren Sie, als dies zum ersten Mal 
auftrat? |__|__| Jahre
Sie können mir auch das Jahr nennen.
|__|__|__|__| Jahreszahl
Wie häufig treten diese Bläschen auf?
<1x jährlich 
1-2x jährlich 
>2x jährlich 
 Weiß nicht
Halsschmerzen, Grippe, Infekte, nicht- eitrige Angina?
 Nein
 Ja        wenn ja, wie häufig
<1x jährlich 
1-2x jährlich 
>2x jährlich 
 Weiß nicht
2. Wurde bei Ihnen jemals ein Zytomegalie-Virus 
(CMV)-Titer bestimmt? 
 Nein  
 Ja    wann? |__|__| Monat |__|__|__|__| Jahr;
Sie können mir auch das Alter nennen, in dem
der Titer bestimmt wurde. |__|__| Jahre
Wie lautete das Ergebnis?
positiv
negativ
weiß nicht
 Weiß nicht
3. Leiden Sie an einer der folgenden allergischen
Erkrankungen?
Asthma?
 Nein 
 Ja       Wie alt waren Sie, als dies zum ersten Mal 
auftrat? |__|__| Jahre
Sie können mir auch das Jahr nennen.
|__|__|__|__| Jahreszahl
Heuschnupfen ?
 Nein 
 Ja      Wie alt waren Sie, als dies zum ersten Mal 
auftrat? |__|__| Jahre
Sie können mir auch das Jahr nennen.
|__|__|__|__| Jahreszahl
Ekzeme? 
 Nein 
 Ja    Wie alt waren Sie, als dies zum ersten Mal 
auftrat? |__|__| Jahre
Sie können mir auch das Jahr nennen.
|__|__|__|__| Jahreszahl
Hörten die Ekzeme auf?
 Nein
 Ja    Wie alt waren Sie, als die Ekzeme aufhörten?
|__|__| Jahre
Sie können mir auch das Jahr nennen. 
|__|__|__|__| Jahreszahl
In der Zeit, als Sie Ekzeme hatten, wie lange waren Sie
davon betroffen?
 den größten Teil des Jahres (mehr als 8 Monate) 
 etwa die Hälfte des Jahres (4 - 8 Monate)
 weniger als die Hälfte des Jahres
(weniger als 4 Monate)
 gelegentlich/ vereinzelt
Trat das Ekzem nur auf, wenn Sie in Kontakt mit
speziellen Stoffen kamen? 
 Nein 
 Ja
Wodurch wurde Ihr Ekzem speziell ausgelöst? 
 Pflanzen
 Cremes, Salben oder Kosmetika
 Metalle
 Chemikalien
 andere Stoffe, welche:____________________________
____________________________
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4. Leiden Sie an weiteren Allergien?
Nein
Ja
Wenn ja, an welchen?
1. ___________________________________
Seit wann? |__|__| Monat |__|__|__|__|Jahr
Sie können mir auch das Alter nennen, in dem die Allergie
zuerst auftrat. |__|__|Jahre
2. ___________________________________
Seit wann? |__|__| Monat |__|__|__|__|Jahr
Sie können mir auch das Alter nennen, in dem die Allergie
zuerst auftrat. |__|__|Jahre
5. Ich werde Ihnen nun weitere Krankheiten vorlesen. 
Wurde eine davon jemals von einem Arzt bei Ihnen
festgestellt?
Epilepsie?
ٱ Nein 
ٱ Ja    Wie alt waren Sie, als dies zum ersten Mal 
auftrat? |__|__| Jahre
Sie können mir auch das Jahr nennen.
|__|__|__|__| Jahreszahl
Tuberöse Sklerose?
ٱ Nein
ٱ Ja   In welchem Alter wurde sie zuerst
diagnostiziert? |__|__| Jahre
Sie können mir auch das Jahr nennen.
|__|__|__|__| Jahreszahl
Neurofibromatose?
ٱ Nein
ٱ Ja   In welchem Alter wurde sie zuerst diagnostiziert?  
|__|__| Jahre
Sie können mir auch das Jahr nennen. 
|__|__|__|__| Jahreszahl
6. Haben Sie Probleme mit dem Hören?
ٱ Nein
ٱ Ja
Wie wurden Sie darauf aufmerksam?
 durch sich selbst  durch Ihre Familie/ Freunde
 durch einen Arzt  durch andere Personen
Wie alt waren Sie, als Sie darauf aufmerksam wurden?   
|__|__| Jahre
Sie können mir auch das Jahr nennen.             
|__|__|__|__| Jahreszahl
Welches Ohr, bzw. welche Ohren waren davon betroffen?
 Linkes Ohr  Rechtes Ohr  Beide Ohren
7. Leiden Sie unter dauerhaften Ohrgeräuschen? 
(z. B. Tinnitus)
 Nein
 Ja
Wie alt waren Sie, als Sie darauf aufmerksam wurden?
|__|__| Jahre
Sie können mir auch das Jahr nennen.
|__|__|__|__| Jahreszahl
Welches Ohr, bzw. welche Ohren waren davon betroffen?
 Linkes Ohr  Rechtes Ohr  Beide Ohren
8. Hat Ihnen ein Arzt jemals gesagt, dass Sie einen
Tumor haben? Darunter verstehen wir auch Krebs, 
Leukämie und Lymphome.
ٱ Nein
ٱ Ja   In welchem Alter wurde er diagnostiziert?
|__|__| Jahre
Sie können mir auch das Jahr nennen.             
|__|__|__|__| Jahreszahl
Was für ein Tumor war dies? ____________________
Hatten Sie jemals noch einen anderen Tumor?
ٱ Nein 
ٱ Ja   In welchem Alter wurde er zuerst diagnostiziert?
|__|__| Jahre
Sie können mir auch das Jahr nennen.           
|__|__|__|__| Jahreszahl
Was für ein Tumor war dies? ____________________
Hatten Sie jemals noch einen anderen Tumor?
ٱ Nein
ٱ Ja   In welchem Alter wurde er zuerst diagnostiziert?
|__|__| Jahre
Sie können mir auch das Jahr nennen.           
|__|__|__|__| Jahreszahl
Was für ein Tumor war dies? _____________________
9. Ist bei Ihnen eine Abwehrschwäche/ Immunschwäche
bekannt, die zum Beispiel durch eine Infektion, eine
Chemotherapie, durch Medikamente oder durch eine
Organtransplantation verursacht wurde?
ٱ Nein
ٱ Ja
Wenn ja, wurde Sie hervorgerufen durch:
eine Infektion?      nein      ja
|__|__| Monat |__|__|__|__| Jahr
welche? ___________________________
eine Chemotherapie/ Medikamente?    nein    ja
|__|__| Monat |__|__|__|__| Jahr
welche? (z.B. Kortison) ______________
eine Organtransplantation?    nein    ja
|__|__| Monat |__|__|__|__| Jahr
welches Organ? _____________________
10. Haben Sie jemals eine Bluttransfusion erhalten?
 Nein
 Ja
Wenn ja, warum? _______________________________
In welchem Alter haben Sie die Infusion erhalten?
|__|__| Jahre
Sie können mir auch das Jahr nennen.    
|__|__|__|__| Jahreszahl
Wenn ja, warum? _______________________________
In welchem Alter haben Sie die Infusion erhalten?
|__|__| Jahre
Sie können mir auch das Jahr nennen.          
|__|__|__|__| Jahreszahl
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Und nun noch eine kurze Frage zu Ihren Impfungen.
11. Können Sie sagen, gegen welche Krankheiten Sie
geimpft sind?
Diphterie  Ja      Nein      Weiß nicht
Tetanus  Ja      Nein      Weiß nicht
Pertussis 
(Keuchhusten)  Ja      Nein      Weiß nicht
Kinderlähmung  Ja      Nein      Weiß nicht
Tuberkulose  Ja      Nein      Weiß nicht
Röteln  Ja      Nein      Weiß nicht
Mumps  Ja      Nein      Weiß nicht
Masern  Ja      Nein      Weiß nicht
MMR – Kombi  Ja      Nein      Weiß nicht
Hepatitis A  Ja      Nein      Weiß nicht
Hepatitis B  Ja      Nein      Weiß nicht
Tollwut  Ja      Nein      Weiß nicht
Frühsommer Meningitis 
(FSME)  Ja      Nein      Weiß nicht
Influenza  Ja      Nein      Weiß nicht
C. Familienanamnese
Ich möchte Sie nun nach einigen Erkrankungen fragen, 
von denen eventuell Ihre Familienangehörigen betroffen
sind oder waren.
Bitte sagen Sie mir zuerst, ob Sie Kinder haben. 
Nennen Sie mir bitte nur Ihre leiblichen Kinder, 
keine Stief- oder Adoptivkinder.
Verstorbene Kinder sind ebenfalls mit zu zählen.
Nein
Ja
Wie viele Söhne? |__|__| Anzahl
In welchem Jahr wurden sie geboren?1. |__|__|__|__| Jahr
2. |__|__|__|__| Jahr
3. |__|__|__|__| Jahr
4. |__|__|__|__| Jahr
5. |__|__|__|__| Jahr
Wie viele Töchter? |__|__| Anzahl
In welchem Jahr wurden sie geboren?1. |__|__|__|__| Jahr
2. |__|__|__|__| Jahr
3. |__|__|__|__| Jahr
4. |__|__|__|__| Jahr
5. |__|__|__|__| Jahr
(Falls keine, bitte 0 eingeben)
2. Hatte eines Ihrer Kinder im ersten Lebensjahr eine
der folgenden Krankheiten? 
Gelbsucht?
ٱ Nein
ٱ Ja Bei welchem Kind wurde sie
diagnostiziert? Bitte geben Sie mir das
Geburtsjahr des betroffenen Kindes an.
|__|__|__|__| Jahr
|__|__|__|__| Jahr
ٱ Weiß nicht
Blutarmut (Anämie)?
ٱ Nein
ٱ Ja Bei welchem Kind wurde sie
diagnostiziert? Bitte geben Sie mir das
Geburtsjahr des betroffenen Kindes an.
|__|__|__|__| Jahr
|__|__|__|__| Jahr
ٱ Weiß nicht
Lungenentzündung?
ٱ Nein
ٱ Ja Bei welchem Kind wurde sie
diagnostiziert? Bitte geben Sie mir das
Geburtsjahr des betroffenen Kindes an.
|__|__|__|__| Jahr
|__|__|__|__| Jahr
ٱ Weiß nicht
Chronische Magen- Darmentzündung?
ٱ Nein
ٱ Ja Bei welchem Kind wurde sie
diagnostiziert? Bitte geben Sie mir das
Geburtsjahr des betroffenen Kindes an.
|__|__|__|__| Jahr
|__|__|__|__| Jahr
ٱ Weiß nicht
Hat eines Ihrer Kinder angeborene Krankheiten
oder Fehlbildungen?
ٱ Nein
ٱ Ja
Wenn ja, welche Krankheit? ______________________
Bitte geben Sie mir das Geburtsjahr des betroffenen
Kindes an. |__|__|__|__| Jahr
Wenn ja, welche Krankheit? ______________________
Bitte geben Sie mir das Geburtsjahr des betroffenen
Kindes an. |__|__|__|__| Jahr
Wenn ja, welche Krankheit? ______________________
Bitte geben Sie mir das Geburtsjahr des betroffenen
Kindes an. |__|__|__|__| Jahr
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D. Allgemeine Informationen II
Im letzten Teil des Interviews möchte ich Ihnen einige
abschließende allgemeine Fragen stellen:
1. Bitte nennen Sie mir Ihren höchsten Schulabschluss:
ٱ kein Schulabschluss
ٱ Hauptschulabschluss
ٱ Mittlere Reife
ٱ Abitur / Fachhochschulreife
ٱ Sonstiges, bitte angeben: |_____________________|
2. Bitte nennen Sie mir Ihren Berufsabschluss:
ٱ keinen
ٱ abgeschlossene Berufsausbildung (Lehre)
ٱ Fachschulabschluss
ٱ Fachhochschulabschluss
ٱ Hochschulabschluss
ٱ Sonstiges, z.B. Verwaltungs- oder Beamtenlaufbahn
3. Bitte nennen Sie mir Ihren Familienstand:
ٱ ledig / Single
ٱ verheiratet oder mit Partner/In
ٱ getrennt lebend oder geschieden
ٱ verwitwet
4. Bitte nennen Sie mir alle Berufe, in denen Sie für min. 
ein Jahr gearbeitet haben. Falls Sie für denselben Arbeit-
geber in zwei ganz unterschiedlichen Tätigkeitsbereichen
gearbeitet haben, dann werten Sie dies bitte als zwei versch. 
Berufe. Beginnen Sie mit dem zuletzt ausgeübten Beruf.
Falls eine identische Tätigkeit bei unterschiedl. Arbeitgebern
durchgeführt wurde, können diese zu einem Beruf zusammen-
gefasst werden. Bezahlte Nebentätigkeiten sind ebenfalls
relevant, wenn sie regelmäßig für mindestens ein Jahr ausgeübt
wurden. Beispiele wären Berufstätige mit einem Nebenverdienst
in der Landwirtschaft oder Hausfrauen/- männer oder Studenten
mit regelmäßiger Nebentätigkeit.Bitte fragen nach Zeitraum, 
Berufsbezeichnung und kurzer Skizzierung typischer Tätigkeiten
Berufsbezeichnung:_____________
Tätigkeit:_____________________     
_____________________________     
_____________________________
Von  |__|__|       
|__|__|__|__|
Bis |__|__|
|__|__|__|__|
4
Berufsbezeichnung:_____________
Tätigkeit:_____________________     
_____________________________     
_____________________________
Von  |__|__|       
|__|__|__|__|
Bis |__|__|
|__|__|__|__|
3
Berufsbezeichnung:_____________
Tätigkeit:_____________________     
_____________________________     
_____________________________
Von  |__|__|    
|__|__|__|__|
Bis |__|__|
|__|__|__|__|
2
Berufsbezeichnung:_____________
Tätigkeit:_____________________     
_____________________________     
_____________________________
Von  |__|__|
__|__|__|__|
Bis |__|__|
__|__|__|__|
1
Berufsbezeichnung
und Tätigkeitsbereich
Datum 
(Monat/ 
Jahr)
Nr.
5. Haben oder hatten Sie in Ihrem Beruf
Kontakt mit Tieren?
 Nein
 Ja
Wenn ja, mit welchem?____________________________
seit wann? |__|__| Monat |__|__|__|__| Jahr; 
bis wann? |__|__| Monat |__|__|__|__| Jahr
bei welcher Tätigkeit?_____________________________
Wenn ja, mit welchem?____________________________
seit wann? |__|__| Monat |__|__|__|__| Jahr; 
bis wann? |__|__| Monat |__|__|__|__| Jahr
bei welcher Tätigkeit?_____________________________
6. Haben oder hatten Sie auch privaten Kontakt zu Tieren? 
 Nein
 Ja
Wenn ja, mit welchem?____________________________
seit wann? |__|__| Monat |__|__|__|__| Jahr; 
bis wann? |__|__| Monat |__|__|__|__| Jahr
Wenn ja, mit welchem?____________________________
seit wann? |__|__| Monat |__|__|__|__| Jahr; 
bis wann? |__|__| Monat |__|__|__|__| Jahr
Wenn ja, mit welchem?____________________________
seit wann? |__|__| Monat |__|__|__|__| Jahr; 
bis wann? |__|__| Monat |__|__|__|__| Jahr
Vielen Dank. Hiermit ist das Interview abgeschlossen. 
Ich danke Ihnen für Ihre Geduld und Ihre Mitarbeit. 
Sie haben damit einen wertvollen Beitrag zur
Unterstützung der Krebsforschung geleistet. 
Wenn Sie möchten, können Sie mir nun noch weitere
Angaben machen, die für Sie von Bedeutung sind. 
Sie können an dieser Stelle auch gerne Kommentare zum
Interview geben.
Kommentare:
____________________________________________
____________________________________________
____________________________________________
____________________________________________
____________________________________________
____________________________________________
____________________________________________
____________________________________________
Falls Sie später noch weitere Fragen haben, 
zögern Sie nicht, uns anzurufen.
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F. Interviewerfragen
Diese Fragen sind direkt nach dem Interview zu beantworten
(NICHT IM BEISEIN DES STUDIENTEILNEHMERS).
Art des Interviews
ٱ im Krankenhaus direkt
ٱ telefonisch
Wie hoch war die Bereitschaft des Studienteilnehmers, 
die Fragen zu beantworten?
ٱ überhaupt nicht (nicht interessiert, zurückhaltend)
ٱ mäßig kooperativ und aufgeschlossen
ٱ sehr kooperativ, aufgeschlossen und interessiert
Ihrer Meinung nach, wie gut konnte sich der Studien-
teilnehmer an frühere eigene Erkrankungen erinnern? 
(nur einmal ankreuzen)
ٱ sehr gut
ٱ gut
ٱ mäßig gut
ٱ nicht gut
ٱ überhaupt nicht
Ihrer Meinung nach, wie gut konnte sich der Studien-
teilnehmer an frühere Erkrankungen seiner Familie
erinnern? (nur einmal ankreuzen)
ٱ sehr gut
ٱ gut
ٱ mäßig gut
ٱ nicht gut
ٱ überhaupt nicht
Bitte ergänzen Sie Angaben zum Interview, die Ihnen
wichtig erscheinen
Bemerkungen/ Ergänzungen:
_______________________________________________
_______________________________________________
In diesem Bereich ist der Status des Interviews festzuhalten.
Geben Sie den Vollständigkeits-Status des Interviews an: 
Das Interview kann z.B. unvollständig sein, wenn Sie
Sektionen übersprungen haben oder das Interview vorzeitig
abgebrochen wurde.
ٱ Vollständig
ٱ Unvollständig, weil:
ٱ Studienteilnehmer verweigerte die weitere
Teilnahme; 
Bitte geben Sie den Grund an:
__________________________________
__________________________________
ٱ andere Gründe, bitte angeben:
_________________________________
_________________________________
Werden Sie das Interview zu einem späteren Zeitpunkt
wieder aufnehmen?
ٱ Ja Wann?___________________________
_________________________________
ٱ Nein Warum?__________________________
_________________________________
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